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ABSTRACT 
Drug-induced liver injury (DILI) is a serious adverse drug reaction (ADR) that is frequently 
encountered during drug development, representing a major cause of drug attrition. 
Furthermore, DILI is also a serious concern in the clinic, accounting for approximately half 
of all acute liver failure cases. Paracetamol overdose (acetaminophen; APAP) accounts for 
the majority of DILI-associated cases of ALF encountered in patients. The identification and 
development of novel biomarkers of DILI that are sensitive, specific, and rise early during 
hepatotoxicity are urgently required in the clinic and in the laboratory. Two liver-specific 
microRNAs (miRNAs) have recently been described that serve as sensitive and early 
markers of APAP-induced acute liver injury (APAP-induced ALI) in a mouse model. 
Together with the superior liver-enrichment of some liver-enriched miRNAs, these potential 
markers need to be assessed in patients for the clinical promise. Moreover, further work is 
warranted to test these potential markers in alternative pre-clinical models with other 
compounds to gain a better understanding regarding sensitivity of release, mechanism of 
release and circulatory kinetics. Furthermore, in separate work discussed in this thesis, the 
mammalian biological clock has been found to exert a powerful influence on the physiology 
of mammalian systems. This regulation hinges on the complex interplay between the clock 
genes and their products that oscillate over a twenty-four hour period and promote a diurnal 
variation in numerous output pathways. Emerging evidence suggests that the efficacy and 
toxicity of many drugs follow a diurnal rhythm and that this may be at least partly 
attributable to the clock-mediated regulation of drug targets and pathways of drug 
metabolism. APAP and FS represent two compounds that elicit hepatotoxicity in the mouse 
through two distinct mechanisms. Both APAP and FS are known to exhibit circadian 
variation in their toxicology and/or pharmacology. However, little is known about the 
molecular mechanisms that govern these differences in circadian variation. 
Two liver-enriched miRNAs (miR-122 and miR-192) were tested alongside serum ALT 
activity, the gold-standard marker of ALI, for sensitivity and time of release in a mouse 
model of APAP-induced ALI. At 2 hours after APAP administration, miR-122 (ΔΔCt 75.0, 
P=0.02) was significantly higher compared to controls (ΔΔCt 4.1) while ALT levels were in 
the normal range (21 U/L) indicating earlier release of miR-122. In a sensitivity study, miR-
122 was not more sensitive than ALT at a 300 mg/kg dose of APAP compared to controls 
(mean values 300 mg/kg vs 0 mg/kg: ALT = 491 U/L vs 38.1 U/L; miR-122 = ΔΔCt 572.9 
vs ΔΔCt 209.4). In patients, serum miR-122 and miR-192 were substantially higher in 
APAP-induced ALI patients, compared to healthy controls (median ΔΔCt  miR-122: 1,265  
versus 12.1, P < 0.0001; miR-192: 6.9 versus 0.44 P < 0.0001). A heart-enriched miR-1 
showed no difference between APAP-ALI patients and controls, whereas miR-218 (brain-
enriched) was slightly higher in the APAP-ALI cohort (ΔΔCt 0.17 versus ΔΔCt 0.07 P = 
0.01). In a cohort comprised of patients who presented early (median time of presentation 
since APAP overdose = 8 hours), miR-122 was significantly raised in patients who develop 
ALI (> 3 x ULN serum ALT activity) compared to those that did not (median ΔΔCt 3.48 vs 
ΔΔCt 0.16, P<0.0001). In contrast, presentation ALT levels were not different between 
patients who developed ALI compared to those that did not (median ALT = 21 U/L vs 19 
U/L). Moreover, miR-122 was significantly raised in patients who develop coagulopathy 
(INR > 1.3) compared to those that did not (ΔΔCt vs 3.48 vs ΔΔCt 0.17, P=0.0004). In 
contrast, presentation ALT levels were not different between patients who developed ALI 
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compared to those that did not (median ALT = 21 U/L vs 19 U/L). In chronotoxicity studies, 
both APAP exhibited greater toxicity in the evening (mean ALT = 12785, 66% survival) 
compared to morning (mean ALT = 380, 100% survival) whereas FS showed greater 
toxicity after morning administration (mean ALT=561, 100% survival) compared to evening 
administration (mean ALT = 69.2, 100% survival). Circadian variation in APAP-induced 
ALI was associated with 38% lower (P=0.003) GSH levels and 20% higher (P=0.024) 
Cyp2e1 levels at 21:00h compared to 09:00.  
This work confirms that miR-122 is released earlier than ALT in a young mouse model of 
APAP-induced ALI. Furthermore, it is shown for the first time that circulating liver enriched 
miRNAs are higher in patients following an APAP overdose. Also, plasma miR-122 is 
raised at emergency room presentation when serum ALT activity is in the normal range. 
Further clinical development of blood-based miR-122 is warranted, this work suggests that 
miR-122 analysis at the point of hospital admission can predict risk of subsequent liver 
injury in patients. Finally, APAP and FS exhibit circadian variation in their toxicity in a 
mouse model associated with circadian variation with genes involved in drug metabolism 
and drug detoxification. Profiling of the hepatic proteome over the circadian phase is now 
warranted. 
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GENERAL INTRODUCTION 
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1.1 INTRODUCTION 
Adverse drug reactions (ADRs) can be defined as any undesirable effect caused by a 
xenobiotic. ADRs can be broadly classified into two types, as follows:  type A reactions are 
more common, often dose-dependent and can be described as an exaggeration of the known 
primary or secondary pharmacology. Type B reactions can be described as idiosyncratic 
reactions; they are unpredictable, rare but often severe. Several studies have shown that 
between 2.4-12 % of all hospital admissions are due to an ADR (Pirmohamed et al, 2004; 
Lazarou et al, 1998). Due to their prevalence, their impact on healthcare systems is 
significant, i.e.  4 out of 100 hospital bed days in the UK equating to an estimated cost of 
£400m per annum (Pirmohamed et al, 2004). They are a major cause of patient mortality, 
two studies found that between 0.13-0.15 % of all patients admitted to hospital died resulting 
from an ADRs, equating to approximately 5,700 deaths in England a year (Pirmohamed et 
al, 2004; Lazarou et al, 1998). Furthermore, ADRs represent one of the leading causes of 
drug attrition during pre-clinical drug development in an increasingly competitive and 
expensive drug discovery process (Kola & Landis, 2004).  The cost of discovering, 
developing and marketing a new chemical entity is approximately $1bn and with increasing 
social and regulatory pressure to produce affordable drugs with exemplary safety profiles yet 
only one in three drugs that reach the market returns a profit (Grabowski et al, 2002). 
Drug-induced liver injury (DILI) is one of the most common ADRs encountered in pre-
clinical and clinical settings. Hepatotoxicity is the most cited reason a drug will be 
withdrawn or restricted by the FDA in the post-marketing phase (Giri et al, 2010). In the 
clinic, DILI is a major concern to physicians as 50% of ALF cases are attributed to drug-
induced hepatotoxicity in the United States (Russo et al, 2004). The liver is susceptible to a 
drug-induced toxicity more than any other organ in the body and it has been estimated that 
over 900 drugs have been associated with hepatotoxicity (Giri et al, 2010). This can be 
explained from a physiological perspective as the liver is the major site of drug metabolism 
and drug biotransformation. Many drugs are hydrophobic and the drug metabolism systems 
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present in the liver will increase the hydrophilicity of these compounds, to facilitate 
clearance from the body. However, in many cases of DILI, these drug-metabolising systems 
inadvertently generate chemically-reactive metabolites (CRMs) which can in turn cause cell 
death. One of the major concerns for the pharmaceutical industry is the lack of predictive 
toxicity models available during pre-clinical drug testing, as many drugs have species-
dependent drug metabolism, and species-dependent drug toxicities. In order for us to better 
understand the molecular mechanisms that underpin drug-induced liver toxicity, studies have 
identified archetypal hepatotoxins that can be utilised as models. Despite a rich literature of 
experimental evidence, the exact molecular pathways with which drugs elicit cell death 
remain poorly understood. Such model hepatotoxins provide a bridge between chemical 
structure, drug metabolism, cellular targets, and cell death pathways. Ideally, it would be 
possible to predict toxicity from the chemical structure to allow generation of safe, non-toxic 
drugs. In some cases, the toxicity cannot be ‘designed out’ of the molecule, as the 
pharmacophore (which provides drug efficacy) and the toxicophore (which provides drug 
toxicity) are the same. 
Two well-defined hepatotoxins that cause predictable liver injury in rodent models are 
paracetamol (acetaminophen; APAP) and FS (frusemide; FS). APAP is a common, over-the-
counter analgesic that has been used for 60 years. Despite an excellent safety profile at 
therapeutic doses (4g/day), in an overdose setting it can cause coagulative centrilobular liver 
necrosis and potentially fatal liver failure. In fact, a U.S. study found that APAP was the 
leading cause of acute liver failure (ALF) accounting for 50 % of cases (Lee, 2004). This 
equates to approximately 10,000 hospitalisations and 500 deaths per annum. APAP is an 
aminophenol compound that undergoes extensive phase II metabolism to yield non-toxic 
APAP-sulphates and APAP-glucuronides. A minor pathway involves phase I oxidation via 
cytochrome P450 (CYP) isoforms which generate a protein-reactive electrophile, n-acetyl-p-
benzoquinoneimine (NAPQI). NAPQI binds to protein thiols and causes cell death due to 
centrilobular liver necrosis in rodents and in man (Mitchell et al, 1973; Gujral et al, 2002). 
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FS, a carboxylic acid diuretic used for the treatment of hypertension has been less well-
studied. FS has been found to cause centrilobular liver necrosis in mice, but not in man, 
(Mitchell et al, 1974; Mitchell et al, 1976). It has been found that FS also generates a CYP-
mediated, chemically reactive metabolite (Williams et al, 2007). Although both APAP and 
FS present a similar pattern of injury in mice, it is considered that they do so through distinct 
mechanisms. 
Specific and sensitive biomarkers of DILI are essential to detect, diagnose, monitor and 
provide mechanistic insight into liver injury. Current biomarkers include protein-based 
markers, e.g. the aminotransferases, liver function markers such as albumin or prothombin 
time and novel mechanistic markers such as HMGB1 and cytokeratin-18 (Amacher, 1998; 
Ozer et al, 2008; Antoine et al, 2009). However, several limitations exist which confound 
the reliability of these markers in clinical and pre-clinical settings. Such limitations include 
unacceptable false-positive / false-negative rates, poor tissue specificity, poor biological or 
technical sensitivity and an excessive latent phase between injury and circulatory signal. An 
ideal biomarker would be accurate (i.e. reflects the physiological/pathophysiological status 
of the liver), sensitive, liver-specific, abundant in a non-invasive biofluid such as blood or 
urine, stable, translatable (i.e. across in vitro, in vivo and in clinical settings), able to be 
assayed quickly and cheaply, and detectable soon after (or even before) injury has occurred. 
MicroRNAs (miRNAs) are short, non-coding RNA species, between 19-25 nucleotides in 
length. They function to repress a distinct set of cognate mRNAs which they do so through a 
variety of mechanisms. miRNAs thereby regulate protein output and the phenotype of the 
cell. To date, over 1500 miRNAs have been described in man (approximately 750 in mice) 
some of which are highly conserved between species (Altuvia et al, 2005). Despite their 
ribonucleic acid make-up, their abundance in RNase-rich matrices including blood and urine 
is surprisingly high suggesting that protection is afforded by auxiliary molecules. The 
potential of circulating miRNAs to inform on a number of pathologies has been reported in a 
number of publications, including cancer, myocardial infarction and hepatitis (Mitchell et al, 
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2008; D’Alessandra et al, 2010; Zhang et al, 2010). Recently, it was reported that miR-122 
and other liver-specific miRNAs were found to be raised in the serum of mice treated with 
APAP (Wang et al, 2009). Furthermore, this study found that miR-122 was detected earlier 
and at lower doses of APAP than serum alanine aminotransferase (ALT) activity, the current 
gold-standard biomarker of liver injury. Liver specific miRNAs have the potential to 
complement existing biomarkers of DILI in clinical and pre-clinical settings, but need 
further work to assess their utility. Therefore, this represents a key focus for the work 
presented in this thesis. 
Another smaller but significant aim of the work in this thesis has focussed on a relatively 
under-researched are in the field of drug toxicity, that of the role of circadian rhythms in 
DILI. Circadian rhythms can be defined as 24 hour rhythms in a biological system. They 
have been found to exist in diverse life forms from cyanobacteria to higher mammals. The 
role of the biological clock is to enable anticipatory behaviour, rather than a reactionary 
activity, to stimuli e.g. food availability.   Many physiological processes are known to 
express a degree of circadian variation, including heart rate, blood pressure, body 
temperature, rest-activity cycles, hepatic blood flow, bile production, endocrine function and 
metabolism.  The discovery of clock genes provided mechanistic insight into the generation 
and autonomy of circadian rhythms (Vitaterna et al, 1994). Initially, it was thought that main 
site of circadian regulation was in the superchaismatic nuclei (SCN) of the central nervous 
system (CNS). However, since then, it has been found that functional clocks exist in almost 
all cell types in the body, including hepatocytes and keratinocytes (Panda et al, 2002; 
Zanello et al, 2000). The association between drug effect and time of day has been 
appreciated for centuries; a concept more recently termed ‘chronopharmacology’. 
Pharmacokinetics, pharmacodynamics and drug toxicities have all been shown to display 
circadian variation in both animal models and in man for a number of drugs. With the 
current burden of ADRs and lack of understanding behind the causal mechanisms, new 
concepts and tools are needed to improve drug safety. Understanding the molecular basis of 
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chronopharmacology represents a potential area to provide a better understanding behind the 
causality of drug toxicities.  
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1.2 ADVERSE DRUG REACTIONS 
ADRs are a major clinical problem in terms of prevalence, patient morbidity, patient 
mortality and cost to healthcare systems. A 2004 UK study found that 1225 (6.5%) of 
18,820 inpatients were admitted between two hospitals were due to an ADR (Pirmohamed et 
al, 2004). The median hospital stay was 8 days (4% of hospital bed capacity), a significant 
amount of clinical resource. This was estimated to equate to an annual cost of £466m to the 
NHS. The overall mortality rate in this study was 0.15%, a figure which is similar to that 
stated in other reports (Lazarou et al, 1998). ADRs were responsible for the withdrawal of 
16 out of 548 new chemical entities (NCEs) from the US market between 1975 and 1999. 
Moreover, 56 out of 548 were labelled with a black box warning which may severely reduce 
the confidence in the utility of a NCE (Lasser et al, 2002). The majority of ADRs that are 
presented in the clinic are type A reactions, which are distinct from rarer type B 
idiosyncratic ADRs. Type A reactions (also known as “on target” reactions) are common, 
predictable, and are considered exaggerations of the known primary and secondary 
pharmacology. Due to the drug-related causality of type A ADRs, reactions usually respond 
well to dose-reduction, and are only in some cases life-threatening. Typical examples of type 
A reactions include bleeding with the anticoagulant warfarin, hypotension caused by 
angiotensin converting enzyme (ACE) inhibitors and bradycardia due to atenolol 
administration.  
 Type B (idiosyncratic) ADRs are unpredictable and not necessarily dose-dependent. 
Although they are much rarer than type A reactions, they are often more severe and life-
threatening. Idiosyncratic ADRs typically occur at a rate between 1 in 10,000 to 1 in 
100,000 individuals and are often not detected in preclinical safety studies or even in the 
early clinical trials when NCEs are evaluated on their safety profile in man (Giri et al, 2010). 
Therefore idiosyncratic ADRs may only be observed in the post-marketing phase of a NCE 
leading to significant patient morbidity and patient mortality. Often idiosyncratic ADRs can 
be linked to host factors in the patient, such as genetic variation or an underlying disease 
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which may predispose that patient to the ADR. One example includes the genetic variant of 
human leukocyte antigen (HLA), HLA-B*5701, an allelic variant of the major 
histocompatibility class I complex (Mallal et al, 2002). This allele occurs at a rate of 
approximately 5% in the general population and was found to predispose patients to 
hypersensitivity reactions with Abacavir (Mallal et al, 2008). However, not all patients with 
this allele, develops toxicity. There is cause for optimism as a 2008 clinical study confirmed 
that prior pharmacogenetic testing for this allelic variant could reduce the risk of 
hypsersensitivity reactions in patients taking abacavir (Mallal et al, 2008). 
1.3 DRUG-INDUCED LIVER INJURY (DILI) 
Of all the different forms of ADRs, the liver is one of the most susceptible organs in which a 
drug can evoke toxicity. The majority of cases (80%) of drug-induced liver failure cases are 
due to APAP intoxication. To date, over 900 different drugs have been associated with liver 
injury which are independent of drug class or disease type (Etxagibel et al, 2008). These 
drugs include prescribed medicines such as antiretrovirals or statins but also widely-
available, over-the-counter medications, e.g. analgesics and NSAIDs. DILI is a multi-
factorial disease that can be influenced by host factors including age, sex, nutrition, other 
drugs (including alcohol), underlying illness, and genetics.  The manifestation of DILI in the 
clinic is diverse, even for the same drug. Drugs can cause a variety of pathologies including 
subtle asymptomatic rises in circulating aminotransferase levels, acute fatty liver, cirrhosis 
and in rare cases fulminent liver failure (Tujios et al, 2011). Despite a rich literature of 
evidence, the causal mechanisms behind which drugs cause DILI are poorly defined. Even 
for model hepatotoxins, such as APAP, which encompasses a huge body of work, the 
proposed mechanisms of toxicity are controversial and remain poorly understood. This 
paradox has been attributed to the lack of diagnostic biomarkers, poor translational ability in 
pre-clinical models and unsuitable in vitro models that poorly reflect in vivo conditions.   
Nevertheless, one of the major advances in molecular toxicology was the establishing the 
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association between drug metabolism, chemically reactive metabolites and the initiation of 
hepatotoxicity (for review, see Kaplowitz, 2005; Park et al, 2005). 
1.3.1 The role of drug metabolism in DILI 
The liver is a multicellular and multifunctional organ, as well as being the major site of drug 
metabolism in the body. The liver receives 30 % of the resting cardiac output, 75 % of which 
reaches the liver direct from the gastrointestinal organs providing the liver with a substantial 
exposure to potentially toxic species ingested through the diet. Regardless of the dosing 
route, the liver is responsible for the biotransformation of most xenobiotics. The liver 
probably gained its repertoire of drug-metabolism pathways throughout evolution as a means 
to detoxify noxious components in the diet (Gonzalez and Gelboin, 1993). Broadly speaking, 
the physiological role of the liver is to convert lipophilic compounds into more hydrophilic 
species in order to facilitate drug clearance from the body, and expunge pharmacological 
activity. The drug metabolism systems between mammals are relatively well conserved 
which allows many drugs to be investigated in clinically-relevant animal models. The 
mammalian drug metabolism system is comprised, traditionally, of three phases; phase I, 
phase II and phase III drug metabolism. The role of each phase is briefly explained in table 1 
below. N.B. Phase I metabolism does not necessarily always preclude phase II metabolism; 
however both of these phases are often required for the conjugation of large polar groups to 
a xenobiotic. 
Table 1: The basic role of phase I, phase II and phase III drug metabolism 
Drug Metabolism Phase Role 
Phase I Small chemical modifications, reveals functional groups 
Phase II Conjugation reactions, vastly increases hydrophilicity  
Phase III Transportation of suitable substrates, e.g. at cell membranes 
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1.3.2. Phase I drug metabolism 
Phase I drug metabolism encompasses oxidation, reduction and hydrolysis reactions to 
substrates which reveal functional groups, usually a hydroxide, an amine or a carboxylic 
acid. These relatively reactive functional groups allow the conjugation of large polar 
moieties to a drug by phase II drug metabolising systems (for review, see Gibson & Skett, 
2001). The major components of the phase I drug metabolising system include the 
cytochrome P450 (CYP450) enzymes, flavin-containing monooxygenases (FMOs), alcohol 
dehyrogenases and epoxide hydrolases, amongst others (Testa et al, 2012). The most 
functionally- and clinically-important group are the CYP450 enzymes, which contribute 
approximately 75% of phase I metabolism to drugs (Ingelman-Sundberg, 2002). The 
CYP450 superfamily (so called, because of the unique spectral absorbance peak of 450 nm 
when bound to carbon monoxide) are a diverse class of metabolising enzymes found 
throughout nature. Humans have approximately 59 active CYP genes, many of which are 
important in the metabolism of endogenous sterols, vitamins and fatty acids (Guengerich, 
2006). However, in man, the majority of xenobiotics are metabolised by eight genes; 
CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP3A5 which 
exhibit different substrate specificities, tissue localisation, zonal expression, and abundance 
in the liver. The characteristics of clinically-important CYP enzymes are summarised in 
table 2. The activity of CYP isoenzymes can differ between individuals, either due to 
different basal levels of expression, or the presence of single nucleotide polymorphisms 
(SNPs) within certain CYP genes which can affect CYP function. This variation explains 
how individuals may respond differently to drugs, as metabolism can affect 
pharmacokinetics, pharmacodynamics and drug-related toxicity. 
The role of phase I metabolism is to reveal functional groups on a xenobiotic for further 
biotransformation and detoxication. However, in some cases, this metabolic process 
generates a more chemically-reactive species. These chemically-reactive metabolites 
(CRMs) may be reactive to nucleophilic intracellular targets such as proteins, RNA and 
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DNA, which may induce toxicity. Covalent binding to cellular proteins is considered an 
important step in the progression of liver injury for many drugs. The individual target 
proteins which CRMs can bind may influence the outcome of toxicity, i.e. the balance 
between critical protein vs non-critical protein modification may be a predictor for the 
outcome of DILI (Park et al, 2005). Carbon tetrachloride, an industrial solvent and potent  
Table 2: Characteristics of eight human CYP genes involved in phase I drug metabolism 
(adapted from Danielson et al, 2002) 
CYP Gene Substrate type Tissue Localisation Typical Drug Substrates 
CYP1A2 Aromatics, Amines, 
Pre-carcinogens 
Hepatic caffeine, naproxen  
CYP2B6 Xenobiotics Hepatic bupropion 
CYP2C9 Xenobiotics Hepatic ibuprofen, fluoxetine 
CYP2C19 Xenobiotics Hepatic lansoprazole, diazepam 
CYP2D6 Xenobiotics Hepatic alprenolol, codeine 
CYP2E1 Solvents, xenobiotics, 
pre-carcinogens 
Hepatic ethanol, APAP 
CYP3A4 Xenobiotics, hormones, 
dietary components 
Hepatic, intestinal lidocaine, hydrocortisone, 
codeine, 
CYP 3A5 Xenobiotics, hormones, 
dietary components 
Hepatic, intestinal lidocaine, hydrocortisone, 
codeine, 
  
hepatotoxin, has been shown to form free radicals mediated by CYP2E1 metabolism 
(Guengerich et al, 1991). Free radicals are recognized cellular stressors that can induce 
oxidative stress and mediate cell death. However, CRMs can induce cell death via several 
different mechanisms including oxidative/nitrative stress, apoptosis, necrosis and 
carcinogenesis and activation of the innate/adaptive immune system. The likelihood of a 
compound to generate a reactive metabolite is a function of its chemistry. Structural alerts 
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are now recognised as potential toxicophores, such as quinones, epoxides and thiophenes, 
which can inform the medicinal chemist to design safer NCEs in an iterative process.  CRMs 
are short-lived species, and difficult to detect in the circulation, and therefore difficult to 
quantify in man. CRMs, usually electrophiles, remain in the cell where they react to cellular 
components, typically electron-rich moieties such as thiol groups on cysteine residues. 
Xenobiotics that are associated with the production of chemically reactive metabolites 
include APAP (Hinson et al, 1981), FS (Mitchell et al, 1976) and bromobenzene (Jollow et 
al, 1974). These compounds can be used as training compounds to understand the role of 
phase I bioactivation in hepatotoxicity in animal models through enzyme induction, enzyme 
inhibition or gene manipulation studies. Therefore, phase I metabolism can be considered, 
for many compounds, an integral step in the detoxication and inadvertent initiation of DILI. 
1.3.2. Phase II drug metabolism 
The phase II drug metabolising systems involve conjugation of large molecular weight 
species, to increase the polarity and hydrophilicity of xenobiotics. Phase II drug metabolism 
can be extremely cytoprotective, and can nullify the toxic capacity of a hepatotoxin and a 
CRM. Phase I and Phase II drug metabolising systems can work in isolation but can also 
provide tightly coupled detoxication pathways for drugs. This explains why not all drugs 
that form reactive metabolites cause hepatotoxicity.  At therapeutic doses of APAP, the 
major clearance pathways involve phase II glucuronidation (the addition of glucuronic acid 
to a substrate) and sulfation (the addition of a sulphate residue to a substrate) mechanisms, 
which yield non-toxic metabolites. However, a minor proportion of the dose is bioactivated 
by phase I metabolism (via CYP2E1) to form small quantities of n-acetyl-p-
benzoquinoneimine (NAPQI), a protein-reactive electrophile. This potentially toxic species 
is rapidly bioinactivated by glutathione (GSH) conjugation, mediated in part by glutathione-
S-transfereases (GSTs), thereby inhibiting the toxic capacity of NAPQI (Henderson et al, 
2000). Due to the large intracellular stores of GSH in the hepatocyte, APAP is an extremely 
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safe drug when administered at therapeutic doses. Phase II drug metabolism involves a 
diverse panel of enzymes and substrates which have been summarised in table 3. 
With respect to DILI, one of the most important detoxication processes against hepatotoxins, 
CRMs, and oxidative stress in general is GSH conjugation. GSH is a ubiquitous tripeptide 
 
Table 3: Characteristics of common phase II drug metabolism reactions 
Reaction Enzyme Substrate 
Glucuronidation UDP-
glucuronosyltransfereases 
UDP-glucuronic acid 
(UDPGA) 
Sulfation Sulphotransferase 3’phosphoadenosine-5-
phosphosulphase (PAPS) 
Methylation Methyltransferase S-adenosylmethionine 
(SAM) 
Acetylation Acetyltransferase acetyl coenzymeA 
Amino acid conjugation CoA ligase glycine, glutamine, 
ornithine, arginine, taurine 
Glutathione conjugation Glutathione-S-transferase / 
sponteaneous 
glutathione 
Fatty acid conjugation  stearic acid, palmitic acid 
 
comprising glycine, cysteine and glutamate residues, and is the most abundant non-protein 
thiol in the hepatocyte (approximately 5-10 mM) (Lu, 1999). GSH is mainly cytosolic, but 
high concentrations are also found in the mitochondria. GSH is an essential antioxidant in its 
own right, maintaining cytocellular redox homeostasis and scavenging free radicals 
generated from endogenous metabolic processes.  However, due to the thiol moiety on the 
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cysteine residue, it exhibits substantial nucleophilic potential, which afford GSH its 
protective capacity against reactive species formed during drug metabolism. GSH can form 
conjugates spontaneously, or can be mediated by the GSTs (Meister et al, 1988). Many 
glutathione conjugates are cleaved by ɣ-glutamyltranspeptidase (GGT) and then dipeptidase 
to generate a cysteinyl conjugate (Lu, 1999). The cysteinyl conjugate can then be N-
acetylated to form the resultant non-toxic mercapturic acid for urinary or biliary excretion. 
GSH synthesis is a two-step active process involving the conjugation of its constituent 
amino acids. An absolute prerequisite for GSH synthesis is the conversion of the essential 
amino acid methionine to cysteine via the transsulfuration pathway. In clinical situations, the 
hepatic pool of glutathione can be repleted by administering methionine, or more commonly 
N-acetylcysteine (NAC), which both provide the requisite donor amino acids for rapid GSH 
synthesis. The first synthetic, rate-limiting step involves the active conjugation of L-
glutamate and L-cysteine to form ɣ-glutamylcysteine via the enzyme, glutamate-cysteine 
ligase (GCL; glutamylcysteine synthetase, GCS). This heterodimeric enzyme consists of a 
heavy catalytic unit (GCLC; 73,000 kDa) and a lighter modifying unit (GCLM; 30,000 kDa) 
which are encoded by separate genes in rodents and humans (Yan & Meister, 1990, Gipp et 
al, 1992). The second active step involves the rapid conversion of ɣ-glutamylcysteine with 
L-glycine by GSH synthetase to form the mature GSH tripeptide. Reduced GSH is the 
predominant form in the cell which when oxidised, forms a disulphide bond with another 
GSH molecule to form GSSG. The ratio of GSH to GSSG has been estimated to be 
approximately 10:1 in the cytosol and mitochondria (Meredith & Reed, 1982; Meister et al, 
1988). 
GSH depletion is considered a hallmark of DILI as many hepatotoxins, but not all, have 
been associated with substantial loss of hepatocellular GSH during injury (APAP: Davis et 
al, 1974, 1,-dichloroethylene: Dowsley et al, 1995, ethanol: Guerri et al, 1980, Randle et al, 
2008). The hepatic capacity to conjugate GSH to hepatotoxins can reflect the detoxication 
potential of the liver. Mice are much more resistant to aflatoxin B1 compared to rats and 
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humans which is associated with the enhanced ability to detoxify the epoxide metabolite by 
GST-mediated GSH conjugation (Hengstler et al, 1999). GSH has been shown to be induced 
after APAP (Goldring et al, 2004) and methapyriline (Mercer et al, 2009) exposure. This 
induction, associated with increased cell defence protects against subsequent exposure to the 
drug (Shayiq,et al, 1999; Aleksunes et al, 2008,). More recently, this adaptive protection can 
be afforded by treatment with novel semi-synthetic triterpenoids (2-cyano-3,12 dioxooleana-
1,9 diene-28-imidazolide, CDDO-Im) at relatively low doses (1 mg/kg) against toxic doses 
of APAP in mice (Reisman et al, 2009).  This is a classic example of cellular adaptation to 
drug-induced stress. 
1.3.2. Phase III drug metabolism 
As discussed, the role of the liver is to detoxify noxious species, including drugs, from 
active lipophilic molecules into more hydrophilic, non-toxic species, whilst concomitantly 
expunging pharmacological activity. This process will ultimately facilitate the clearance of 
the drug. Glucuronides, sulphates and glutathione conjugate metabolites are often  substrates 
for transporters, a class of membrane bound proteins that represent members of the phase III 
drug metabolising system. Although phase III drug metabolism doesn’t account for a 
chemical modification to the drug itself, it has an important role in the ultimate disposition 
and clearance of the drug. Phase III transporters can be broadly classified into two groups; 
solute carriers and ABC transporter superfamilies. These are summarised in table 4. 
Table 4: Members of two classes of phase III transporter proteins 
Solute Carriers ABC transporters 
Organic anion transporters (OATs) Multi-drug resistance protein (MRP) 
Organic cation transporters (OCTs) Breast cancer resistance protein (BCRP) 
 Bile salt export pump (BSEP) 
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The MRP class of transporters are important during APAP metabolism in toxicity. It has 
been shown that MRP3 and MRP4 are implicated in the efflux of APAP metabolites 
including the glutathione-conjugate from hepatocytes (Zamek-Gliszczynski et al, 2006, 
Aleksunes et al, 2008). Furthermore, in mice, MRP3 and MRP 4 are upregulated after a 
toxic dose of APAP by the nrf2-keap1 cell defence system (Aleksunes et al, 2008). Drug-
induced cholestasis is a feature of perturbed phase III drug metabolism, in which cytotoxic 
bile acids are retained in the liver which can cause both acute and chronic liver injury. 
Clinical markers of drug-induced cholestasis include elevations in circulating bilirubin and 
alkaline phosphatase (ALP) (Stapelbroek et al, 2010). Many drugs that are associated with 
drug-induced cholestasis are substrates for transporters, examples include rifampicin-
mediated BSEP inhibition. Transporters are also subject to genetic variation which might 
predispose individuals to drug-induced cholestasis or liver disease in general (Lang et al, 
2007). Clearly, phase III metabolism is an important contributing factor in both the 
detoxication and the potential pathophysiology of DILI.  
 
1.4. APAP-INDUCED ACUTE LIVER INJURY (APAP-induced ALI) 
APAP is a widely-available, over the counter analgesic that has provided effective pain 
relief for six decades. APAP is available in single formulation or coformulation with other 
drugs, e.g. codeine or phenylephrine. APAP is well tolerated at therapeutic doses (4g/day) in 
the general population, despite reports of subtle asymptomatic rises in circulating ALTs 
(Watkins et al, 2006) at this dose. However, when the therapeutic dose is exceeded, APAP 
can cause severe centrilobular liver necrosis and potentially fatal liver failure. APAP is the 
leading cause of liver failure in the United States, accounting for 56,000 emergency room 
visits, 2,600 hospitalisations and approximately 500 deaths per annum (Lee, 2004). This 
equates to almost 50 % of the annual cases of liver failure in the United States (Lee, 2008). 
Despite a UK legislation to restrict pack sizes of APAP, from 16 g to 8 g per pack, the rate 
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of APAP-related deaths remain unchanged (Bateman, 2009). Most APAP overdose patients 
survive, due to rapid antidotal treatment in hospital with N-acetylcystine. However, a small 
percentage (usually < 10 %) of patients will succumb to their illness. Two major factors 
dictate the severity of liver injury; the ingested dose of APAP, and time from ingestion to 
treatment. APAP overdose patients can be stratified into two groups; those who intentionally 
overdose (i.e. suicide attempt) and those who unintentionally overdose (Larson et al, 2005). 
Paradoxically, patients who intentionally overdose are usually at lower risk, and have a good 
prognosis. This can be attributed to the fact that most intentional overdose patients ingest 
one large single dose of APAP and are treated within 4 hours of ingestion (Schiødt et al, 
1997). In the same study, it was found that only 20% of patients who intentionally overdose 
ever exhibited an ALT activity over 1,000 U/L. Conversely, unintentional overdose patients 
are associated with high risk and poor prognosis (Shayiq et al, 1999). This group of patients 
usually present with staggered APAP ingestion that has occurred over several days, when 
the process of liver injury may have already initiated. Other factors can affect patient 
susceptibility, including serious cases of hepatotoxicity from therapeutic doses of APAP in 
chronic alcoholics (Rex & Kumar, 1992). Patients who have recently fasted or who are 
malnurished, e.g. due to dental pain, are also at higher risk of developing APAP-induced 
ALI (Whitcomb et al, 1994). Drug-drug interactions have also been reported to influence the 
risk of APAP-induced ALI in patients who are concomitantly taking isoniazid or rifampacin 
(Murphy et al, 1990; Nolan et al, 1994). 
 
1.4.1. Molecular toxicology of APAP-induced ALI 
APAP has a superb safety profile at therapeutic doses. However, at supratherapeutic doses, 
APAP has the propensity to elicit liver injury which could lead to potentially fatal liver 
failure. The pathophysiology of APAP-induced hepatotoxicity is strikingly similar between 
man and rodent. This has led to a substantial body of work which has set about 
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characterising the molecular events that lead to APAP-induced hepatotoxicity. Despite 
significant progress over the past four decades in the understanding of APAP-induced ALI, 
many aspects remain controversial or unknown. At therapeutic doses of APAP, the large 
majority of the dose is directly modified by phase II metabolising systems. Approximately 
50% of the dose is glucuronidated by several members of UGTs to form a stable non-toxic 
metabolite whilst a smaller proportion, approximately 30%, is sulphated by members of the 
SULT enzymes (Schenker et al, 2001). These metabolites can be detected in serum and are 
excreted in the urine alongside a small proportion of parent drug and other minor 
metabolites. A small but significant proportion of the therapeutic dose (5-15%) undergoes 
oxidative metabolism via CYP2E1 (and to a lesser extent by CYP1A2 and CYP3A4) (Patten 
et al, 1993; Thummel et al, 1993; Chen at al 1998). This oxidative metabolism yields a 
reactive electrophilic intermediate, NAPQI, which has the propensity to bind 
macromolecular components of the cell and elicit toxicity. However, due to the relatively 
low abundance of NAPQI at therapeutic doses of APAP and the vast intracellular stores of 
GSH, this potentially toxic metabolite is rapidly bioinactivated by GSH. NAPQI, an 
electrophile, can independently bind to the nucleophilic thiol group on the cysteine residue 
of GSH, however GST π has been shown to catalyse this reaction in vitro (Coles et al, 1988). 
GSH conjugates are then biotransformed into stable non-toxic cysteinyl conjugates or 
mercapturic acids which are then eliminated in the urine. 
In an overdose setting, the two major routes of metabolism, glucuronidation and sulfation, 
become overwhelmed. In particular, the sulfation pathway is a low capacity system and the 
maximal rate of sulfation is exceeded in APAP overdose. In this case, oxidative metabolism 
bioactivates a greater proportion of the dose and relatively large quantities of NAPQI can be 
formed. CYP2E1 has been shown to be the predominant CYP isoform responsible for 
NAPQI formation and is certainly the most clinically relevant in APAP-induced ALI. The 
CYP2E1 enzyme has a wide but unique substrate specificity, as it is responsible for the 
metabolism of flat planar molecules, including many solvents and industrial chemicals such 
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as benzene, ethylene glycol, and vinyl chloride. CYP2E1 also catalyses the turnover of many 
endogenous metabolic by-products, such as acetone. It is also primarily responsible for the 
conversion of ethanol to acetaldehyde. Coadministration of ethanol with APAP is common 
and can cause increased uncertainty as to the prognosis of overdosed patients. The 
relationship between ethanol and APAP coadministration is complex; acute and chronic 
alcohol ingestion may have opposing effects. A large single dose of ethanol may 
paradoxically protect the liver from APAP-induced ALI by competing for the CYP2E1 
active site. However, chronic administration of ethanol causes CYP2E1 induction as has 
been shown in rodent models (Roberts et al, 1995) which increases the capacity for NAPQI 
formation. Alcoholics are also considered to be particularly sensitive to APAP-induced ALI 
where cases of liver injury have been reported even at therapeutic doses of APAP. Work 
from the Gonzalez lab showed the importance of CYP2E1 in APAP-induced ALI when 
CYP2E1-deficient mice were found to be more resistant after APAP exposure (Lee et al, 
1996). This study found that at a dose of 400 mg/kg of APAP, 50% of wild-type mice died 
(LD50) whereas all CYP2E1-deficient mice survived an exhibited normal circulating 
transaminase activity. However, CYP2E1-deficient mice were not entirely resistant as the 
highest dose caused aminotransferase elevations suggesting other enzymes may be 
implicated in NAPQI formation.  In accordance with the mechanism of bioactivation, 
several studies have shown the importance of CYP2E1 in APAP-induced liver injury by 
using a panel of CYP2E1 inducers and inhibitors. The susceptibility of animals to APAP-
induced ALI was increased by prior administration of CYP2E1 inducers such as 
phenobarbitone and 3-methylcholanthrene. Furthermore, protection to APAP-induced ALI is 
afforded after pre-dosing with CYP2E1 inhibitors such as piperonyl butoxide, 4-
methylpyrazole and acute ethanol exposure (Mitchell et al, 1974; Jollow et al, 1974; 
Thummel et al, 1989). Even after large doses, the intracellular pools of GSH prevent toxicity 
by sequestering large quantities of NAPQI for elimination. However, intracellular GSH 
stores are finite and if the dose of APAP is sufficiently large, GSH can be depleted and 
NAPQI can target alternative intracellular proteins. It is estimated that > 90% GSH depletion  
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Figure 1: Metabolism and bioactivation of APAP.  
The major pathways of activation include glucuronidation (~50%) and sulphation (~30%) 
pathways. These non-toxic metabolites are elimatied in the urine. However, a small proportion of 
the overall dose is bioactivated through oxidative metabolism by several CYP enzymes to yield an 
electrophilic protein-reactive metabolite. Large intracellular stores of GSH sequester and 
bioinactative the potentially toxic metabolite. In overdose settings, the GSH pool is exhausted and 
toxicity results via protein arylation and oxidative stress. 
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is required before APAP can form protein adducts and initiate toxicity (Mitchell et al, 1974). 
The mechanism of APAP metabolism and bioactivation is summarised in Fig 1.  
The causal molecular mechanisms which bring about hepatocyte death after a toxic exposure 
to APAP remain controversial and poorly understood. Two theories that themselves are not 
mutually exclusive include protein binding and generation of secondary reactive oxygen 
species. After GSH depletion, which is a prerequisite step in the progression of APAP-
induced ALI, the first contact between the molecule and the cell occurs during protein 
binding. NAPQI, an electrophile, can covalently bind to nucleophilic components in the cell, 
particularly lysine or cysteine residues on proteins. The propensity of a compound to 
covalently bind to proteins does not always determine toxic outcome. Rather, it is the 
specific spectrum of proteins that are irreversibly modified which induces a series of 
molecular events that results in cell death, i.e. the critical protein hypothesis. Several studies 
have identified a list of proteins which become modified during APAP-induced ALI 
providing a chemical ‘fingerprint’ of adducts. 
 
1.4.2. NAPQI and critical protein modification 
One postulated mechanism of cell death is NAPQI-mediated covalent modification of key 
proteins in the hepatocyte. Upon forming the NAPQI-protein complex, the target protein 
function is irreversibly corrupted thereby shifting cell homeostasis and impairing cell 
defence systems. Work in the Mitchell lab first identified an APAP-modified cell membrane 
protein, plasma membrane Ca
2+
 ATPase (PMCA) (Tsokos-Kuhn et al, 1985). They reported 
a 76% reduction in vesicular Ca
2+
 accumulation caused after a toxic APAP dose in rats. Ca
2+ 
dysregulation is considered a hallmark of APAP-induced ALI. Nelson and colleagues 
identified that mitochondrial proteins form a disproportionate amount of covalent adducts 
with APAP compared to the regioisomer AMAP (N-acetyl-3-hydroxy-aminophenol), which 
is approximately 10-fold less toxic (Holme et al, 1991; Tirmenstein & Nelson, 1991). 
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Corcoran and colleagues also reported early inhibition of Na+/K+ ATP ion pump 3 hours 
after APAP exposure in the rat (Corcoran et al, 1987) which they concluded may contribute 
to the pathogenesis of APAP-induced ALI. Cohen and Khairallah stated that APAP-
modified proteins appear to be specific and not necessarily the most abundant hepatocellular 
proteins (Cohen & Khairallah, 1997). Their group published a number of papers isolating 
and identifying individual APAP-modified proteins including cytosolic targets such as 
selenium binding protein and N-10-THF-formyl dehydrogenase (Bartolone et al, 1992), 
microsomal glutamine synthetase (Bulera et al, 1995) and mitochondrial aldehyde 
dehyrogenase (Landin et al, 1996). Subsequently, Qiu and colleagues used a more global 
approach to identify APAP-modified proteins using two-dimensional electrophoresis 
coupled with mass spectrometric identification (Qiu et al, 1998). This method complemented 
previous work by confirming previously-identified adducts whilst revealing novel adducts 
such as GSH peroxidise, GSTπ and ATP synthetase (α subunit); important cell-defence 
enzymes. Overall thirty modified proteins were identified, six of which were mitochondrial. 
Abrogation of GSH peroxidase and ATP synthetase has functional consequences; GSH 
peroxidise provides antioxidant activity by sequestering hydrogen peroxide (H2O2), a potent 
oxidative stressor. ATP synthetase is critical in maintaining energy homeostasis which is 
known to be dysregulated in APAP-induced ALI. Substantial protein modification in the 
mitochondria suggests that APAP-induced hepatotoxicity is mediated, at least in part, 
through abrogation of mitochondrial function and therefore disruption to ATP homeostasis, 
increased oxidative stress and enhanced Ca
2+
 dysregulation. 
1.4.3. APAP and oxidative/nitrative stress: propagation of liver injury 
A competing hypothesis to the critical protein hypothesis was that APAP triggered 
substantial oxidative stress in the hepatocyte (Wendel et al, 1979). Whilst protein 
modification is an obligatory event for toxicity to occur, alone it is not sufficient to provoke 
cell death directly (Jaeschke et al, 2012). There is also a poor correlation with protein 
binding and provocation of liver injury as has been demonstrated with AMAP. Despite that, 
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protein binding with APAP appears to be a targeted phenomenon. It was reported that 
modified mitochondrial proteins associate with increased oxidative stress and enhanced 
toxicity in APAP-induced ALI (Jaeschke et al, 2003). The mitochondrion is a vital organelle 
responsible for ATP production, cell signalling and cellular metabolism. Many drugs, 
including APAP, are known to interfere with mitochondrial signalling and induce toxicity 
through a number of mechanisms (Labbe et al, 2008). In the mitochondria, superoxide can 
react with nitric oxide (NO) to form peroxynitrite (ONOO
-
), a potent oxidative and oxidative 
species (Denicola & Radi, 2005). Normally, peroxynitrite is scavenged by GSH via GSH 
peroxidise, however NAPQI has not only been found to modify GSH peroxidise directly, but 
also deplete cellular GSH (including mitochondrial GSH). In an oxidative environment, such 
as that found in APAP-induced ALI, peroxynitrite is highly toxic. Peroxynitrite can induce 
oxidative stress and can oxidise a wide range of intracellular targets, including lipids 
(Rubbo, 1998), proteins and DNA bases (Pryor & Squadrito, 1995). Furthermore, a hallmark 
of APAP-induced liver injury is the formation of nitrotyrosine protein adducts, which 
disproportionately occur in the mitochondria. Nitrotyrosine modification occurs through the 
reaction of peroxynitrite (ONOO
-
) and tyrosine residues on target proteins. One such protein 
that becomes nitrated is manganese superoxide dismutase (MnSOD) which is actually 
involved in clearing superoxide and therefore prevents peroxynitrite formation (Agarwal et 
al, 2011). Heterozygous MnSOD (+/-) mice were more susceptible to APAP-induced ALI 
highlighting the importance of this enzyme in APAP hepatotoxicity (Fujimoto et al, 2009, 
Ramachandran et al, 2011). Upon nitration, MnSOD loses activity which thus potentiates the 
oxidative/nitrative burden in the mitochondria and exaggerates dysfunction. The important 
role of nitrative stress in APAP-induced ALI was exemplified by Ishida and colleagues who 
reduced serum ALT activity  8-fold in mice by administering a nitric oxide synthetase 
inhibitor, N-(G)-nitro-L-arginine methyl ester (L-NAME) or almost 70-fold using a nitric 
oxide scavenger 2-phenyl-4,4,5,5,-tetramethylimidazoline-1-oxyl-3-oxide (PTIO) (Ishida et 
al, 2002). 
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The consequences of prolonged oxidative/nitrative stress in the mitochondria lead to 
increased dysfunction culminating in opening of the mitochondrial membrane permeability 
transition MPT which causes collapse of the mitochondrial membrane potential and 
therefore abolition of ATP generation. Furthermore, Ca
2+
 homeostasis is perturbed and the 
mitochondria release injurious factors which can promote apoptosis or necrosis. MPT occurs 
after GSH depletion and oxidative/nitrative stress but before necrotic cell death (Bajt et al, 
2004). Although many pro-apoptotic species are released from the mitochondria during 
APAP-induced ALI, such as cytochrome c, the massive bioenergetic catastrophe and 
oxidative environment results in a muted apoptotic response in vivo (Lawson et al, 1999). 
Furthermore, inhibition of caspases, the ‘executioners’ of apoptotic cell death, do not protect 
against APAP-induced ALI (Gujral et al, 2002). One report did show that protection could 
be afforded by a pan-caspase inhibitor (El-Hassan et al, 2003), however, Jaeschke and 
colleagues refuted this finding by suggesting the vehicle used (dimethylsulphoxide, DMSO) 
had inhibited APAP bioactivation (Jaeschke et al, 2006). It is generally accepted that the 
final form of cell death is via necrosis in animals and in man. Nevertheless, Antoine and 
colleagues in the CDSS showed that circulated caspase-cleaved cytokeratin-18 is evident in 
mouse models of APAP-induced ALI (Antoine et al, 2009). Although a caspase inhibitor 
prevented the cleaved metabolite being formed, it did not protect against overall injury. This 
suggests that the hepatocyte becomes primed for apoptosis during APAP-induced ALI, but 
cannot perform the energy-dependent process of apoptosis. Therefore, cell death occurs via 
necrosis due to massive oxidative and nitrative stress and ATP depletion. 
1.4.4. APAP-induced ALI modulatory factors  
As discussed, APAP bioactivation, GSH reduction, protein binding and mitochondrial 
dysfunction are all pre-requisite steps in the evolution of APAP-induced ALI. However, 
APAP toxicity is not a disease limited to the hepatocyte. The liver is largely comprised of 
hepatocytes, which make up approximately 80% of the cells. However, other cell types are 
found in the liver which have been shown to contribute to the progression of APAP induced 
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ALI. Kupffer cells, around 5% of liver cells, are specialised hepatic macrophages which are 
important in the innate immune response. Kupffer cell activation is associated with cytokine 
and chemokine release, which can provide both anti-inflammatory (protective) and pro-
inflammatory signals (injurious) to dying hepatocytes. The injurious role of Kupffer cells 
was first identified by Laskin and colleagues when they reported that pre-treatment with 
gadolinium chloride (GdCl3), a Kupffer cell inactivator, protected against APAP-induced 
ALI in rats (Laskin et al, 1995) and mice (Michael et al, 1999). Conversely, it was later 
shown that using clodronate-conjugated liposomes, which deplete Kupffer cells more 
efficiently than GdCl3, caused increased injury after APAP exposure (Ju et al, 2002) due to 
removal of IL-10 and other protective factors. Conflicting studies like this highlight the 
difficulty in examining the roles of inflammatory mediators in toxicity studies. Nevertheless, 
Kupffer cells and other immune cells are recognised as cellular reservoirs of inflammatory 
signalling molecules which may be implicated in the progression of DILI. Clearly there is an 
important balance between pro- and anti-inflammatory signals has been shown in a variety 
of rodent models of APAP-induced ALI . Table 5 summarises various models that have been 
utilised to gain mechanistic understanding and to highlight the significance of different 
factors in the progression of APAP-induced ALI. 
Clearly, the roles of inflammatory mediators are important in the late stages of liver injury. 
The anti-inflammatory interleukin factor, IL-10 appears to be very important in reducing the 
progression of liver damage, and allowing healing and regeneration of hepatocytes (Bourdi 
et al, 2002). However, TNFα and IFNɣ promote inflammation and provoke leukocyte 
infiltration to the damaged area, most notably neutrophils and macrophages. Ishida noted 
that hepatic IFNɣ levels correlated with severity of APAP-induced ALI in mice (Ishida et al, 
2002). Administration of an anti-IFNɣ antibody could reduce both circulating transaminase 
levels and histological changes. The same group reported similar findings with TNFα, with 
TNF receptor deficient mice more resistant to APAP-induced ALI than wild type mice 
(Ishida et al, 2004). In parallel with IFNɣ, protection could be afforded with post-
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administration of an anti-TNF antibody. These studies not only provide mechanistic insight 
but also highlight potential candidate species in order to develop new medicines to protect  
Table 5: A summary of genetic manipulation or targeted cell depletion studies to gain better 
understanding of the role of different factors which influence APAP hepatotoxicity. 
Abbreviations: IL, interleukin; TNF, tumour necrosis factor; MIF, macrophage migration 
inhibitory factor; ASK-1, apoptosis signal-regulating kinase-1; nrf-2, nuclear factor 
erythroid 2-related factor; COX-2, cyclooxygenase 2, CCR2, C-C motif chemokine receptor 
2. 
Protective models Enhanced injury models 
Experimental model Reference Experimental model Reference 
Cyp2e1 
(-/-)
 Lee et al, 1996 GSH depletion Jollow et al, 1973 
Gstπ (-/-) Henderson et al, 2000 nrf2 (-/-) Enomoto et al, 
2001 
IL-1 
(-/-)
 Blazka et al, 1996 IL-6 
(-/-)
 Masubuchi et al, 
2003 
IL-6 administration Masubuchi et al, 
2003 
IL-10 
(-/-)
 Bourdi et al, 
2002a 
IL-10 and MIP2 
administration 
Bone-Larson et al, 
2001, Hogaboam et 
al, 1999a, Hogaboam 
et al, 1999b 
COX-2 
(-/-)
 Reilly et al, 2001 
anti-TNF-α ab, 
TNF-R  
(-/-)
 
Ishida et al, 2004 CCR2 
(-/-)
 Hogaboam et al 
2000 
anti-IFN ɣ ab 
IFN-ɣ (-/-) 
Ishida et al, 2002 JNK2 
(-/-)
 Bourdi et al, 2008 
MIF  
(-/-)
 Bourdi et al , 2002b Kupffer Cell depletion 
(liposome/clodronate) 
Ju et al, 2002 
ASK-1 
(-/-)
 Nakagawa et al, 2008   
NO inhibition Ishida et al, 2002   
VEGF 
administration 
Donahower et al, 
2010 
  
TLR4 
(-/-)
 Yohe et al, 2006   
CAR 
(-/-)
 Zhang, 2002   
Kupffer Cell 
depletion, 
(gadolinium 
chloride) 
Laskin, 1995   
 
against the progression of APAP-induced ALI in the clinic, which has extremely limited 
therapeutic options. The key point here is that the balance between pro- and anti-
inflammatory signals from outside the hepatocyte may influence the progression and 
outcome of APAP-induced ALI. 
  Chapter One
27 
 
1.4.4. Clinical manifestation of APAP-induced ALI 
APAP-induced ALI is a short intense illness which can provoke ALF and death if the 
appropriate therapy is not provided at the appropriate time. As discussed, APAP is 
responsible for the majority of ALF cases in the western world resulting in approximately 
500 deaths a year in the United States (Lee, 2004). Whilst APAP causes severe 
hepatotoxicity, less common cases of acute renal failure have also been reported (Jeffery & 
Lafferty, 1981). Early recognition of APAP overdose and liver injury by the physician are 
essential to reduce the risk of morbidity or mortality. The clinical manifestations of APAP-
induced ALI can be grouped into four stages (Rumack et al, 1981). Stage I APAP toxicity 
describes the events before liver injury has occurred; typically in the first 12 hours after drug 
ingestion. Usually, patients may present non-specific symptoms typified by vomiting, 
nausea, and general malaise. Even in patients who have taken huge doses of APAP, there 
may be an absence of direct liver-related symptoms and clinical chemistry markers provide 
normal readings at this stage. In stage II toxicity, between 12-36 hours, the onset of early 
liver injury has occurred. APAP-induced ALI usually mimics hepatocellular diseases such as 
hepatitis. The symptoms of APAP-induced ALI will vary depending on the severity of injury 
but are typified by upper-right quadrant pain with continued general malaise. During this 
stage, the earliest biochemical indices can identify the occurrence of liver injury. Alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) are the current gold standard 
biomarkers of liver injury that are currently widely employed in the clinic. They are 
relatively sensitive and specific markers for liver injury that precede the liver function 
abnormality markers, such as bilirubin or prothrombin time. Stage III toxicity (48-72 hours 
after drug ingestion) includes time of peak hepatotoxicity. At this stage, the liver degenerates 
further from an injured state into late-stage liver failure. Whilst ALT and AST are useful 
biomarkers to detect injury, they are poor at correlating outcome. Even very high ALT and 
AST readings (>10,000 U/L) do not always associate with liver failure. The best clinical 
markers of liver function at this stage are serum albumin levels, prothrombin time (clotting 
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tendency), bilirubin, glucose, lactate and phosphate concentrations, which are all useful 
determinants of liver failure and prognosis. Extra-hepatic toxic manifestations such as coma 
(encephalopathy), haemorrhage, hypotension and tachycardia also occur at this stage. Death 
is most likely to occur at this point, around 4 days after initial drug ingestion, most 
commonly due to complications arising from multi-organ failure which is commonly 
manifested by respiratory stress, sepsis or cerebral edema. Patients who spontaneously 
survive, enter phase IV recovery. The liver has the unique ability to regenerate and whilst 
recovery rates vary, most patients recover 5-7 days after initial overdose. Remarkably, 
survivors are unlikely to suffer any chronic hepatic dysfunction despite the massive 
chemical insult to the organ. 
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1.4.4. Assessing risk and clinical triage  
With such a rapid progression of toxicity, it is essential that the physician can provide 
therapy as soon as possible to ‘at risk’ patients. Whilst deaths due to overdoses of APAP do 
occur, in many cases they can be prevented by antidotal NAC therapy. However, many 
APAP overdose patients are not at risk of developing liver injury at any time. Therefore an 
approach is necessary to avoid the huge cost and strain on clinical resource of unnecessary 
treatment. Furthermore, whilst NAC therapy is efficient at providing antidotal therapy to 
APAP poisoned patients, treatment itself requires > 20 hours of intravenous administration. 
Oral NAC has been utilised in the United States to protect against APAP toxicity (Rumack 
Figure 2: The Rumack-Matthew nomogram (reconstructed) used to determine risk in APAP 
poisoned patients from a single drug ingestion. Plasma APAP concentration is plotted against time 
from drug ingestion. The bold line is the “200 line” which was first used (Rumack & Matthew, 
1975).  The dashed line represents the “150” line and may be used in patients who may exhibit 
risk factors (e.g. alcoholism). Readings that fall above the line are to be considered high-risk 
where NAC therapy should be initiated at once. 
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& Peterson, 1978), however it appears to be less effective than intravenous administration 
(Jones, 1998).  Furthermore, NAC treatment has been associated with several ADRs of its 
own, from minor complications such us pruritis and nausea to rare anaphylactoid reactions 
that can be fatal (Elms et al, 2011). Nevertheless, NAC appears to be less toxic than other 
cysteine-based antidotes such as methionine or cysteamine (Prescott et al, 1974, Prescott et 
al, 1976, Meredith et al, 1978).  One of the most common methods to assess risk in APAP 
overdose patients is through use of the Rumack-Matthew nomogram. The nomogram was 
devised based on the observation that patients who develop transaminase rises > 1000 U/L 
could be separated from patients who did not, based on their admittance plasma APAP 
concentration. The nomogram itself is based on a plasma half-life of 4 hours for APAP, 
which is extrapolated to 24 hours whilst readings before 4 hours are unreliable due to 
continuing APAP absorption.  The original cut-off line devised by Rumack & Matthew 
which read 200 ug/mL APAP at 4 hours and 50 ug/mL at 12 hours was lowered to 150 
ug/mL at 4 hours and 37.5 ug/mL at 12 hours by the FDA. This was done to provide a 25% 
safety margin during the clinical trial to demonstrate efficacy of NAC (Rumack et al, 1981) 
which had hitherto been unlicensed in clinical practice. Despite very rare ‘idiosyncratic’ 
cases where patients below the “150 line” still develop hepatotoxicity, the nomogram 
continues to serve reasonably well for the majority (Rumack & Bateman, 2012). In the UK, 
the “150” line was dropped further to “100” to provide enhanced safety for ‘at risk’ patients 
(Ferner et al, 2011). From a blood sample that is taken upon arrival in hospital, the plasma 
concentration of APAP is ascertained. This can be plotted against time from ingestion to 
determine the risk of serious liver toxicity developing in patients. If the patient exhibits a 
risk factor such as malnourishment, alcoholism or underlying hepatic or renal complications, 
the patient is deemed ‘high risk’ and the ‘100 line’ should be utilised to assess risk. Only 
when all risk factors can be satisfactorily excluded can a physician use the ‘200 line’ (Ferner 
et al, 2011).  The clinician must also rely on an accurate time of ingestion from the patient or 
otherwise, which is often unreliable. Whilst the use of the nomogram has several drawbacks, 
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it does however provide the clinician with a relatively rapid and sensitive method to 
determine overall risk of liver damage.  
1.4.5.  Antidotal therapy with NAC 
The treatment of APAP-induced ALI will depend upon two factors; the dose of APAP and 
the time since APAP ingestion. If the patient presents very early, i.e. within 1 hour of 
overdose, the patient can be administered activated charcoal or undergo stomach lavage to 
reduce APAP absorption. However, few cases will present this early and in patients that 
present more than 1 hour after APAP ingestion, preventive measures against APAP 
absorption are no longer effective (Chyka & Segar, 2005). The mainstay of APAP-induced 
ALI treatment is through NAC administration. Several NAC dosing regimens have been 
utilised, including oral and intravenous administration, both of which appear safe and 
effective. NAC therapy should be initiated if there is evidence of liver injury (raised ALT) or 
if the nomogram provides a ‘high risk’ reading once the plasma APAP concentration has 
been measured. It is accepted that NAC therapy should be continued past the recommended 
dosing time of 20 hours if there is still evidence of either raised ALT (>100 U/L) or 
detectable plasma APAP concentrations (10 µg/mL) (Goldfrank et al, 2006).  NAC, a 
sulfhydryl donor, affords therapy by providing cysteine, a precursor amino acid of GSH, to 
hepatocytes to boost GSH levels. As discussed, GSH levels become depleted after an APAP 
overdose, therefore repletion of GSH boosts NAPQI detoxication and protection against 
oxidative stress. An additional benefit of NAC administration, is that the thiol residue on 
cysteine can react with NAPQI directly, therefore providing direct chemical detoxication 
against NAPQI and indirect biological protection via GSH repletion. NAC-based therapy is 
considered most effective within 10 hours (within stage I of APAP-induced ALI) of drug 
ingestion, i.e. during drug absorption and bioactivation when pronounced liver injury has not 
yet occurred Even after 10 hours post drug ingestion, NAC may not completely protect 
against liver injury, but can reduce the severity of injury. Prescott and colleagues reported 
that administering NAC within 10 hours of APAP ingestion provides almost complete 
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protection against APAP-induced ALI (Prescott et al, 1979). However, the same study 
showed that when NAC treatment was administered 10-24 hours after drug ingestion, it 
provided little benefit to the patients. Clearly, timing is crucial for this antidote to be most 
effective. It was later shown that late-administration of NAC beyond 15 hours (in stage III of 
APAP-induced ALI) had no ameliorative effects against liver damage per se (with respect to 
prothrombin time) but significantly more patients survived on NAC therapy compared to 
controls which was associated with less cerebral edema. It is known that NAC 
administration also protects against forms of kidney injury (Fishbane et al, 2004) therefore it 
is entirely possible that extra-hepatic protection is afforded by NAC in late-stage liver 
failure. 
1.4.6.  APAP-induced ALI: assessing prognosis 
If a patient presents within 8-10 hours of taking an acute APAP overdose, the physician can 
administer NAC to prevent serious hepatic injury from occurring. However, if the patient 
presents later than 10 hours, or if the overdose is staggered, which may occur over hours or 
even days, it is more challenging to assess risk and provide an accurate prognosis. However, 
patients who present late and those who have had staggered ingestions are considered to be 
at higher risk of developing serious liver injury or ALF. If patients do develop serious liver 
injury, intensive care is provided alongside NAC therapy. In patients who have late-stage 
liver failure, NAC therapy is no longer a viable treatment option, and orthotopic liver 
transplantation may become a drastic but absolutely necessary measure to save a patient’s 
life. Before liver transplantation became an established treatment option, prognosis of end-
stage liver disease was very poor, with less than 20% survival (Riordan & Williams, 2008). 
However, in the era of liver transplantation, survival rates now exceed 65% in the US (Lee, 
2003). ALF is defined as an abrupt loss of hepatocellular function in a patient with 
previously normal liver function, the expression of which includes coagulopathy and 
encephalopathy. A healthy liver secretes a range of clotting factors including fibrinogen 
(coagulation factor I) and prothrombin (coagulation factor II) in the peripheral circulation. If 
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liver degeneration is sufficient, the generation and secretion of these hemodynamic proteins 
ceases which causes circulating levels to fall. Sufficient levels of circulating coagulation 
factors are required to provide adequate hemostasis (cessation of blood loss from damaged 
vessels) and maintenance of hemodynamics. Therefore, bleeding tendency and risk of 
haemorrhage is increased in patients with ALF. Coagulopathy can be quantified using the 
prothrombin time measurement assay on citrated plasma samples. The prothrombin time is 
simply the length of time for a plasma sample to clot after addition of a coagulation 
activator, usually CaCl or thromboplastin (tissue factor), which can be measured optically or 
mechanically. The normal healthy reference range for prothrombin time is considered 8.8-
11.6 seconds (Jordan et al, 1992). Prothrombin times exceeding 2 minutes are not 
uncommon in APAP-induced ALF patients. In the 1980’s the World Health Organisation 
introduced the International Normalised Ratio INR which aimed to reduce variation in the 
prothrombin time assay between laboratories. The INR is a ratio of a test sample to the mean 
normal prothrombin time (prothrombin ratio), which is then raised to the power of the 
International Sensitivity Index (ISI), a pre-defined value reflecting the relative activity of the 
manufacturer’s tissue factor. 
 
INR =      Prothrombin Time (Test)       
ISI
 
             (Prothrombin Time (Normal) 
 
Clearly the onset of ALF is an immediate concern for the physician when treating a patient 
with severe liver injury. Firstly, it is essential that ALF is recognised as early as possible in 
the clinic, due to the speed of deterioration and risk of death. Well-defined biological 
parameters such as INR can help detect and diagnose ALF. Secondly, it is necessary for the 
physician to decide whether to administer NAC treatment. Thirdly, it is the responsibility of 
the physician to determine if the patient needs to be transferred to a liver transplantation 
unit. Due to a lack of healthy liver donors and limited clinical resources, this expert decision 
( ) 
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needs to be based on patient prognosis coupled with psychosocial factors such as age, mental 
status and history of substance abuse. Only 25% of ALF patients in the US undergo liver 
transplantations, therefore strict patient candidate criteria is unfortunately a factor (Lee et al, 
2008).  
In the setting of ALF, the INR is used as a strong predictor of patient outcome; in fact, 
coagulapathy itself is defined biologically as an INR > 1.5 (Fontana et al, 2008). However, 
the most accepted prognostic method for ALF is through use of the Kings College Criteria 
(KCC) (Stravitz & Kramer, 2009). The Kings College Criteria was introduced in 1989 when 
a retrospective study associated spontaneous survival from ALF with arterial blood pH, 
prothrombin time and serum creatinine. The Kings College Criteria for APAP-induced ALF 
is summarised in table 6. 
Table 6: Kings College Criteria for poor prognosis in APAP-induced ALF. 
Biomarker Value 
Arterial pH (after fluid resuscitation) < 7.3 
OR ALL OF THE FOLLOWING 
FEATURES 
 
Prothrombin Time > 100 seconds (INR > 6.5) 
Serum Creatinine Concentration > 259 µmol/L (3.4 mg/dL) 
Encephalopathy Grade > Grade 2 
Validation studies have showed that patients who meet the KCC and do not receive liver 
transplantation, survival rates are less than 15% (Shakil et al 2000; Makin et al, 1995; 
Mitchell et al, 1998; Bernal et al, 1998). Whilst KCC criteria is relatively accurate in 
identifying patients who are at most risk of death, it was found that 26% of patients were too 
unwell to receive liver transplantation by the time they met KCC (Simpson et al, 2009). 
Moreover, whilst KCC is reasonably specific in identifying ‘at risk’ patients, KCC 
sensitivity is less impressive as many patients who do not meet KCC still die (Shakil et al, 
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2000, Bernal et al, 1998, Anand et al, 1997). Other strategies have been sought to improve 
upon KCC performance to predict clinical outcome in APAP-induced ALF including 
measurement of blood lactate, alpha-fetoprotein, APACHE II score, MELD score, 
interleukin-6 levels and HMGB1 levels. Nevertheless, these novel markers have not been 
well validated in multi-centre prospective studies. Therefore, KCC remains the most widely 
used and robust method to determine prognosis in ALF patients (Craig et al, 2010). 
 
1.4.6. Novel Biomarkers for APAP-induced ALI 
In the wider context of DILI, novel biomarkers are urgently sought to facilitate pre-clinical 
and clinical research. In drug development, identification of high-performance translational 
biomarkers could potentially detect organ toxicities earlier, reduce costs, reduce drug 
attrition and accelerate drug development. Such is the pressing need for novel disease 
biomarkers that the National Institute of Health awarded over $2.5 bn in grants between 
2008 and 2009 for biomarker research (Ptolemy & Rifai, 2010). In order to screen for novel 
biomarkers of organ toxicity, it is important to have a clear definition of a biomarker. The 
official FDA definition of a biomarker is “a characteristic that is objectively measured and 
evaluated as an indicator of normal biologic processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention” (Woodcock et al, 2011). Some 
required characteristics of a clinical biomarker are separate from that required in the pre-
clinical field. However, many of these ‘ideal’ characteristics are shared between the two 
settings. In 2010, Dear described 8 desirable qualities of a high-performance clinical 
biomarker of APAP-induced ALI, which are summarised in Table 7 (Dear, 2010). Further to 
these clinical requirements, more general qualities of a novel biomarker include ease of 
access (non-invasiveness), have a high dynamic range, have a high signal to noise ratio, 
translational capability between species, translational capability between test systems, i.e. in 
vivo and in vitro, and provide mechanistic information, i.e. mode of cell death. 
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A catalogue of biomarkers for the detection of DILI now exist. However, four individual 
biomarkers deserve mention; ALT, AST, alkaline phosphate (ALP) and total bilirubin 
concentration which together form the markers which are recognised by the FDA to define 
DILI (Shi et al, 2010). Hy’s law describes ALT elevations three times the upper limit of 
normal (3x ULN) and bilirubin concentrations 2x ULN to define severe hepatotoxicity, 
which when used in combination is considered more specific than any single marker on its 
own (Senior, 2006). During hepatocellular necrosis, the cell membrane ruptures allowing 
intracellular contents to leak into the extracellular space and then into the circulation. Due to 
the stability of the enzyme in the blood (half life = approximately 42 hours), a correlation 
exists between serum ALT activity and amount of hepatocellular damage (Ozer, 2008). A  
Number Characteristic 
1 The biomarker assay should be easy to measure in the standard hospital 
laboratory without the need of specialist equipment or technology. 
2 There should be a rapid turnaround from blood sampling to test result 
3 The assay should be robust and reproducible between different laboratories 
4 An accurate time of drug ingestion should not be required 
5 The assay should be informative in cases of delayed or staggered APAP overdose 
6 The biomarker should identify liver injury early, with high sensitivity and 
specificity 
7 The biomarker should exclude liver injury early, with high sensitivity and 
specificity 
8 The biomarker should predict hard clinical end-points such as the need for hepatic 
transplantation or need for renal replacement therapy 
Table 7: Ideal characteristics of novel clinical biomarkers for APAP-induced ALI. Adapted 
from Dear, 2010. 
common misconception of ALT is that the enzyme is liver specific. ALT consists of two 
isoforms, ALT1 and ALT2 both of which are found in rat liver and extrahepatic tissues 
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(Yang et al, 2009). The standard laboratory optical assay cannot discriminate between the 
two isoforms, therefore both isoenzymes contribute to the serum ALT activity reading. 
Whilst it is certainly an abundant enzyme in the liver, both isoforms are also expressed in 
lower levels in other tissues; indeed, transamination reactions occur in many cell types. In 
fact, the first use of serum ALT activity was to confirm diagnosis of acute myocardial 
infarction highlighting the modest levels of the enzyme in myocardial tissue (Agress et al, 
1955). AST has similar characteristics to ALT but is less liver-enriched therefore less 
specific in detecting DILI (Ozer et al, 2008). De Ritis and colleague noted that the ratio 
between AST and ALT can differentiate different forms of liver injury (normal = 1.33, acute 
viral hepatitis = 0.6, liver cirrhosis = 1.34) (De Ritis et al, 1956).  
ALP is a useful biomarker recognised in the FDA guidelines. ALP offers mechanistic insight 
into the aetiology of DILI due to the specific tissular expression in the hepatic biliary ducts. 
ALP can therefore be used as a marker of cholestatic DILI, a sub-type of DILI where toxic 
biliary components exert a local toxic effect, which, in part, may be caused by inhibition of 
phase III metabolism.  It is important to note that whilst elevations in circulating 
transaminases indicate hepatocellular injury has occurred, functionally, the liver may not be 
affected. Watkins reported in a prospective study that some patients exhibit transient rises in 
circulating ALTs whilst taking therapeutic doses of APAP (4 g/day) (Watkins et al, 2006). 
Such rises were mild, asymptomatic, and although concerning, are assumed to clinically 
irrelevant. A subset of DILI biomarkers include the functional markers which reflect the 
effect of liver in jury that has occurred. These liver function tests include prothrombin time, 
discussed earlier, and total bilirubin concentration. Bilirubin is a product of heme 
catabolism, a liver-specific process. If hepatocellular function is perturbed, hepatic bilirubin 
levels cannot be cleared and lead to elevations of circulating bilirubin (hyperbilirubinaemia; 
jaundice). Bilirubin is an accurate marker of liver function, but for APAP-induced ALI, rises 
occur late when the patient becomes sick. Furthermore, false positive readings in total 
bilirubin have been attributed to red blood cell lysis, which may be a confounding factor in 
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patients with haematological diseases. liver function have been validated which reflect more 
accurately the effect of the injury on the liver. When these functional markers are assessed in 
combination with liver injury biomarkers, it provides the toxicologist with a more accurate 
reflection of the degree of hepatotoxicity. The current set of FDA-endorsed biomarkers lack 
sensitivity and specificity. Novel biomarkers are needed to complement or supersede the 
existing catalogue of DILI biomarkers to help detect, diagnose, monitor and predict APAP-
induced ALI in the clinic. More generally however, the validation and qualification of novel 
DILI biomarkers can aid drug development to detect potential hepatotoxins earlier whilst 
also possibly providing better mechanistic understanding that can generate safer medicines 
of the future. 
 
1.5 MICRORNAs 
In recent years, microRNAs (miRNAs) have shown great promise for their use as stable 
blood-based biomarkers of a range of pathologies. MiRNAs are small (approximately 22 
nucleotides in length) non-coding RNA species found to modulate the protein output, and 
therefore the phenotype of the cell. The discovery of this vast family of small RNAs was 
only made relatively recently by the inspiring work of Ambros and Ruvkun (Wightman et al, 
1993, Arasu et al, 1991, Lee et al, 1993). The discovery of the first miRNA, lin-4, in 
caenorhabditis elegans (c.elegans) was initially thought to be an isolated finding only 
applicable to nematodes. However, almost a decade later, let-7 was discovered in c.elegans 
and then homologues were found in drosophila and human (Reinhart, et al, 2000; Slack et al, 
2000; Pasquinelli et al, 2000). This created an explosion of research in the field. To date, 
25,141 mature sequences have been catalogued in 193 different species encompassing 
viruses to higher mammals (www.mirbase.org). The number of human sequences stands at 
approximately 1600, whilst 855 and 446 species have been identified in mouse and rat 
respectively. Many miRNA species are highly conserved; some are annotated as “vertebrate-
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specific” such as miR-194 and miR-130. This level of conservation between species hints at 
the evolutionary importance of these modulatory factors. 
1.5.1 MiRNA nomenclature 
MiRNAs are usually identified by species, number, genome location (for identical 
transcripts in the same organism), and their relationship with other closely-related 
sequences. However, there are some exceptions such as let-7 and lin-4 which retain their 
unique identification for historical reasons, being some of the first miRNAs discovered. A 
prefix to the miRNA identifier indicates the relevant species, e.g. human (hsa-), rat (rno-), 
mouse (mmu-), etc). The miRNA identification (ID) number itself is simply the sequence 
number in which the miRNA was discovered (therefore miR-1 does not necessarily share 
any functional or structural similarity with miR-2). However, closely related microRNAs 
(i.e., in genomic location/nucleotide sequence) are given a suffix of a letter after the miRNA 
ID, e.g. miR-302a, miR-302b, miR-302c, miR-302d. MiRNA cloning studies can discover 
two sequences from an initial hairpin precursor. If the relative abundances show that one 
sequence is predominantly expressed, it will be annotated in the conventional way, with the 
Figure 3: Examples of miRNA annotation 
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less dominant ‘passenger’ sequence given an asterisk following the miRNA ID (e.g. miR-
122*). When the relative abundances are similar, they can be distinguished by whether they 
originate from the 3’ or 5’ strand (e.g. miR-302d-3p and miR-302d-5p). Some examples of 
miRNA annotation are shown in figure 3.  
1.5.2 MiRNA biogenesis and maturation 
MiRNA loci occur throughout the genome. Some related miRNAs can occur in close 
proximity such as miR-302 family; all four members (a-d) occur within 553 bases on 
chromosome 4. Many miRNAs are coded in introns of host genes, where miRNA 
transcription occurs before mRNA splicing (Kim & Kim, 2007). Nascent miRNA sequences 
are found in stem-loop structures in the genome. Transcription of these “hair-pin” structures, 
in most cases, is mediated by RNA polymerase II in the nucleus to yield long sequences 
(approx 100-100000 bp in length) which are termed primary transcripts and denoted pri-
miRNAs. RNA polymerase II and RNA polymerase III also transcribe other members of the 
small RNA family including small nuclear and small nucleolar RNAs. Pri-miRNA 
transcripts can harbour more than one stem loop, and therefore more than one mature 
miRNA sequence (Lagos-Quintana et al, 2002). 
Once the pri-miRNA is generated, it undergoes a maturation step involving a multiprotein 
complex containing Drosha (RNase III endonuclease) which recognise, bind, and cleave 
both strands at the base of the hair-pin structures away from their flanking regions. This 
liberates a ~70 nt hairpin precursor (pre-miRNA) with 5’ phosphate and a 2-nt 3’ overhang, 
which is characteristic of RNase III enzymatic cleavage (Basyuk et al, 2003; Lee et al, 
2003). The pre-miRNA is then actively transported by Ran-GTP and Exportin-5 from the 
nucleus into the cytoplasm. Once the pre-miRNA enters the cytoplasm, the hair-pin structure 
is cleaved further by Dicer (RNase III endonuclease) complexed with TRBP (the human 
immunodeficiency virus transactivating response RNA-binding protein). The mature 
sequence of around 22nt is then liberated (Chendrimada et al, 2005). In each hairpin, the 
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miRNA sequence is usually encoded on the 5’ arm, which is then incorporated into the 
miRNA-induced silencing complex (miRISC) with argonaute 2 (Ago2), TRBP and glycine-
tryptophan repeat-containing protein of 182kDa (GW182). The 3’ complementary strand 
from the pre-miRNA sequence, often termed the passenger strand (denoted miRNA*), is 
selectively degraded. It has been generally considered that miRNA passenger strands afford 
no regulatory activity; however, this concept is currently being challenged (reviewed by 
Mah et al, 2010). 
 
1.5.3 MiRNA function 
Once the single-stranded mature miRNA has been generated and associated within the RISC 
complex, it is able to guide the complex to cognate messenger RNA targets. Numerous 
mechanisms have been proposed for miRNA-mediated mRNA destabilisation but our 
complete understanding of the molecular mechaniams behind target mRNA silencing is not 
fully understood. The degree of complementarily between miRNA and mRNA is thought, in 
part, to govern the mechanism. A perfect or near-perfect degree of complementarity confers 
Ago2-mediated cleavage and degradation of target mRNAs. This miRNA-mediated cleavage 
has been found to be consistent between the nucleotide complementary to the 11
th
 and 12
th
 
nucleotide of the miRNA. Upon cleavage, the miRNA remains intact and active for further 
regulatory action. However, this cleavage mechanism is thought to play a minor role in 
mammalian miRNA function, yet being surprisingly well conserved (Bartel, 2004). More 
commonly in mammals, the degree of complementarily is less perfect with only a small 
number of cognate base pairs. The ‘seed sequence’ in the miRNA is described as the first 6-
8 nucleotides at the 5’ end of the miRNA. The seed sequence was found to be 
overrepresented of conservation of matches between miRNA and target, i.e. the seed 
sequence is the key determinant that defines target specificity. miRNA targets usually occur 
in the 3’UTR region of mRNAs in AU-rich sequences. One mRNA may contain numerous 
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miRNA binding sites for one or more miRNAs and it has been estimated that 30% of 
mammalian genes contain at least one miRNA target motif. The major mechanism of 
mammalian miRNA-mediated silencing is through interference with mRNA translation. 
Mammalian mRNAs contain a 5’GpppN motif known as the 5’ cap, which interacts with 
eIF4E (eukaryotic translation initiation factor 4E). This interaction is thought to be important 
in ribosomal recruitment and the initiation of mRNA translation. The miRISC is known to 
inhibit cap dependent translation which can occur at the initiation of translation, or during 
protein elongation.  
An alternative mechanism for miRNA-induced silencing is through mRNA denadenylation. 
The miRISC is known to associate with CCR4-NOT complex and PAN2-PAN3 
deadenylation complex to augment deadenylation from the 3’ end of the target mRNA. 
Following this, m
7
G decapping and Xrn-1 5’-3’ exonuclease-mediated mRNA cleavage 
occurs resulting in mRNA degradation. Furthermore, the extent of miRNA-mediated 
silencing can be modulated further by auxiliary RNA-binding proteins such as PUF proteins, 
HuR proteins and other 3’UTR binding proteins such as Dead end 1 (Dnd1). These auxiliary 
factors have been shown to positively and negatively regulate miRISC binding by altering 
local 3’UTR secondary structures which affect the efficiency of miRNA binding. 
 
1.5.4 Extracellular miRNAs: stability and circulatory form 
The apparent stability of miRNAs in formalin-fixed tissue preparations lead Mitchell and 
colleagues to investigate their stability in plasma and serum (Mitchell, 2008). Coupled with 
the fact that miRNAs can be highly abundant, exhibit remarkable tissue specificity, and 
show altered expression in pathophysiological conditions they were identified as being a 
potentially valuable class of blood-based biomarkers. Mitchell and colleagues identified a 
total of 98 miRNAs, three of which (miR-15b, miR-16 and miR-24) were measured by 
absolute quantification and found to be abundant in plasma (10,000-100,000 copies/µL) 
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despite high blood nuclease activity. Furthermore, all three miRNAs showed impressive 
plasma stability at room temperature for at least 24 hours, and after 8 freeze-thaw cycles. 
Intriguingly, spiked-in (exogenous) miRNAs were undetectable unless the plasma was 
previously denatured, indicative of RNase-mediated degradation, which led the authors to 
conclude that the endogenous miRNAs studied were protected from RNase activity by an 
unknown mechanism. MiRNAs have also been detected at appreciable concentrations in 
many biofluids such as urine, saliva, cerebro-spinal fluid and breast milk. The form of 
extracellular protection was investigated by Wang and colleagues who found that miRNAs 
were contained within cell-derived vesicles (up to 1µm in size) and exosomes (50-100 nm), 
however, substantial amounts were also detected in the vesicle-poor supernatant during 
centrifugation studies (Wang et al, 2010). The same study found that exogenous miR-122 
could be protected by nucleophosmin 1 (NPM1), an RNA-binding protein, in cell-free 
supernatant during RNase challenge. It was later found in differential centrifugation studies 
that vesicle-enveloped miRNAs account for a minor proportion of circulating miRNAs 
(Arroyo et al, 2011). This study found that miRNA species existed in three predominant 
populations; vesicle-enveloped miRNAs (miR-142, let7a), protein-bound miRNAs (miR-
122, let-7d) or miRNAs split equally amongst vesicles and proteins (miR-126, miR-720). 
Immunoprecipitation experiments revealed that Ago2 proteins co-fractionate with protein-
bound miRNAs, but not vesicle-enveloped miRNAs. Furthermore, protein-bound miRNAs 
were resistant to RNase challenge but not resistant after pre-treatment with proteinase K 
suggesting argonaute proteins play an important role in extracellular protection of miRNAs. 
 The role of these extracellular miRNAs is unclear, however it has been shown that 
exosomes containing mRNA and miRNA can be exchanged between mast cells, a vesicle-
rich cell type (Valadi et al, 2007). The ectopic mRNA in the recipient cell was found to be 
active, i.e. capable of translating protein in. At the time of publication, this represented a 
novel mechanism of genetic exchange between cells. The spectrum of exosomal miRNAs 
did not reflect the host cell abundance of cellular miRNAs suggesting that exosomal loading 
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of miRNAs was targeted and regulated by an unknown mechanism. A later study showed 
that transfer of miRNA can also occur at the immune synapse between T-cells and antigen-
presenting cells (APCs) during antigen recognition. Not only was this exchange 
unidirectional and exosome-mediated, (i.e. only from T-cell to APC), but that exchanged 
miRNAs were active in recipient APCs (Mittelbruun et al, 2011). These findings have 
prompted groups to speculate on the potential therapeutic potential of circulating exosomal 
miRNAs, both for their diagnostic promise and as a possible vector for therapeutic siRNA 
delivery (reviewed in Ramachandran & Palanisamy, 2012). 
1.5.5 Liver-enriched miRNAs as potential markers of liver injury 
The liver is host to a spectrum of miRNAs, some of which exhibit remarkable liver-
enrichment. Liver-enriched miRNAs include miR-192 and miR-29a, however the most 
abundant and liver-specific miRNA is the vertebrate-conserved species, miR-122. The sheer 
abundance and liver-specificity was exemplified in Chang et al who reported that primary 
human hepatocytes contained approximately 135,000 copies per average cell (Chang et al, 
2004). Adult mouse liver contained 66,000 copies/average cell, which shows great 
enrichment when compared to lung, kidney, spleen and skeletal muscle, which all contained 
less than 50 transcripts. The promise of miRNAs as potential biomarkers of cancer detection 
led Wang and colleagues to test whether circulating liver-enriched miRNAs could inform on 
DILI in a rodent model. This landmark paper reported that liver enriched miRNAs 
(especially miR-122 and miR-192) exhibited massive elevations in mouse plasma (with a 
concomitant decrease in liver) after a toxic dose of APAP, therefore confirming detection of 
APAP-induced ALI. Furthermore, this study found that elevations in liver-enriched miRNAs 
(miR-122 and miR-192) occurred as early as 1h, before detectable rises in ALT in APAP-
treated mice suggesting that these have potential as earlier markers of APAP-induced ALI. It 
was also found that small rises in miR-122 and miR-192 could be detected at APAP levels 
of 150mg/kg whereas ALT elevations only occurred at 300 mg/kg, which also suggest liver-
enriched miRNA could be more sensitive markers than currently used clinical biomarkers. 
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Laterza and colleagues also reported that plasma miR-122 levels were raised in rats after 
treatment with carbon tetrachloride and trichlorobromomethane, confirming that elevations 
of liver-enriched miRNAs were not compound- or species-specific (Laterza et al, 2009). 
Many liver-enriched miRNAs (including miR-122 and miR-192) are perfectly conserved 
between rodents and humans which further highlights the translational potential between 
preclinical and clinical models of DILI. Zhang and colleagues reported that plasma miR-122 
significantly correlated with serum ALT levels in patients with hepatitis B virus (HBV) 
induced liver disease (Zhang et al, 2010). Furthermore, in patients with muscle injury, 
induced by either intense endurance exercise or polymyositis, plasma miR-122 levels did not 
increase, unlike serum ALT activity which exhibited a 7.8-fold increase in these patients. 
This finding highlights the higher liver-specificity of miR-122 compared to ALT, which is 
expressed in muscle tissue at modest levels. Together with an enhanced liver-specificity, 
earlier time of release and increased sensitivity compared to currently used clinical markers, 
circulating liver-enriched miRNAs may lend themselves well to be useful clinical 
biomarkers for APAP-induced ALI and other potential liver toxicants. 
1.5.6 Hepatic function of miR-122 
A growing body of evidence shows that miRNAs play a significant role in development with 
regard to cell lineage determination and tissue specification. miR-122 plays an important 
role in liver homeostasis, cell proliferation and cellular metabolism. Several internet-based 
miRNA target prediction algorithms, based on nucleotide recognition suggest that miR-122 
may target over 4,000 genes in humans. However, relatively few genes have been 
experimentally verified. Several methods have evolved to knockdown miRNAs in vivo using 
antisense oligonucleotides, either with cholesterol-conjugated “antagomiRs” or hybrid 
locked nucleic acid (LNA)/DNA “antimiRs”. It was shown in mice that plasma cholesterol 
and plasma triglycerides were significantly reduced after 4 weeks of antisense 
oligonucleotide administration (Esau et al, 2006). Furthermore, this study identified 
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glycogen synthase (GYS1) and aldolase A (ALDOA) as miR-122 targets using 
complementary in vitro and in vivo approaches. An earlier study had also found that the 
expression of several genes involved in cholesterol metabolism was reduced after miR-122 
inhibition in mice (Krutztfeldt et al, 2005). More recently, a miR-122 deficient mouse was 
generated which lacks the MiR-122a gene (Tsai et al, 2012). These mice also exhibit 
significantly reduced serum cholesterol and serum triglycerides throughout the first 12 
months of life which reflects reduced expression of genes responsible for lipogenesis, bile 
metabolism, very low density lipoprotein (VLDL) export and lipid transcriptional regulation. 
It is clear from these studies that miR-122 plays a pivotal role in lipid metabolism and 
cholesterol homeostasis. 
Another important role of miR-122 is the maintenance of the hepatic phenotype and control 
over cell proliferation. It was found that cyclin G1 is a target of miR-122 that shows an 
inverse correlation in HCC cell lines. Kutay and colleagues found that miR-122 was 
significantly decreased in hepatocellular carcinomas (HCCs) induced in rats by folic-acid-, 
methionine- and choline-deficient diet (Kutay et al, 2006). Similarly, analysis of human 
primary found significantly reduced levels of miR-122 when compared to surrounding 
healthy tissue. The authors suggest that miR-122 may have a causal role in 
hepatocarcinogenesis. In miR-122-deficient mice, liver lesions and spontaneous HCC 
developed in early stages of growth. However, older mice developed larger tumours with an 
invasive morphology. Genetic analysis of these tumours indicated an upregulated panel of 
oncofetal genes including Afp, Igf2, Src, Prom1, Thy1 and Epcam (prom1 is a miR-122 
target). Tumour size and rate of tumour incidence could be reduced by rescuing mice with 
miR-122 injection providing a direct link between miR-122 status and hepatocarcinogensis. 
1.5.7 Regulation of miR-122 
Like many miRNAs, miR-122 plays a pivotal role in development. miR-122 is strongly 
upregulated during mouse liver embryonic development reaching maximal expression just 
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before birth (Chang et al, 2004). Therefore, it is likely that miR-122 is involved directly in 
the differentiation of the hepatocyte (Xu et al, 2010). The expression of miR-122 is closely 
correlated with a group of liver-enriched transcription factors including hepatocyte nuclear 
factor (HNF) 1α, HNF3β, HNF4α and CCAAT/enhancer binding protein (C/EBP) during 
mouse embryogenesis. Li and colleagues found that HNF4α binds to the miR-122 promoter 
directly via a conserved DR-I element and HNF4α positively regulates miR-122 in Huh7 
cells and in mouse liver (Li et al, 2010). The expression of miR-122 is also under circadian 
control via positive regulation by REV-ERBα, a bona fide clock gene (Gatfield et al, 2009). 
Whilst the transcription of miR-122 (pri-miR-122) is highly dynamic over the course of the 
day, the absolute levels of mature miR-122 remain constant over the circadian phase due to 
the long intracellular half-life of miR-122. However, it was also found that many circadian 
genes are miR-122 targets themselves providing a clear link between miR-122 and circadian 
regulation. 
 
1.6 The role of circadian rhythms in DILI 
The pipeline of NCEs represents an essential asset to improve the quality of life and reduce 
morbidity and mortality in man. However, adopting novel tools and approaches to improve 
the safety and efficacy of existing drugs may also substantially improve human health (Kola 
& Landis, 2004). There is a growing body of evidence which suggests that the intrinsic 
biological clock has an important role in the coordination of drug metabolism, and therefore 
drug efficacy and drug detoxification. A better understanding in the link between circadian 
physiology and its effects on drug response may lead to safer and/or more efficacious drug 
regimens in the clinic (Levi &Schibler, 2007). 
1.6.1 Cellular coordination of circadian physiology 
The biological clock has been found to regulate daily physiological changes in a plethora of 
different ways; from diurnal effects on heart rate and blood pressure to behavioural sleep-
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wake cycles. Circadian (derived from latin circa-diem, ‘about a day’) rhythms are thought 
have developed in virtually all light-sensitive organisms, including cyanobacteria, simple 
eukaryotes and higher mammals. Rosbash and Gehring explained how circadian rhythms 
may have evolved in primitive organisms to confer a selective advantage in anticipating 
daily cycles of UV light (Gehring & Rosbash, 2003). Indeed, a light sensitive family of 
proteins, the cryptochromes, are integral in the coordination of the mammalian biological 
clock. The generalised role of the biological clock is to optimise metabolism and energy 
utilisation by conferring an anticipatory response, rather than reactionary response, to the 
availability of nutrition or energy in an organism. Therefore, it is not surprising that 
circadian coordination affects mammalian physiology in such a marked way. 
 The mammalian circadian system is organised in a hierarchical structure.  The 
circadian axis is orchestrated by the ‘master’ clock which is present in the suprachiasmatic 
nuclei (SCN), a 10,000 neuron paired structure in the anterior hypothalamus of the brain 
(Reppert & Weaver, 2002). Light is transduced by photopigments in the retina, which 
produce long-lasting non-image forming signals (as opposed to image-forming rods and 
cones) which are relayed to the suprachiasmatic nuclei (SCN) via the retinohypothalmic 
tract completing the sensory limb of the circadian system. However it should be noted that 
light-dark cycles only entrain the clock, i.e. the biological clock will oscillate regardless of 
external light cues. The actual dynamics of the biological clock is achieved through the 
temporal interplay between proteins in a transcriptional/post-transcriptional negative 
feedback loop (Freedman et al, 1999). When one considers that that the period of expression 
of these clock genes is approximately twenty four hours, then the basis of diurnal control on 
downstream pathways can be appreciated. The components of the molecular oscillator in the 
SCN are very similar in make-up to those in peripheral tissues. The master clock can 
synchronise peripheral clocks which are known to exist in many cell types, including 
hepatocytes, fibroblasts and keratinocytes (Balsalobre et al, 1998, Panda et al, 2002, Zanello 
et al, 2000). However, clocks in peripheral organs are not tightly coupled like those in the 
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SCN, which communicate locally via paracrine and synaptic signalling (Liu et al, 2007, 
Maywood et al, 2006). Although cellular clocks will continue to free-run in peripheral cells, 
they become gradually desynchronised if the entrainment by the SCN is lost, i.e. in SCN-
lesioned animals or cells in culture (Guo et al 2006, Nagoshi et al, 2004). Such SCN ablation 
experiments lead to perturbations in hormonal production, sleep patterns and locomotor 
activity (Ralph et al, 1990). The exact mechanisms governing this remote signalling of 
peripheral clocks is not fully understood, but is thought to be regulated through both 
synaptic and humoral signalling. Candidate circulating peripheral synchronisers include 
prokineticin-2 (PROK-2, PK2), a light-sensitive protein secreted by the SCN, and 
transforming growth factor α (TGFα), both of which have been implicated in controlling 
behaviour and locomotor activity and exhibit circadian expression. Glucocorticoids are also 
likely to be implicated. Hence, each organ in the body can be synchronised in coordination 
but as independent entities. 
1.6.2 Molecular architecture of the biological clock 
The molecular architecture behind the generation of self-sustained, autonomous circadian 
rhythms is complex involving multiple regulatory loops. However, advances have been 
made in the last decade to improve the understanding behind the dynamics and interactions 
of the clock components. At the heart of the mammalian clock are two classes of genes, the 
cryptochromes (CRY1 and CRY2) and period genes (PER1 and PER2). A third member of 
the period genes was discovered but is thought not to play an important role in the regulation 
of the molecular clock (Im et al, 2010). The expression of these two clock gene classes are 
under positive regulation by two heterodimeric transcription factors, CLOCK and BMAL1 
which are members of the basic helix-loop-helix (bHLH)-PAS (Period-Arnt_Single-minded) 
transcription factor family. Clock acetylates Bmal1 at a conserved lysine residue (Lys 537) 
to bind and form the active heterodimer. The active Clock:Bmal1 complex can then bind to 
cognate E-box or G-box motifs within cis-acting promoter or enhancer regions of the 
PER1/2 and CRY1/2 genes and promote transcription. PER and CRY proteins then 
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accumulate in the cytoplasm and themselves form heterodimers with a number of auxiliary 
proteins such as casein kinase 1δ, casein kinase 1ε (Lee et al, 2009), NonO, and WDR5 
(Brown et al, 2005). When these factors reach a threshold concentration, they actively 
repress their own transcription by affecting the binding affinity of CLOCK:BMAL1 thereby 
attenuating CRY and PER expression. The half-life of CRY and PER proteins is a factor of 
the time of this repression, i.e. once the levels of these proteins fall, the expression of CRY 
and PER can then resume, completing the rhythm. A working model for the molecular 
mechanism governing circadian regulation is shown in figure 3. Another regulatory loop that 
is very important in circadian regulation involves two members of the nuclear orphan 
receptor family, REV-ERBα (Nr1d1) and REV-ERBβ (Nr1d2). The CLOCK-Bmal1 
heterodimer can transactivate expression of both REV-ERB isoforms in a strong circadian 
manner (>100-fold increase in expression within 6 hours). REV-ERBα and REV-ERBβ 
compete then bind to RORE elements of Bmal1 and strongly repress with members of the 
RAR-related orphan nuclear receptors (RORs), mainly RORα and RORɣ, which counteract 
Bmal1 repression by promoting expression at the same RORE elements. Therefore, the 
status of Bmal1 expression depends on a balance between REV-ERB-mediated repression 
and ROR-mediated activation. Whilst these two regulatory systems are important in the 
regulation of circadian regulation, they peak at different times allowing downstream E-box 
driven regulation and RORE-driven regulation to occur at different phases. 
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 Remarkably, it has been found that at least 10% of transcripts in many tissues 
oscillate with circadian rhythmicity (Akhtar et al, 2002). Several key circadian regulators 
have been described that provide a link between the molecular oscillator and the circadian 
expression of hundreds of genes, some of which are important in drug detoxification. 
Members of the proline and acidic amino acid rich-domain basic leucine zipper (PAR bZip) 
transcription factors, including D-site albumin promoter binding protein (DBP), thyrotroph 
embryonic factor (TEF) and hepatic leukaemia factor (HLF), are directly regulated by key 
clock components and are expressed with strong circadian rhythmicity (Ripperger & 
Schibler, 2006). They are not clock genes per se, as they are not involved in clock 
entrainment but act immediately downstream and can be considered molecular adapters 
between core clock components and downstream circadian regulation. Identification of 
targets for the PAR bZIP transcription factors was achieved through the generation of a 
triple knockout mouse, i.e. DBP 
(-/-)
, TEF 
(-/-)
, HLF 
(-/-)
 (Gachon et al, 2006). Many genes 
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Figure 3. Schematic mechanism (adapted from Lim et al, 2006) showing the molecular 
oscillator model. The model is based on a cyclic transcriptional/post-transcriptional negative 
feedback mechanism where Bmal1 and Cry isoform expression is in anti-phase. This 
molecular oscillator drives daily fluctuations in output ‘circadian’ genes (e.g. D-site albumin 
binding promoter) which, in turn, will positively regulate various endogenous 
signalling/enzymatic pathways with a 24 hour period. 
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involved in xenobiotics metabolism were found to be significantly underexpressed in PAR 
bZIP deficient mice including members of the CYP450 superfamily (Cyp2a4/5, Cyp2b9, 
Cyp2b10, Cyp2c37, Cyp2c50), carboxylesterases (Ces1, Ces3), UGTs (UGT2b37) GSTs 
(Gstα3, Gstθ1), aldehyde dehydrogenases (Aldh1a1, Aldh1a7) and drug transporters (MRP4, 
BCRP1). Other genes thought to be implicated with drug detoxification were also altered, 
such as aminolevulinic acid synthase (Alas1), which provides a rate-limiting step to heme 
biosysnthesis and constitutive androstane receptor (CAR) which is responsible for induction 
of genes implicated in drug detoxification. Strikingly, in PAR bZIP deficient mice, genes 
involved in all three phases of drug metabolism were underexpressed. This shows the high 
level of significance that circadian regulation may have over drug detoxification systems. 
A transgenic mouse model with a system-driven conditionally active liver clock has been 
developed (Kornmann et al, 2007). This model was produced in an attempt to avoid the 
severe phenotypic observations that complicate other whole-genome clock deficient models 
(Gachon et al, 2006). Importantly, this conditionally active model offers clock disruption in 
a liver-specific manner through exogenous constitutive REV-ERBα over-expression, under 
the control of an albumin promoter. When the liver clock was “switched off”, the robust 
circadian expression of many genes involved in drug disposition was lost including Cyp2b9, 
Cyp2b10, Fmo5 and P450 oxidoreductase. In total 351 transcripts with circadian expression 
was identified, 90% of which lost rhythmicity when the local liver clock was perturbed. A 
small subset of genes retained circadian rhythmicity during liver clock perturbation 
suggesting some genes are influenced by remote zeitgebers, such as temperature. Together, 
these studies confirm that the biological clock plays an important role in the expression of 
many genes important in the detoxification and disposition of drugs.  
1.6.3 The role of the biological clock: clinical significance 
 The fixed-dose lethality of many drugs in laboratory rodent models is dependent on 
the time of administration. This is particularly marked in halothane and APAP toxicity 
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(Chassard & Brugerolle, 2004; Matsunaga et al, 2004). These findings have led to 
investigative studies on the time-of-day dependence on the efficacy or toxicity of medicines 
in humans, studies which have been termed “chronopharmacology” studies. As predicted, 
drug chronopharmacology often displays reciprocal circadian patterns in humans relative to 
rodent models reflecting the diurnal human system and the nocturnal rodent system. As 
discussed, circadian rhythms are displayed in many physiological systems such as gastric 
acid secretion, intestinal motility and hepatic blood flow, all of which can play an important 
role in drug disposition (Moore & Halberg, 1986; Kumar et al, 1986; Lemmer & Nold 
1991). Substantially reduced pharmacokinetics have been observed in asthmatic children 
when administered sustained-release theophylline in the morning when compared to evening 
dosing (Smolensky et al, 1987). Moreover, in cancer patients, a pronounced circadian 
rhythm in plasma 5-fluorouracil (5-FU) concentration exists despite constant rate 
intravenous infusion (Petit et al, 1988; Metzger et al, 1994). 
Further to time-of-day differences in pharmacokinetics, the pharmacodynamics of some 
drugs also follow a 24-hour rhythm. For example, the anticoagulation potency of heparin 
was almost doubled in the mid-dark phase (early morning) in patients with venous 
thromboembolic disease during constant rate infusion. However, the most striking circadian 
differences in efficacy and toxicity of drugs exist in the cancer field. Two anti-cancer agents 
that when combined are effective in the treatment of gastrointestinal cancers including 
colorectal cancer are 5-FU and oxaliplatin (L-OHP). Despite being efficacious, both agents 
exhibit serious ADRs due to their non-specific cytotoxic action. The main metabolising 
enzyme of 5-FU is dehydropyrimidine dehydrogenase (DPD) which exhibits strong 
circadian expression. Furthermore, the target enzyme of 5-FU thymidilate synthetase (TS) 
also displays circadian variation. Likewise, L-OHP is better tolerated in rodents when GSH 
levels are highest, thereby providing greater cytoprotection. These findings guided the 
development of a modified chronopharmacological-based regimen in an attempt to both 
improve efficacy and reduce ADRs with these cytotoxic agents. Therefore, a multi-channel 
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programmable pump was devised to automatically change the dosing rate of each drug 
individually according to the time of day. This administered 5-FU (supplemented with 
folinic acid; a chemotherapy adjuvant) to peak at 04:00 to coincide with high DPD levels 
and low TS levels thus providing maximal enzyme inhibition without producing toxic levels 
of the drug (Levi et al, 1992). Alongside this, L-OHP was administered with a peak infusion 
rate at 16:00 to coincide with higher GSH levels in bone marrow to attempt to reduce the 
risk of L-OHP-induced haematological complications. The tolerability and efficacy of these 
modified regimens have been assessed in phase I, phase II and phase III clinical trials 
involving over 2000 patients (Mormont & Levi, 2003, Levi et al, 1997). It was found that 
the chronomodulated regimen achieved 51% objective tumour responses compared to 30% 
who received constant rate infusion. Furthermore, the incidence of serious toxicities related 
to severe mucositis, peripheral sensory neuropathy and toxicity requiring hospitalisation all 
fell by at least two-fold.  
These studies show how understanding the daily variations in target or metabolising proteins 
that ultimately effect drug response can help improve drug effectiveness and reduce the risk 
of ADRs in the clinic. Similar methodologies could be applied to other drugs currently used 
in the clinic that are associated with poor efficacy or ADRs that may be avoidable. 
Chronopharmacology studies may also become standard practice in the development of 
NCEs to identify the optimal time for drug administration to gain the most efficacy with the 
lowest possible risk of an ADR. Essentially, a better understanding in the dynamics of the 
molecular clock and how it affects drug response may improve the risk:benefit ratio of drugs 
in clinical and pre-clinical settings. 
 
 
 
 
  Chapter One
55 
 
1.7 AIMS OF THESIS 
New biomarkers of DILI are urgently required in the clinic and in pre-clinical settings 
during pharmaceutical evaluation. Circulating miRNAs represent a promising class of 
biomarkers that have been successfully utilised in a range of pathologies from cancer 
detection to cardiovascular dysfunction. Recently, two liver-enriched miRNAs (miR-122 
and miR-192) were found to be superior biomarkers of liver injury compared to the current 
gold-standard biomarker, ALT, in a murine model of APAP-induced ALI. However, these 
markers have not yet been tested in a real-life clinical setting in a heterogeneous cohort of 
APAP-overdosed patients. If these potential biomarkers of liver injury can provide earlier 
detection with enhanced liver-specificity and/or correlate to real clinical outcomes, they may 
provide the physician with a more accurate and prognostic marker of liver injury. 
Furthermore, little is known about the release mechanism or site of loss of miRNAs during 
liver injury. It is also not known if miRNAs can serve as biomarkers of DILI during different 
mechanisms of DILI. 
This thesis will set about addressing the following hypotheses: 
 Circulating liver-enriched miRNAs can be used as biomarkers of liver injury in a 
rodent APAP model of DILI and a FS model of DILI. 
 Can circulating liver-enriched miRNAs inform on two models of DILI that 
injure through two separate mechanisms? 
 Can we corroborate previous studies to show that miR-122 and miR-192 can 
be released earlier and at lower toxic doses of APAP? 
 
 Circulating liver-enriched miRNAs can be used as sensitive, non-invasive 
biomarkers to detect DILI in a heterogeneous cohort of APAP-overdose patients. 
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 Do circulating, liver-enriched, miRNAs correlate with ALTs or any 
functional marker of liver or kidney damage, such as serum bilirubin, 
prothrombin time or serum creatinine? 
 Do circulating, liver-enriched, miRNAs inform on non-APAP-induced liver 
injury such as liver damage associated with hepatitis? 
 Is the half-life of circulating miRNAs shorter than that of ALT, i.e. do 
miRNAs reflect the actual status of the liver more accurately during liver 
recovery? 
 
 A rise in circulating liver-enriched miRNAs can detect APAP-induced ALI before a 
rise in ALT and can predict patients who will develop ALF. 
 Do circulating liver-enriched miRNAs increase within 8 hours of APAP 
ingestion in cohort of APAP overdose patients? 
 Do circulating liver-enriched miRNAs correlate with peak ALT or peak INR 
levels which are accurate markers of liver failure? 
 
 APAP and FS murine models of DILI show distinct time-of-day dependence on 
severity of toxicity. 
 Is it possible to associate any differences in toxicological outcome with 
endogenous variations in circadian physiology? 
 Do circadian rhythms exist in the expression of important genes involved in 
drug disposition, how can they be implicated in the circadian variation in 
APAP- or FS- induced liver injury 
 
The work in this thesis has been undertaken in an attempt to better understand the utility of a 
promising marker of DILI by bridging between pre-clinical models and clinical settings. 
This may ultimately add to the catalogue of available biomarkers that can be used either by 
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the physician to better direct the most appropriate treatment to patients and/or by pre-clinical 
scientists to detect liver injury sensitively during NCE evaluation. This work will also aim to 
characterise the circadian variation in two archetypal hepatotoxins, which may reveal a 
better mechanistic understanding behind drug disposition and toxic outcome. 
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MICRORNAS AS POTENTIAL BIOMARKERS OF DILI USING IN VIVO MODELS 
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2.1  Introduction 
The identification and development of novel biomarkers of DILI is a pressing need in 
clinical and pre-clinical settings. In drug development, NCEs require rigorous pre-clinical 
testing to ensure efficacy is achieved whilst providing an excellent safety profile. However, 
many NCEs fail due to the development of organ-related toxicity either in pre-clinical 
species or in late-stage drug development during clinical trials. One of the most common 
organ-targeted toxicological outcomes encountered during drug development is 
hepatotoxicity (Mandenius et al, 2011). Ideally, NCEs that contain a chemical liability to 
provoke DILI in man would be identified early in pre-clinical testing. However, this is often 
not the case. The current models for NCE hepatotoxicity testing include the use of in vivo 
methods with non-human pre-clinical species such as rodents, dogs and cynomolgus 
monkeys. Although these can predict human hepatotoxicity in most cases, drug metabolism 
can be species-specific which may be critical if toxicity is mediated through the generation 
of a chemically reactive metabolite. Other models to test for potential hepatotoxicity include 
in vitro methods. The advantage of in vitro methods is the utilisation of human cells and 
tissues. However, there is a general consensus among pharmaceutical companies that the 
current in vitro models for safety testing need to be improved upon. For example, the 
popular use of immortalised hepatocellular cell lines is a poor translational tool for 
modelling various types of DILI as these cell lines do not express important proteins 
implicated in drug disposition, e.g. specific CYP450s isoforms A great effort is currently 
underway to develop more physiologically-relevant, in vivo-like in vitro systems such as 3-D 
cell bioreactors or human hepatocytes derived from pluripotent stem cells. 
The identification and development of novel sensitive biomarkers are also urgently required. 
The current gold-standard laboratory biomarker of DILI is ALT (Amacher, 1998). This 
liver-enriched enzyme is highly sensitive and reasonably specific for liver injury. The photo-
optical activity assay is also translational between pre-clinical species and man. Despite 
these advantages, several limitations are also recognised. The ALT enzyme exists in two 
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isoforms; ALT1 is highly liver-enriched and ALT2 is expressed at lower levels in muscle. 
The photo-optical assay does not discriminate between the two isoenzymes; therefore, ALT 
is prone to producing false-positive results in animals. Furthermore, O’Brien and colleagues 
found that ALT could be inhibited by isoniazid and lead nitrate induced by cyproterone and 
dexomethosome in rats, which lead to hepatic and serum increases in ALT levels (O’Brien et 
al, 2002). These findings suggest that under specific toxic conditions, serum ALT activity 
had the potential to over-estimate or under-estimate the true degree of liver injury. Ideal 
characteristics of novel DILI biomarkers for use in pre-clinical settings include: ability to 
detect liver injury with a high degree of sensitivity and specificity, translational capability 
between pre-clinical species and man, good stability in an easily accessible biofluid (blood 
or urine), rise early during hepatotoxicity, good analytical sensitivity with a large dynamic 
range, and provides strong correlation between readouts and the true degree of injury present 
in the liver. 
Circulating miRNAs from host tissues/cells have been found to exist in a remarkably stable 
form in various biofluids including blood, urine, cerebrospinal fluid and breast milk. This 
has prompted an intense world-wide effort to evaluate miRNAs for their potential in various 
disease states, tissue injury and to report on drug efficacy. Recently, Wang and colleagues 
discovered a panel of liver-enriched miRNAs (notably miR-122 and miR-192) that rise in 
blood in a mouse model of APAP-induced ALI (Wang et al, 2009). Most striking was the 
observations that a) liver-enriched miRNAs were increased earlier than ALT in blood and b) 
liver-enriched miRNAs were elevated at lower toxic doses of APAP than ALT. These 
findings suggest that liver-enriched miRNAs could serve to be informative biomarkers of 
liver injury with an earlier time of release and increased sensitivity over ALT. Furthermore, 
miRNA screening across approximately 40 human tissue types found that miR-122, a 
highly-abundant liver miRNA, exhibited extremely high enrichment in liver tissue (Liang et 
al, 2007). Coupled with the fact that miR-122 is highly conserved throughout most 
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mammalian species, this growing body of evidence increasingly suggests miR-122, and 
other liver-specific miRNAs, have the potential to serve as powerful biomarkers of DILI. 
In this chapter, the utility of liver-enriched miRNAs (miR-122 and miR-192) is assessed in 
an established mouse model of APAP-induced ALI. Specifically, miR-122 is measured 
alongside ALT in time-response and dose-response studies to ascertain the relative earliness 
and sensitivity of liver-enriched miRNAs. Furthermore, the loss of miR-122 from liver 
during APAP-induced injury is examined through miR-122 in situ hybridisation studies. 
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2.2  EXPERIMENTAL ANIMALS AND METHODS 
2.2.1 Materials 
Purified reduced GSH, acetaminophen, beta-nicotinamide adenine dinucleotide phosphate 
tetrasodsium salt (NADPH), sulfosalicylic acid (SSA), 5,5-dithiobis(2-nitrobenzoic acid) 
(DTNB), GSH reductase and neutral buffered 10% formalin were all purchased from Sigma 
Aldrich (St Louis, MO). miRNeasy kits and minElute kits were purchased from Qiagen 
(Venlo, Netherlands). Stem-loop reverse transcription primers and Taqman stem-loop 
reverse transcription primers/reporter (miRNA assays) were purchased from Applied 
Biosystems (Foster City, CA). Thermo Infinity ALT Liquid stable reagent was purchased 
from Thermo (Waltham, MA). miRCURY LNA detection probes (miR-122, U6 snRNA and 
scramble control) were purchased from Exiqon (Vedbaek, Denmark). 
 
2.2.2 Experimental animals 
The protocols described were performed according to the regulations defined in the project 
licence granted under the Animals (Scientific Procedures) Act 1986 and approved by the 
University of Liverpool Animal ethics committee. All animals were purchased from Charles 
River (Manston, UK) and housed at constant temperature and humidity with free access to 
food and water. All animals were allowed to acclimatise to a 12-hour light-dark cycle (lights 
on: 08:00/lights off: 20:00) for at least 14 days prior to experimentation. Mice were 
humanely culled via rising concentration of CO2 before exsanguinations according to the 
Humane Killing of Animals Under Schedule 1 to the Animals (Scientific Procedures) 1 Act 
1986. 
 
2.2.3  Animal dosing schedule 
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Male CD-1 mice (5-7 weeks old / ~ 30g) were used in all studies. For time-response studies, 
mice were administered a single i.p. injection of APAP (530 mg/kg) in warm 0.9% saline for 
1-8 hours. For dose response studies, mice were administered APAP (i.p.) (30-530 mg/kg) in 
warm 0.9% saline for 5 hours. Control animals received a single i.p. injection of warm saline 
equivalent to a 530 mg/kg dose. Treatment groups consisted of four mice each. 
 
2.2.4  Serum ALT Activity Determination 
Complete exsanguination was performed via cardiac puncture using a 25 gauge needle. 
Blood was collected in microtubes and allowed to clot overnight at 4°C. The blood clot was 
initially separated and serum removed by centrifugation (1500g, 5 mins, 4 °C). Residual red 
blood cells were pelleted by centrifugation (10,000g, 5 mins, 4 °C) to yield cell-free 
supernatant. Serum ALT levels were determined immediately (to prevent freeze-thawing) 
using a Thermo Infinity ALT Liquid stable reagent-based (Thermo, Waltham, MA) kinetic 
assay, at 37°C, according to the manufacturer’s instructions. 
 
2.2.5  miRNA extraction 
miRNA was extracted using an miRNeasy kit (Qiagen, Venlo, Netherlands), following the 
manufacturer’s instructions, with minor modifications. Briefly, 40 µL of biofluid was made 
up to 200 µL with nuclease-free water, then combined with 700 µL of QIAzol. The sample 
was mixed and left for 5 minutes before the addition of 140 µL of chloroform. In some 
experiments, 10µL of cel-lin-4 (5fM) was added to denatured serum before the addition of 
chloroform (to serve as exogenous control). Samples were then mixed vigorously for 15 
seconds and centrifuged at 12,000 g for 15 minutes at 4 °C. Equal volumes (350 µL) of the 
upper aqueous phase and 70% ethanol were mixed in a fresh microtube before adding the 
total volume to an miRNeasy minispin column. The column was centrifuged at 8,000g for 
15 seconds at room temperature. The flow-through, containing the small RNA fraction, 
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including the miRNA complement, was mixed with 450 µL of 100% ethanol. The elute was 
then purified using a MinElute kit (Qiagen, Venlo, Netherlands). 
 
 
2.2.6  miRNA purification 
The small RNA elution mixture was applied to a MinElute column, 700 µL at a time. The 
immobilized RNA was then washed with various buffers before a final 80 % ethanol wash. 
The column was then dried by centrifugation. The small RNA fraction was eluted in 14 µL 
of nuclease-free water and stored at -80 °C. 
 
2.2.7  Quantitative Polymerase Chain Reaction Analysis. 
miRNA levels were measured using Taqman-based quantitative polymerase chain reaction 
(qPCR). The small RNA elute was reverse transcribed using specific stem-loop reverse-
transcription RT primers (Applied Biosystems, Foster City, CA) for each target miRNA 
species, following the manufacturer’s instructions. Next, 2 µL of RNA was used to produce 
the complementary DNA (cDNA) template in a total volume of 15 µL. Then, 1.33 µL of 
cDNA was used in the PCR mixture with specific stem-loop PCR primers (Applied 
Biosystems, Foster City, CA) in a total volume of 20 µL. Levels of miRNA were measured 
by the fluorescent signal produced from the Taqman probes on an ABI Prism 7000 (Applied 
Biosystems). All samples were assayed in duplicate. miRNA levels were normalized to 
levels of U6 snRNA, a ubiquitous small nuclear RNA (snRNA) species used as an 
endogenous control, as described elsewhere (Zhang et al, 2010). 
 
 
2.2.9  FFPE tissue preparation 
In a separate experiment, a time-course study was performed in mice receiving APAP (530 
mg/kg) dissolved in warm saline for 1-8 hours (n=4). Time-matched controls received warm 
saline equivalent to a 530 mg/kg APAP dose (n=4). Mice were culled as described. The right 
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lobe of the liver was fixed in neutral buffered 10% formalin for 24 hours, the remaining liver 
was snap frozen. The liver tissue was then dehydrated with increasing concentrations of 
ethanol before a xylene wash. Cassettes containing dehydrated liver tissue were infiltrated 
with molten paraffin wax and allowed to cool to create FFPE blocks. 
 
 
2.2.10  miRNA in situ hybridisation 
miRNAs (miR-122, U6 snRNA and scrambled control) were visualised using miRCURY 
LNA anti-sense DIG-labelled probes. First, 4 µm sections were cut from the FFPE blocks 
and mounted on Superfrost Plus slides (Thermo Scientific, Waltham, MA). Method 
optimisation experiments determined that an annealing temperature of 54 °C (miR-122) and 
55 °C (U6 snRNA) provided the best sensitivity and specificity for each probe. Briefly, the 
slides were baked at 60 °C for 8 minutes before deparaffinisation at 62 °C for 12 minutes. 
For partial digestion, proteinase K was added to each slide and incubated at 37 °C for 8 
minutes (U6 snRNA) or 24 minutes (miR-122). After denaturisation of the enzyme, the 
antisense DIG-labelled probes (miR-122, 12.5 mM; U6 snRNA 10 mM) were incubated for 
1 hour (U6 snRNA) or 3 hours (miR-122). Each slide was washed with increasing stringency 
(2.0 X SSC - 0.5 X SSC) at 55 °C (U6 snRNA) or 37 ° C (miR-122). One drop of alkaline 
phosphate-conjugated antibody was applied to each slide and incubated at 37 °C for 32 
minutes. Next, one drop of NBT was added to each slide before counterstaining. The miR-
122 is visualised by alkaline phosphate mediated reduction of NBT to the NBT formazan 
precipitate. The slides were cleaned and mounted with cover slides using lab-grade gelatine. 
 
2.2.11  Statistical analysis 
Each data group was tested for normality using the Shapiro-Wilk normality test. Descriptive 
statistical analysis was performed on each data group. For normal data sets, the mean and 
standard deviation was determined for each group. For non-normal data sets, the median and 
interquartile range was determined for each group. To determine statistical significance, 
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comparisons were made using the Student’s t-test (for two parametric groups), the Mann-
Whitney U test (for two nonparametric groups), the ANOVA (for more than two parametric 
groups) and the Kruskall-Wallis test (for more than two nonparametric groups) (StatsDirect, 
Cheshire, UK). For graphical interpretation GraphPad Prism 5 software was used (GraphPad 
Software, La Jolla, CA). Statistical significance was set at P < 0.05. 
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2.3 Results 
2.3.1  Serum miR-122 is increased earlier than serum ALT activity in a murine model 
of APAP-induced ALI 
CD-1 male mice (5-7 weeks old, fed ad libitum) were administered a single toxic dose (530 
mg/kg, i.p.) as described for 1-8 hours. Hepatic GSH levels were significantly decreased 
early after APAP exposure (figure 2.1). Mean hepatic GSH levels (SD) for control animals 
(saline-injected) were 59.4 µmol/g protein. However, in APAP-exposed mice, mean hepatic 
GSH levels (SD) were 10.6 (4.2), 8.1 (4.9) 37.0 (21.3) and 63.2 (0.5) at 1h, 2h, 4h and 8h 
respectively. Hepatic GSH levels were significantly lower at 1h and 2h after APAP exposure 
compared to the control group, showing a 82.2% (P = 0.0007) and 86.4% (P < 0.0001) drop 
respectively. 
Small RNA was extracted from serum where four separate miRNAs were measured 
including liver-enriched miRNAs (miR-122 and miR-192), a muscle-enriched miRNA 
(miR-1), and a brain-enriched miRNA (miR-218).  Serum miRNAs were quantified against 
a reference species (U6 snRNA) using 2 ^ - (ΔCt) method. In the same samples, serum ALT 
activity was measured as described. Serum ALTs exhibited a time-dependent increase after 
APAP administration (figure 2.2A). Median serum ALTs (IQR; interquartile range) are 
shown in table 1. Serum ALTs were significantly raised at 4h (P=0.007) compared to control 
mice. Liver enriched miRNAs (miR-122 and miR-192) in serum also showed a time-
dependent increase (figures 2.2 B-C; table 1). Serum miR-122 levels were significantly 
higher at 2 hours (P=0.02) compared to control mice. Serum miR-192 levels were 
significantly higher at 4 hours (P=0.001) compared to control mice. 
Serum levels of non-liver enriched miRNAs (miR-1, muscle-enriched; miR-218, brain-
enriched) were relatively unchanged throughout APAP-induced ALI compared to liver-
enriched miRNAs (figures 2.2 D-E; table 1). Serum miR-1 levels were significantly higher 
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at 4 hours (P=0.03) compared to control mice. Serum miR-218 levels were not significantly 
higher at any time in APAP-treated mice compared to control mice. 
 
Table 1: Serum ALT activity and miRNA values during APAP exposure in mice 
 Control 1h  2h 4h 8h 
ALT 
U/L (± SD) 
12.5 (3.5, 25) 14.5 (11.5, 16.8) 21.0 (11.5, 54.5) 856 (732, 2405) 299 (278, 320) 
miR-122 
ΔCt (± SD) 
4.1 (1.1, 8.0) 87.2 (12.2, 153.4) 75 (37.5, 441.1) 
4096 (910.2. 
15393) 
8984 (709.2, 
17258) 
miR-192 
ΔCt (± SD) 
4.83 (1.7, 33.6)   30.0 (12.5, 68.2) 23.6 (12.8, 90.7) 
1448 (105.1, 
3180) 
1332 (167.8, 
2495)   
miR-1 
ΔCt (± SD) 
2.1 (1.3, 3.7) 9.8 (6.9, 26.3) 10.1 (4.6, 12.3) 28.4 (5.3, 53.4) 
37.0 (0.01, 
74.0)   
miR-218 
ΔCt (± SD) 
0.2 (0.1, 1.6) 2.3 (1.1, 3.6), 1.0 (0.4, 1.5), 1.6 (0.2, 3.1) 9.1 (0.9, 17.3) 
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Figure 2.1: Hepatic GSH levels fall dramatically early after exposure to a toxic APAP 
dose. Hepatic GSH levels were measured from whole liver homogenates generated from 
flash-frozen liver sections taken at the time points indicated on the x-axis. Control mice 
received saline (i.p.) equivalent to a 530 mg/kg APAP dose for 8 hours. Each open circle 
represents a protein-corrected GSH level from individual mice. Hepatic GSH levels were 
significantly lower 1h (P=0.0007) and 2h (P<0.0001) after APAP administration (Kruskall-
Wallis test). 
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Figure 2.2: Serum miR-122 levels are significantly raised 2 hours after APAP exposure 
unlike serum ALT activity. Serum ALT activity and serum miRNAs were measured in 
serum taken from individual mice. Each panel shows the median (grey bar) and the whiskers 
represent the IQR for each group (n=4; 8h: n=2 due to mortalities). Panels show serum ALT 
activity (A), miR-122 (B), miR-192 (C), miR-1 (D), and miR-218 (E). Statistically 
significant differences are shown in panels (Kruskall-Wallis test) 
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2.3.2  Serum ALT and serum miR-122 provide similar sensitivity in a murine model 
of APAP-induced liver injury. 
CD-1 male mice (5-7 weeks old, fed ad libitum) were administered a single dose of APAP 
ranging from 30-530 mg/kg, i.p. as described for 5 hours, to test the sensitivity of serum 
miRNAs against the serum ALT activity (figures 2.3 A-E). Small RNA was extracted from 
serum where four separate miRNAs were measured including liver-enriched miRNAs (miR-
122 and miR-192), a muscle-enriched miRNA (miR-1), and a brain-enriched miRNA (miR-
218).  Serum miRNAs were quantified against a reference species (U6 snRNA) using 2 ^ -
 (ΔCt) method. Median (IQR) Serum Serum ALT activity was significantly higher at 4 hours 
(P = 0.003; figure 2.3A; table 2). Serum miR-122 levels were not significantly different 
between 300 mg/kg vs 0 mg/kg (and 530 mg/kg vs 0 mg/kg) due to variation in the 0 mg/kg 
group (P=0.27) (figure 2.3B, table 2).  However, they were significantly raised when 
compared to low-dose APAP groups; either 30 mg/kg (P=0.013) or 75 mg/kg (P=0.017) 
which showed no hepatotoxicity. For miR-192, a statistically significant difference was 
observed between 530 mg/kg and 0 mg/kg group (P=0.02) and also between 530 mg/kg and 
30 mg/kg APAP group (P=0.046) (figure 2.3C, table 2). For miR-1, statistical significance 
was observed between 0 mg/kg and 150 mg/kg (P=0.01), and between 0mg/kg and 300 
mg/kg (P=0.048) (figure 2.3D; table 2). For miR-218, statistical significance was not 
observed between differences in any groups (figure 2.3E; table 2). 
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Table 2: Serum ALT activity and miRNA values in an APAP dose-response study in 
mice 
 
,  
 0 mg/kg 30 mg/kg 75  mg/kg 150  mg/kg 300  mg/kg 530  mg/kg 
ALT 
U/L (± SD) 
38.1 (27.5, 
79.3) 
38.7 (23.5, 
79.3) 
29.6 (26.9, 
43.1) 
36.4 (14.6, 
91.8) 
490.4 
(293.7, 
5699) 
4251 
(170.4, 
13069) 
miR-122 
ΔCt (± SD) 
282.9 (124.1, 
437.6) 
109.3 (88.9, 
186.0) 
131.3 (71.5, 
163.1), 
282.9 (124.1, 
437.6) 
572.9 
(214.9, 
3150) 
2069 
(598.4, 
2628) 
miR-192 
ΔCt (± SD) 
29.5 (8.1, 34.9) 23.3 (9.0, 39) 
9.38 (8.5, 
16.0) 
8.4 (7.4, 
21.9) 
224 (33.9, 
1060) 
106 (47.6, 
464) 
miR-1 
ΔCt (± SD) 
1.8 (0.9, 2.2) 1.8 (0.7, 2.7) 
2.3 (0.1, 
3.5), 
5.7 (3.2, 
6.7), 
3.2 (2.1, 
15.0) 
2.8 (1.6, 
3.5) 
miR-218 
ΔCt (± SD) 
0.17 (0.10, 
0.32) 
0.17 (0.09, 
0.22) 
0.12 (0.10, 
0.14) 
0.16 (0.01, 
0.22), 
0.17 (0.01, 
0.23) 
0.12 (0.06, 
0.20) 
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Figure 2.3: Serum ALT activity and serum miR-122 levels provide similar sensitivity to 
inform on APAP-induced liver injury. Serum ALT activity and serum miRNAs were 
measured in serum taken from individual mice. Each panel shows the median (grey bar) and 
the whiskers represent the IQR for each group (n=4). Panels show serum ALT activity (A), 
miR-122 (B), miR-192 (C), miR-1 (D), and miR-218 (E). Statistically significant differences 
are shown in panels (Kruskall-Wallis test). 
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2.3.4 miR-122 is lost progressively from centrilobular zones in mouse liver during 
APAP-induced ALI 
In a separate time-course study, CD-1 male mice (5-7 weeks old, fed ad libitum) were 
administered APAP (530 mg/kg, i.p.) for 1h, 2h, 4h and 8h with time-matched controls 
which received 0.9% saline vehicle equivalent to a 530 mg/kg APAP administration. Livers 
were removed at the indicated time-points and fixed in formalin for 24 hours. From FFPE 
preparations, miR-122 and U6 snRNA were stained using specific riboprobes as described. 
In saline administered mice, miR-122 is visible as a blue stain due to presence of the 
nitroblue tetrazolium formazan precipitate, against a pink counter-stain. miR-122 staining in 
control mice exhibited mild zonal variation with strongest staining in peri-portal hepatocytes 
and slightly milder staining in centrilobular hepatocytes. However, miR-122 was present in 
all hepatocytes with no observable evidence of miR-122 loss in control mice (figure 2.4 A-
D). In liver sections generated from APAP-treated mice, miR-122 staining appears normal 1 
hour after APAP administration (figure 2.4E), with no observable changes compared to 
saline-treated mice. However, noticeably less staining is observed around centrilobular and 
midzonal regions 2 hours after APAP dosing (black arrows, figure 2.4F) when the pink 
counterstain becomes visible. This loss of miR-122 staining becomes increasingly evident at 
4 hours (figure 2.4G) and 8 hours (figure 2.4H) after APAP dosing. 
To investigate the mechanism of cell release at early time points, one single mouse was 
selected from the two hour time point which showed miR-122 loss around centrilobular and 
midzonal regions. A higher-magnification image (10x) was focussed on one central vein 
showing typical miR-122 loss, indicated by black arrows (figure 2.5A). From the same 
section of liver, a H&E stain was performed to visualise necrotic cells. H&E staining 
showed no visual signs of necrotic cells with intact parenchyma (figure 2.5B). Furthermore, 
a riboprobe against U6 snRNA, a small nuclear RNA (and popular choice of reference 
species in miRNA studies) was also stained in the same centrilobular region. The central  
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Figure 2.4: miR-122 is lost progressively from centrilobular hepatic regions during 
APAP-induced ALI. Panels show staining images (2.5x magnification) from individual 
mice taken at the indicated time (left-hand side). Left-hand panels show liver sections 
stained for miR-122 in mice who received saline injections for 1 hour (A), 2 hours (B), 4 
hours (C) and 8 hours (D). No loss of miR-122 is apparent. Right hand columns show liver 
sections stained for miR-122 in mice who received APAP (530 mg/kg, i.p.) for 1 hour (E), 2 
hours (F), 4 hours (G) and 8 hours (H). Black arrows indicate centrilobular regions where 
miR-122 staining appears less intense (pink counterstain) noticeable at 2 hours, becoming 
more pronounced at 4 hours and 8 hours. Scramble control showing pink counterstain only is 
shown in control mice administered saline for 1h (I) and mice administered APAP for 8h (J). 
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vein is less obvious in this tissue slice due to the variable three-dimensional architecture of 
the liver, however U6 snRNA staining in intact nuclei in cells is clear (figure 2.5C). 
 
2.3.5 miR-122 is a hepatocyte-specific miRNA expressed in cytosolic and nuclear 
intracellular compartments. 
To ascertain the specificity of cell expression of miR-122 in the liver, liver slices were 
generated from control mice from the time-course study. The image was focussed on a portal 
triad (PT) (hepatic artery, hepatic portal vein and bile duct) which contains substantial 
amounts of cells other than hepatocytes including endothelial cells and connective tissue. 
From this image, miR-122 staining (blue) is specific to the surrounding parenchyma tissue 
made up of hepatocytes (black arrows, figure 2.6A). Endothelial cells and connective tissue 
comprising the vessels of the portal triad are clearly not stained (pink counterstain). Red 
blood cells can be visualised within the hepatic portal vein. 
In the same mouse, a high-magnification (40x) image was focussed on the hepatic 
parenchyma to resolve the intracellular location of the miR-122 staining. Localised miR-122 
staining (blue) is visible in both cytosolic (white arrow, figure 2.7A) and nuclear (black 
arrow, figure 2.7B) compartments. Hepatic sinusoids are unstained (white). 
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Figure 2.5: miR-122 is lost from hepatocytes which are not yet necrotic 2 hours post 
APAP administration. Panels show staining and histology images (10x magnification). 
Centrilobular and midzonal in situ hybridisation of miR-122 appears considerably lighter 
suggesting loss of miR-122 (A). Histological (H&E) analysis of the same region shows no 
signs of necrosis (B). In situ hybridisation against U6 snRNA shows strong nuclear staining 
in intact cells (C).
CV 
CV 
CV 
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Figure 2.6: miR-122 is expressed specifically in hepatocytes. Panel shows in situ hybridisation against miR-122 at a portal triad junction (20x 
magnification) in a saline-treated mouse. The three main vessels are visible; branch of hepatic portal vein (PV), branch of hepatic artery (HA), branch of bile 
duct (BD). In situ hybridisation against miR-122 reveals hepatocyte-specific staining (black arrows). Endothelial cells and connective tissue are visible in 
light pink (counterstain, white arrows). Red blood cells are visible in the hepatic portal vein. 
PV 
HA 
BD 
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Figure 2.7: miR-122 staining in the hepatic parenchyma is localised to cytosolic and nuclear compartments. Panel shows in situ hybridisation against 
miR-122 in the parenchyma (40x magnification) in a saline-treated mouse. Cords of hepatocytes are visible punctuated with sinusoids (white areas between 
cells). In situ hybridisation against miR-122 reveals strong cytosolic (white arrow) and nuclear (black arrow) intracellular staining.
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2.4 Discussion 
There is an urgent requirement for the identification and development of novel biomarkers 
of DILI in pre-clinical and clinical settings. In recent years, miRNAs have emerged as a 
class of molecules that have the potential to serve as biomarkers of various disease states, 
pathophysiological conditions and drug response. MiRNAs are small (~22nt in length) non-
coding RNA molecules that function to repress a set of target mRNAs through cognate 
nucleotide binding thereby regulating protein output and the phenotype of the cell. MiRNAs 
exist in a remarkably stable form in various biofluids including blood and urine. Although 
species-specific miRNAs exist, as a class they confer true translational potential as many 
miRNAs show high conservation between mammalian species, including pre-clinical 
species. Furthermore, the expression of miRNAs can exhibit high tissue specificity 
combined within high abundance in tissues. These characteristics together provide promise 
for the identification and development of miRNAs as novel biomarkers of DILI. 
In this chapter, the earliness and sensitivity of two liver-enriched miRNAs (miR-122 and 
miR-192) were tested in a 6 week old male CD-1 model of APAP-induced hepatotoxicity. 
These two miRNA species were previously reported to be earlier and more sensitive markers 
of APAP-induced liver-injury in 6-month old male Balb/C mice that were overnight fasted 
(Wang et al, 2009). Hepatic GSH depletion occurs very early in the evolution of APAP-
induced ALI, confirming early biochemical stress in the mouse model (figure 2.1A).  In our 
non-fasted model, miR-122 was raised in some animals at 1 hour, but as a group, this did not 
reach statistical significance. However, miR-122 was significantly raised at 2 hours (P=0.02) 
in our model, while serum ALT activity was still not raised indicating earlier release of miR-
122 into the circulation (figure 2.2A-B). Serum miR-192 levels were not as abundant as 
miR-122 and did not show a significant rise until 4 hours after APAP administration 
(P=0.001, figure 2.2C), although this may be due to the low power of the experiment (n=4). 
The main finding that miR-122 is raised earlier than ALT in the CD-1 male model 
corroborates previously published findings by Wang et al. Furthermore, miR-1 showed 
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modest changes in serum after APAP with a statistical significant rise occuring after 4 hours 
(P=0.03, figure 2.2D). Brain-specific miR-218 was not different at any time (figure 2.2E) 
confirming that non-specific rises in global miRNAs after APAP-overdose occuresd. The 
finding that miR-122 is released earlier than ALT suggests that these markers do not share 
the same release mechanism from injured hepatocytes. ALT is believed to be leaked 
passively from necrotic hepatocytes into the circulation. The mechanism of miR-122 release 
from hepatocytes is unknown, however, it has been shown that miR-122 exists in various 
forms in the circulation; coupled with auxiliary proteins such as Argonaut 2 or encapsulated 
within exosomes and cell-derived vesicles (Arroyo et al, 2011, Bala et al, 2012). It is 
possible that miR-122 release may provide a specific signal to stressed hepatocytes to 
promote cell defence and cell proliferation. Indeed, loss of miR-122 is known to be 
associated with hepatogenesis and cell proliferation (Tsai et al 2012, Hsu et al 2012). 
However, this hypothesis requires testing. 
In another mouse study, the sensitivity of liver-enriched miRNAs was tested alongside the 
“gold-standard” sensitive marker for DILI, serum ALT activity. The data showed that miR-
122 was not more sensitive than ALT in this CD-1 mouse model. From this study, statistical 
significance was not reached for miR-122 at any time when compared to control animals 
(figure 2.3 B). However, this can be accounted for by the unexpected greater variation of 
miR-122 in control animals compared to other non-toxic groups. Indeed, if the comparison 
was made against low-dose (non-toxic) APAP groups (30 mg/kg and 75 mg/kg), a strong 
significant increase was observed at 300 mg/kg (P=0.01) and 530 mg/kg (P=0.002), similar 
to serum ALT activity (figure 2.3A). Nevertheless, this finding is contrary to the findings by 
Wang et al, who found rises in miR-122 and miR-192 at 150 mg/kg APAP doses after 3 
hours in Balb/C mice (Wang et al, 2009). This may be explained by differences in 
experimental design and quantification technique used in the two studies. The mice in this 
study were exposed to APAP for 5 hours at each dose whereas Wang et al used 3 hours 
exposure, which is an early point during APAP-induced hepatotoxicity in rodent models. 
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Increases in circulating miRNAs at 3 hours are evident, however serum ALTs typically peak 
at a point beyond 4 hours, suggesting that the difference in sensitivity observed by Wang 
and colleagues may be due to, in part, different times of biomarker release. Nevertheless, we 
cannot discount fundamental biological differences between the two mouse strains that may 
also account for this. Further work is required with high-powered toxicity studies to 
elucidate the true sensitivity of liver-enriched miRNAs versus other biomarkers. 
To better understand the origins of miR-122 release into the circulation, an APAP time-
course study was performed in the CD-1 mouse model. From mice treated with and without 
APAP, hepatic miR-122 content was analysed via in situ hybridisation. A progressive loss of 
miR-122 staining was observed as early as two hours from centrilobular and midzonal areas 
in liver treated with a toxic dose of APAP (figures 2.4E-H). Importantly, comparator 
time-matched controls treated with vehicle showed consistent miR-122 staining at all time 
points (figures 2.4A-D). Zonal toxicity with APAP is well recognised (Mitchell et al, 1973, 
James et al, 2003) with necrosis occurring most predominantly around centrilobular areas. 
This can be explained in part due to the relatively high levels of CYP2E1 that are expressed 
in centrilobular hepatocytes (Forkert et al, 1995) which generates the toxic metabolite. These 
morphological changes are consistent between rodent models and man (Mitchell et al, 1973). 
This study confirms that miR-122 release at early and late time points occurs from the same 
areas of liver where toxicity is manifested. 
At two hours, hepatic miR-122 depletion is visible (figure 2.4F) which coincides with a 
concomitant rise in the serum at this time (figure 2.2B). To gain insight into the release 
mechanism, a H&E stain was performed in the same histology samples. In the same APAP-
treated mouse (2 hours), a high-magnification image shows centrilobular miR-122 depletion 
in individual hepatocytes (black arrow, figure 2.5A). H&E staining from sections taken from 
the same central vein branch indicate that the hepatocytes are not yet necrotic in nature 
(figure 2.5B). Viable hepatocytes can clearly be defined with sinusoids providing obvious 
borders between cells. Furthermore, a stain directed against a small nuclear RNA species 
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(U6 snRNA), shows clear nuclear staining in cells around the same central vein branch. This 
provides further confirmation that cells are not severely necrotic and that not all small RNA 
species are lost at the same rate as miR-122 (figure 2.5C). The fact that miR-122 depletion 
occurs in cells which appear still viable provides insight into the release mechanism. It is 
likely that during APAP-induced ALI, miR-122 release is associated with necrosis at later 
times; however this work suggests that a proportion of intracellular miR-122 appears to be 
released at times before substantial necrosis occurs. Clearly more work is required to 
identify the exact biological mechanism that governs early release. These findings allow one 
to speculate that miR-122 release may be bi-phasic, with an early energy-dependent step 
occurring before massive miRNA loss during necrosis. However, this concept has yet to be 
examined specifically in the context of DILI.  
This histology data also provides further insight into the hepatocellular expression of miR-
122. Although miR-122 is liver-enriched, the liver is a heterogenous organ comprising 
multiple cell types. From this data, we focussed on a portal triad which defines the borders 
of the hepatic lobule (figure 2.6A) and contains hepatocytes, endothelial cells and 
connective tissue. Analysing such data should inform on whether miR-122 is expressed 
equally among all hepatic cell types or whether there is cellular specificity. The cellular 
expression of miR-122 is striking; strong expression in periportal hepatocytes with no 
visible staining in the vessels of either the hepatic portal vein or the hepatic artery. This 
specificity is likely to provide added confidence in the utility of miR-122 as a biomarker of 
DILI by indicating stress/injury strictly to cells in the liver-parenchyma. Furthermore, 
analysis of high-magnification images of the liver parenchyma allows one to determine miR-
122 localisation within individual hepatocytes. Strong staining occurs within the cytosolic 
and nuclear regions providing evidence that miR-122 is localised to multiple cellular 
compartments (figure 2.7A). 
In summary, this chapter tests miR-122 as a potential marker of DILI in various models, 
including in vivo and in vitro approaches. This data shows that miR-122 can inform on 
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APAP-induced ALI in a young murine model, with good sensitivity and early detectability. 
Amongst the miRNA tested, miR-122 appears to the most promising biomarker of DILI with 
high circulating abundance, coupled with a high dynamic range and high liver-enrichment. 
miR-122 also holds promise as an in vitro marker of DILI using human cells, further 
highlighting the translational potential of this marker. However, obviously more work is 
needed to study the kinetics and extra-cellular form of miR-122 after treatment with APAP 
and other drugs. Finally, the release of miR-122 occurs at hepatocytes surrounding the 
central vein, cells which become necrotic during APAP-induced ALI. More information can 
be taken from the fact that miR-122 is expressed exclusively within hepatocytes and is 
localised within cytosolic and nuclear compartments. Further work is now required to define 
miR-122 baselines in different species, study the biological form in early and late phases of 
APAP-induced ALI, optimise assays to study miRNA release in vitro, examine the 
biological fate/turnover of circulating miRNA species and evaluate the possible clinical role 
of miR-122 in DILI. 
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CIRCULATING MICRORNAS AS POTENTIAL CLINICAL BIOMARKERS OF 
DILI 
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3.1  INTRODUCTION 
The development of informative biomarkers of DILI is a primary goal for the clinic and for 
pre-clinical pharmaceutical evaluation. The challenge for the development of useful clinical 
markers includes identification and development of biomarkers that are ideally stable, 
non-invasive (i.e. can be sampled easily from patients), reflect accurately the 
(patho)physiological state of the liver (Adler et al, 2010), detect injury early with high 
sensitivity and high specificity without the need of specific patient information (i.e. an 
accurate time of ingestion) and be able to predict hard clinical end-points (reviewed by Dear, 
2010) . The current set of clinical markers includes the aminotransfereases (ALT/AST), 
functional markers of liver impairment such as prothrombin time or total bilirubin levels. 
More recently, novel mechanistic markers have emerged such as HMGB1 and cytokeratin-
18 have been discovered, however these have yet to be validated in multi-centre prospective 
clinical studies (Antoine et al, 2009). Limitations exist within the current set of established 
markers such as an unacceptable rate of false positive/negatives, poor sensitivity and lack of 
liver-specificity which together reduce the reliability of such biomarkers in the clinic. Due to 
the burden of DILI in the clinic and in drug development, novel markers that can 
complement or supersede the existing catalogue of biomarkers are urgently sought. 
(Amacher, 2010) 
 
APAP is a well characterised hepatotoxin that has been used clinically as a mild analgesic 
and antipyretic for six decades. Despite an excellent safety profile at therapeutic doses, in an 
overdose setting APAP can cause centrilobular coagulative liver necrosis and possibly fatal 
fulminant hepatic liver failure. APAP is the leading cause of liver failure in the United 
States, reported to be responsible for 10,000 hospitilisations and 500 deaths per annum due 
to intentional or unintentional overdose (Lee, 2004; Larson et al, 2005; Ostapowicz et al, 
2002). Although NAC therapy can provide effective antidotal therapy, in some cases (e.g. in 
patients who present late after drug ingestion) this treatment is not an option and orthoptopic 
liver transplantation may be required to save lives. New biomarkers of DILI (in this case, 
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APAP-induced ALI) are required to identify injury at the earliest possible stage to help the 
physician better manage patient therapy. Novel markers with enhanced liver-specificity 
would also provide added confidence in the utilisation of the marker in the clinic by 
potentially reducing the risk of false positives. 
 
The promise of liver-enriched miRNAs serving as sensitive and specific biomarkers in the 
mouse model of liver injury needs to be evaluated in a patient population. In this chapter, the 
translational ability (i.e. from mouse to man) of these biomarkers to detect liver injury was 
tested in a cohort of patients who have overdosed on APAP and developed severe liver 
injury. miRNAs are measured in four patient cohorts (APAP-overdosed patients who 
develop injury, APAP ALI); APAP-overdosed patients who do not develop injury, APAP 
NO ALI; patients who develop liver injury not caused by APAP e.g. through hepatitis 
infection, NON-APAP ALI; and patients who have chronic kidney disease, CKD, in order to 
test organ injury specificity) versus a group of healthy volunteers. We measured four 
miRNAs; miR-122 (liver-enriched), miR-192 (liver/kidney-enriched) miR-1 (heart/muscle 
enriched) and miR-218 (brain-enriched) alongside U6 snRNA which was used as a reference 
species. In the same samples, we correlated our miRNA data with retrospective clinical 
chemistry data. Moreover, we tested whether miRNAs returned to baseline earlier than ALT 
in serial samples obtained from selected patients. Finally, we tested the performance of 
different normalisers (hsa-miR-376, U6 snRNA hsa-let-7d and cel-lin-4) between healthy 
volunteers and test APAP ALI patients. 
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3.2  PATIENTS AND METHODS 
 
3.2.1 APAP-ALI patients 
This study was prospectively approved by the local research ethics committee, and informed 
consent was obtained from all patients, or the patient’s next of kin, before entry into the 
study. A total of 53 adult patients (age >16 years) admitted to the Royal Infirmary of 
Edinburgh with acute liver injury (ALI) secondary to APAP ingestion were entered into the 
study. ALI was defined as a sudden deterioration in liver function with associated 
coagulopathy in the absence of a history of chronic liver disease.13 Clinical parameters were 
recorded and are summarized in Table 1. Day 1 was defined as the day of entry into the 
study, and on this, and subsequent days, peripheral blood samples were collected. Patients 
were monitored up to day 30, whereupon the outcome of each patient was recorded as either 
poor (died/required liver transplantation) or survived. All serum and plasma samples used in 
this study were obtained by centrifugation, separated into aliquots, and stored at 80 °C until 
analysis. 
 
3.2.2.  Healthy controls 
Blood was collected from a cohort of 25 selected healthy volunteers with ethical approval 
(National Research Ethics Service, Bristol, UK). Median age was 38, and the female-to-male 
ratio was 6:4 to reflect the age and sex bias in the poisoned-patient cohort. Analysis was 
performed in a single-blinded fashion. 
 
3.2.3.  Non-toxic APAP overdosed patients (APAP NO ALI) 
Six patients were recruited from the Royal Infirmary of Edinburgh. Consent was obtained 
from all patients before recruitment, and the study received appropriate local ethical 
approval. The entry criterion was a history of a single APAP ingestion in overdose that 
required treatment with N-acetylcysteine (NAC). Blood was collected at the end of 
intravenous acetylcysteine infusion for measurement of ALT and other biomarkers. Absence 
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of liver injury was confirmed by a normal serum ALT activity (defined as ≤ 3 x upper limit 
of normal [ULN]). 
 
3.2.4  Non-APAP induced ALI patients (NON-APAP ALI) 
Eleven patients were recruited from the Royal Infirmary of Edinburgh. Informed consent 
was obtained from all patients, or the patient’s next of kin, before entry into the study. The 
entry criterion was presentation of ALI independent of APAP ingestion. Clinical 
characteristics of these patients, including etiology of ALI, are summarized in table 1. 
 
3.2.5  Chronic kidney disease patients 
Twenty-two patients (mean age, 46 ± 3 years) were recruited from the Royal Infirmary of 
Edinburgh. Informed consent was obtained from all patients, or the patient’s next of kin, 
before entry into the study. All patients had been diagnosed with chronic proteinuric kidney 
disease (CKD). The mean urinary protein excretion rate was 1,570 ± 371 µg/min, with a 
mean glomerular filtration rate of 43 ± 5 mL/min/1.73 m
2
. 
 
3.2.7  miRNA extraction 
miRNA was extracted using an miRNeasy kit (Qiagen, Venlo, Netherlands), following the 
manufacturer’s instructions, with minor modifications. Briefly, 40 µL of biofluid was made 
up to 200 µL with nuclease-free water, then combined with 700 µL of QIAzol. The sample 
was mixed and left for 5 minutes before the addition of 140 µL of chloroform. In some 
experiments, 10µL of cel-lin-4 (5fM) was added to denatured serum before the addition of 
chloroform (to serve as exogenous control). Samples were then mixed vigorously for 15 
seconds and centrifuged at 12,000 g for 15 minutes at 4 °C. Equal volumes (350 µL) of the 
upper aqueous phase and 70% ethanol were mixed in a fresh microtube before adding the 
total volume to an miRNeasy minispin column. The column was centrifuged at 8,000g for 
15 seconds at room temperature. The flow-through, containing the small RNA fraction, 
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including the miRNA complement, was mixed with 450 µL of 100% ethanol. The elute was 
then purified using a MinElute kit (Qiagen, Venlo, Netherlands). 
 
3.2.8  miRNA purification 
The small RNA elution mixture was applied to a MinElute column, 700 µL at a time. The 
immobilized RNA was then washed with various buffers before a final 80 % ethanol wash. 
The column was then dried by centrifugation. The small RNA fraction was eluted in 14 µL 
of nuclease-free water and stored at -80 °C. 
 
3.2.9  Quantitative Polymerase Chain Reaction Analysis. 
miRNA levels were measured using Taqman-based quantitative polymerase chain reaction 
(qPCR). The small RNA elute was reverse transcribed using specific stem-loop reverse-
transcription RT primers (Applied Biosystems, Foster City, CA) for each target miRNA 
species, following the manufacturer’s instructions. Next, 2 µL of RNA was used to produce 
the complementary DNA (cDNA) template in a total volume of 15 µL. Then, 1.33 µL of 
cDNA was used in the PCR mixture with specific stem-loop PCR primers (Applied 
Biosystems, Foster City, CA) in a total volume of 20 µL. Levels of miRNA were measured 
by the fluorescent signal produced from the Taqman probes on an ABI Prism 7000 (Applied 
Biosystems). All samples were assayed in duplicate. Assay performance was assessed 
(figure 3.3.94), providing acceptable variation and reproducibility. miRNA levels were 
normalized to levels of U6 snRNA, a ubiquitous small nuclear RNA (snRNA) species used 
as an endogenous control, as described elsewhere. 
 
3.2.10  Statistical analysis 
Descriptive statistical analysis was performed on each data group, including medians and 
interquartile ranges. Each data group was tested for normality using the Shapiro-Wilk 
normality test. To determine statistical significance, comparisons were made using the 
Student’s t-test (for two parametric groups), the Mann-Whitney U test (for two 
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nonparametric groups), and the Kruskall-Wallis test (for more than two nonparametric 
groups) (StatsDirect, Cheshire, UK). For correlative analysis, a Pearson’s   correlation test 
was used, employing GraphPad Prism software (GraphPad Software, La Jolla, CA). 
Statistical significance was set at P < 0.05. 
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3.3  RESULTS 
 
3.3.1 Liver-Enriched miRNAs Are Higher in APAP ALI Patients 
Serum ALT activity (figure 3.1) was measured alongside two liver-enriched miRNAs (miR-
122 and miR-192; figure 3.2) and two non-liver-enriched miRNA species (miR-1 and miR-
218; figure 3.3) in serum or plasma obtained from four patient cohorts and one healthy 
cohort. Two cohorts comprised patients with ALI: APAP ALI (n = 53) and non-APAP ALI 
(n = 11). Two control cohorts comprised healthy controls (n = 25) and APAP no ALI 
overdosed patients (n = 6). A control disease cohort comprised patients diagnosed with CKD 
(n = 22). The characteristics of the cohort of patients with APAP ALI and non-APAP ALI 
are presented in Table 3.1 and Table 3.2, respectively. No underlying pathologies were 
recorded in the control cohorts. Serum ALTs were raised in APAP ALI patients (P < 0.0001) 
and non-APAP ALI patients (P < 0.0001) relative to healthy controls (figure 3.1; table 3.3). 
Moreover, these data also show that liver-enriched miRNAs are significantly higher in the 
serum of APAP ALI patients, compared to healthy controls (miR-122: P < 0.0001; miR-192: 
P < 0.0001) (figure 3.2 A,B). Also, miR-122, but not miR-192, was significantly higher in 
non-APAP ALI patients, compared to healthy controls (miR-122: P < 0.001; miR-192: P = 
0.3) (figure 3.2 A,B). The heart-enriched miRNA, miR-1, was not statistically different 
between both ALI (APAP and non-APAP) groups and healthy controls (figure 3.3A). The 
brain-enriched miRNA, miR-218, was significantly higher in the APAP ALI patients, 
compared to healthy controls (P = 0.015), but only over a small dynamic range (figure 
3.3B). In CKD patients, liver-enriched miRNAs showed a modest elevation, when compared 
to the healthy controls (figure 3.2 A,B). Nevertheless, levels of liver-enriched miRNAs in 
APAP ALI patients were substantially higher, compared to CKD patients (miR-122: P < 
0.0001; miR-192: P = 0.0004) (figure 3.2A,B). Levels of miR-1 were not different between 
CKD patients and healthy controls (figure 3.3A). Circulating levels of miR-218 were 
substantially higher in CKD patients, when compared to healthy controls (P < 0.0001) 
(figure 3.3B). 
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Table 3.1: Clinical parameters of the APAP ALI patient cohort. Various parameters 
from the patient cohort. Abbreviations: POD, acetaminophen overdose; KCC, Kings College 
criteria for transplantation; OLT, orthotopic liver transplant; CVVH, continuous veno-
venous hemofiltration; ALT, alanine aminotransferase; n, number; s, seconds. 
 
 No. of cases (POD) 
Gender  
Male (%) 22 (42%) 
Female (%) 31 (58%) 
  
Age (years)  
Median (range) 37 (16-66) 
<50 47 
≥50 6 
  
KCC met  
Yes 19 
No 34 
  
Required CVVH  
Yes 17 
No 33 
Data not available 3 
  
OLT performed  
Yes 5 
No 48 
  
Day One Encephalopathy Score  
Grade 0 25 
Grade 1 9 
Grade 2 4 
Grade 3 2 
Grade 4 13 
  
Max Encephalopathy Score  
Grade 0 21 
Grade 1 7 
Grade 2 2 
Grade 3 3 
Grade 4 20 
  
Died  
Yes 10 
No 43 
  
Poor Outcome (OLT/Died)  
Yes 15 
No 38 
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Four patients presented with miR-122 levels within the normal range (figure 3.2A). The 
clinical data for these patients were analysed in more detail (table 3.4). All four patients 
presented with coagulopathy (INR> 1.3) and three out of four patients presented with 
advanced encephalopathy (HE grade >2) and high serum creatitine levels indicating 
perturbed kidney function. These data taken together suggest that this small group of 
patients presented late after drug ingestion, although clinical data is limited for subject 68 so 
these assumptions should be taken with caution. In this small group, one patient (subject 61) 
died on day 2 of the study - this patient is likely to have presented very late after drug 
ingestion when intensive care therapy was futile.
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   Patient Aetiology Age 
(yrs) 
Sex ALT 
(U/L) 
Day 1 
Creatinine 
(µmol/L) 
Day 1 
PT (sec) 
Day 1 
Bilirubin 
(µmol/L) 
Day 1 
KCC  RRT OLT  Day 1 
Encephalopat
hy grade (0-4) 
Max 
Encephalopath
y grade (0-4) 
Died Poor 
outcome 
(died / OLT) 
miR-122 / 
U6 
1 Acute HBV 44 M 2665 77 19 319 No No No 0 0 No No 329.698 
2 Acute HCV 41 M 1676 61 15 256 No No No 0 0 No No 1108.966 
3 AFLP 32 F 73 299 17 72 No Yes No 1 4 No No 238.03 
4 AIH 71 F 854 55 56 478 Yes No Yes 2 4 No Yes 205.074 
5 AIH 64 M 3393 83 12 199 No No No 0 0 No No 349.706 
6 AIH 69 F 145 105 16 199 Yes Yes Yes 0 4 No Yes 279.17 
7 DILI 58 F 2773 91 15 138 No No No 0 1 No No 831.746 
8 HBV 41 M 794 482 82 375 Yes Yes No 0 4 Yes Yes 922.88 
9 HBV 26 M 2966 89 16 279 No No No 0 0 No No 82.998 
10 Ischaemia 42 F 5192 102 18 84 Yes No 0 4 4 No No 28.345 
11 Malignancy 59 F 310 368 27 121 No Yes 0 3 3 Yes Yes 1172.198 
 
Table 3.2. Clinical characteristics of non-APAP acute liver injury patients. HBV – hepatitis B virus; HCV – hepatitis C virus; AFLP – acute fatty liver 
of pregnancy; AIH – autoimmune hepatitis; DILI – drug-induced liver injury (clarithromycin); Malignancy – breast cancer hepatic infiltration; Day 1 – entry 
into study; KCC – King’s College Criteria; RRT – renal replacement therapy; OLT – orthotopic liver transplantation.  
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Cohorts ALT (U/L) miR-122 (∆Ct) miR-192 (∆Ct) miR-1 (∆Ct) miR-218 (∆Ct) 
 Range 
Healthy Controls Und-26.5 2.98 – 65.8 0.119 – 1.80 0.007 – 0.61 0.022 – 0.313 
APAP no ALI 9-24 2.14 – 54.0 0.120 – 2.20 0.01- 2.39 0.01 – 0.132 
CKD Und-35.6 11.9 – 54.4 0.142 – 6.06 0.008 – 0.502 0.586 – 3.76 
Non APAP ALI 73-5192 8.57-1172 0.006-27.7 Und -1.93 0.014 -0.396 
APAP-induced ALI 452-18040 11.4 - 53231 0.13 - 406 Und – 1.15 0.002 – 1.44 
 
  Median (25
th
 percentile, 75
th
 percentile) 
Healthy Controls 5.948 (3.618, 14.19) 12.13 (6.99, 26.91) 0.4350 (0.295, 0.694) 0.0580 (0.021, 0.089) 0.07 (0.04, 0.1215) 
APAP no ALI 19.0 (14.25, 23.25) 23.21 (3.192, 45.95) 0.941 (0.359, 1.784) 0.0575 (0.00875, 1.423) 0.0280 (0.009. 0.09075) 
CKD 6.13 (4.044, 10.37) 32.03 (21.14, 40.86) 1.230 (0.741, 1.912) 0.0580 (0.0365, 0.1058) 1.714 (1.087, 2.271) 
Non APAP ALI 2665 (794, 2966) 279.2 (194.7, 922.9) 2.420 (0.196, 8.225) 0.0130 (0.00325, 0.06925 0.0950 (0.017, 0.269) 
APAP-induced ALI 5199 (2966, 7984) 1265 (491.3, 4270) 6.940 (1.96, 29.16) 0.0270 (0.006, 0.129) 0.170 (0.0675, 0.504) 
  
 Fold change (Mean) 
APAP ALI vs Healthy controls 665 252 65.5 1.02 3.5 
APAP ALI vs APAP no ALI 313 189 35.2 1.12 6.67 
CKD vs Healthy Controls 1.03 1.73 2.93 0.931 20.3 
Non-APAP ALI vs Healthy controls 245 26.4 11.7 2.72 1.57 
APAP ALI vs CKD 647 146 22.3 1.1 0.17 
  
 P value 
APAP ALI vs Healthy controls < 0.0001 < 0.0001 < 0.0001 0.7093 0.0147 
APAP ALI vs APAP no ALI 0.0009 0.0031 0.056 0.9383 0.06 
Healthy controls vs APAP no ALI 0.0662 0.9997 0.837 > 0.9999 0.465 
CKD vs Healthy Controls 0.9999 0.0063 0.0054 0.9989 < 0.0001 
Non-APAP ALI vs Healthy controls < 0.0001 0.0005 0.2988 0.5164 > 0.9999 
APAP ALI vs CKD < 0.0001 < 0.0001 0.0004 0.420 0.0001 
Table 3.3: ALT and miRNA measurements from six cohorts of patients, healthy controls (n=25), APAP-overdosed patients presenting no liver injury (APAP no ALI, n=6), 
chronic kidney disease patients (CKD, n=22), liver injury patients not caused by APAP (non-APAP ALI, n=11) and APAP-overdosed patients presenting liver injury (n=53). 
P values determined by Kruskall-Wallis multiple comparison test.
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Figure 3.1: Circulating serum ALT activities are significantly higher in patients with 
ALI. Dynamic ranges of serum ALT activities were evaluated in human serum in grouped 
controls (n = 25), APAP no ALI patients (n = 6), CKD patients (n = 22), non-APAP ALI 
patients (n = 11), and APAP ALI patients (n = 53). Each open spot represents an individual 
serum ALT activity. Bars represent the interquartile range (25th and 75th percentiles) from 
the median (horizontal line). The data is shown in table 3.3. 
 
 
 
 
 
 
 
  Chapter Three
99 
 
 
 
Figure 3.2: Circulating liver-enriched miR-122 and miR-192 species are significantly 
higher in patients with APAP ALI. Relative dynamic ranges of two liver-enriched miRNA 
species were evaluated in human serum or plasma in grouped controls (n = 25), APAP no 
ALI patients (n = 6), CKD patients (n = 22), non-APAP ALI patients (n = 11), and APAP 
ALI patients (n = 53). Panels show the relative levels of circulating (A) miR-122 and (B) 
miR-192 across six cohorts. Bars represent the interquartile range (25th, 75th percentiles) 
from the median (horizontal line). The data is shown in table 3.3. Four patients who had 
miR-122 levels within the normal range are highlighted by closed circles (panel A). Clinical 
data from these patients is presented in table 3.4 
 
Study # ALT (U/L) miR-122 (ΔCt) INR HE Grade Day Death Creatinine 
(µmol/L) 
Patient 61 
2188 8.574 2.3 4 2 246 
Patient 64 
3386 11.432 1.8 4 Survived 234 
Patient 63 
482 13.785 2.2 3 Survived 179 
Patient 68 
1385 20.112 N/A 0 Survived N/A 
 
Table 3.4: Clinical analysis of 4 patients with serum miR-122 levels in the normal range 
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Figure. 3.3: Circulating muscle-enriched miR-1 is not significantly higher in patients 
with ALI, compared to healthy controls, and brain-enriched miR-218 is significantly 
higher in APAP ALI patients over a small dynamic range, compared to healthy 
controls. Relative dynamic ranges of a heart-enriched (miR-1) and a brain-enriched (miR-
218) miRNA was evaluated in human serum or plasma in grouped controls (n = 25), APAP 
no ALI patients (n = 6), CKD patients (n = 22), non-APAP ALI patients (n = 11), and APAP 
ALI patients (n = 53). Panels show the relative levels of circulating miR-1 (A) and miR-218 
(B) across six cohorts. Each open spot represents an individual relative amount of miRNA 
(ΔCt). Bars represent the interquartile range (25th, 75th percentiles) from the median 
(horizontal line). The data is shown in table 3.3. 
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3.3.2 miR-122 Correlates With ALTs, But Not Prothrombin Time or Total Bilirubin 
Concentration, in APAP ALI Patients. 
To assess the performance of the two liver-enriched miRNAs as markers of liver injury, the 
relative abundance of each miRNA was compared against serum ALT activity. Serum miR-
122 showed a statistically significant correlation (figure 3.4A) with ALT activity (P = 
0.0004, Pearson R = 0.47), whereas miR-192 (figure 3.4B) showed no significant correlation 
(P = 0.14, Pearson R = 0.20). When the two non-liver-enriched miRNAs were plotted 
against ALT, miR-1 showed no significant correlation (P = 0.46, Pearson R = -0.10) (figure 
4C) and miR-218 showed a significant positive correlation over a small dynamic range (P = 
0.004, Pearson R = 0.39) (figure 3.4D). In the same serum samples, we plotted the relative 
abundance of miR-122 versus prothrombin time and total serum bilirubin concentration 
(figures 3.5A-B), clinical markers of liver function, and serum creatinine levels (figure 5C), 
the standard marker of kidney function. There was no statistical correlation between miR-
122 abundance and prothrombin time (Pearson R = 0.14, P = 0.34, figure 3.5A), total 
bilirubin concentration (Pearson R = 0.10, P = 0.48, figure 3.5B), or serum creatinine 
(Pearson R = -0.16, P = 0.25, figure 3.5C). 
 
3.3.3 Day 1 miR-122 Levels and Outcome in APAP ALI Patients 
 
To determine the predictive value of miR-122, miRNA abundance in serum samples 
obtained from APAP ALI patients on day 1 was assessed relative to outcome: Whether that 
person met Kings College Criteria (KCC) for liver transplantation (figure 3.6A) and 
recovery versus poor outcome (died/required liver transplant) (figure 3.6B). In patients 
satisfying KCC, miR-122 levels and serum ALT activities were 96.3% and 11.4% higher, 
respectively, compared to those that did not meet KCC (miR-122: 6,848 ± 3,144 versus 
3,488 ± 1,018, P = 0.15; ALT: 6,123 ± 694 versus 5,496 ± 658, P = 0.46). The average 
(mean ± standard error) miR-122 levels and serum ALT activities were 110% and 3.5% 
higher, respectively, in patients who had poor outcome, compared to those who recovered 
  Chapter Three
102 
 
(miR-122: 7,522 ± 3,966 versus 3,576 ± 928, P = 0.39; ALT: 5,863 ± 890 versus 5,664 ± 
590, P = 0.93). 
 
 
 
Figure 3.4: Liver-enriched miR-122 levels and brain-enriched miR-218 levels 
significantly correlate with peak serum ALT activity in APAP ALI patients. Correlation 
between relative miRNA abundances and ALTs from APAP-induced ALI patients (A) miR-
122, (B) miR-192, (C) miR-1, and (D) miR-218. Scatter graphs show the correlation 
between the relative abundance of each miRNA (ΔCt) versus the serum ALT activity in that 
sample. Pearson R values (statistical P values) are 0.47 (P = 0.0004), 0.20 (P = 0.14), -0.10 
(P = 0.46), and 0.39 (P = 0.004) for miR-122, miR-192, miR-1, and miR-218, respectively, 
versus serum ALT (Pearson’s correlation test). 
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Figure 3.5: Circulating liver-enriched miR-122 does not correlate with prothrombin 
time, total serum bilirubin concentrations, or serum creatinine levels. Blood was taken 
from each patient on day 1 of the study. Prothrombin time, serum bilirubin levels, serum 
creatinine, and serum miRNAs were measured as described. Scatter graphs show the 
correlation between the relative abundance of miR-122 versus (A) prothrombin time, (B) 
total serum bilirubin, and (C) serum creatinine. Pearson R values (statistical probabilities) 
are 0.14 (P = 0.34), 0.10 (P = 0.48) and -0.16 (P = 0.25) for prothrombin time, total serum 
bilirubin concentration,and serum creatinine, respectively (Pearson’s correlation test). 
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Figure 3.6:  Day One miR-122 levels and outcome in APAP ALI patients. The data for 
each biomarker (ALT - left, miR-122 - right) was categorized into groups based on patient 
outcome. (A) Patients who satisfied Kings College Hospital Criteria (KCC) for liver 
transplant during the study. The average day one (mean ± standard error) ALT values (U/L) 
for patients who meet KCC criteria and those who do not meet KCC are 6123 ± 694 vs 5496 
± 658 respectively (P = 0.46). The average day one miR-122 values (∆∆Ct) for patients who 
meet KCC criteria and those who do not meet KCC are 6848 ± 3144 and 3488 ± 1018 
respectively (P = 0.15). (B) Day one serum ALT data is not predictive of outcome in 
patients who have poor outcome (death or liver transplant). The average day one (mean ± 
standard error) ALT values (U/L) for patients who recovered and those who died/required 
liver transplantation are 5664 ± 590 and 5863 ± 890 respectively (P = 0.93). Average 
relative miR-122  levels (∆∆Ct) in patients who survived and those who died/required liver 
transplantation are 3576 ± 928 and 7522 ± 3966 respectively (P = 0.39, Mann-Whitney U 
test). Columns represent means, error bars represent standard error. 
 
 
 
 
a 
b 
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Figure. 3.7: Longitudinal analysis of circulating biomarkers in APAP ALI patients. (A) 
miR-122 (right) levels return to baseline sooner than serum ALT activity (left). Eleven 
APAP ALI patients had their blood taken on day one of the study and again between days 
three and seven. Serum ALT activity and relative miR-122 abundance was measured (as 
described) to understand the disposition of these biomarkers in a longitudinal fashion.  
Average (mean ± standard error) serum ALT activity values for day one and follow-up 
analysis are 6583 ± 719 and 2603 ± 500 U/L respectively. Average miR-122 ∆∆Ct values for 
day one and follow-up analysis are 5734 ± 3115 and 56.8 ± 16.6 respectively (B) miR-122 
levels return to baseline after liver transplantation. Three APAP ALI patients who required 
orthotopic liver transplantation had their blood taken on day one of the study and again after 
liver transplantation to understand the effects of invasive surgery on the abundance of these 
circulatory biomarkers. Average (mean ± standard error) serum ALT activity values for day 
one and post-transplantation analysis are 7256 ± 3766 and 546 ± 95.8 respectively. Average 
relative miR-122 levels (∆∆Ct) for day one and post-transplantation analysis are 19301 ± 
16989 and 27.9 ± 15.2 respectively. Each closed spot represents the individual value for 
ALT activity or relative miR-122 abundance with a solid line connecting the values from the 
same patient between day one and follow-up (A) or post transplantation (B) analysis.  
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3.3.4 miR-122 Levels Return to Baseline Before Serum ALT Activity in APAP ALI 
Patients Both With and Without Liver Transplantation 
We selected 11 APAP-poisoned patients, based on day 1 analysis, with a range of ALTs 
(2,782-9,760 U/L) and relative miR- 122 concentrations (ΔCt 264-35,364). These patients 
had blood retaken between days 3 and 7, and the same biomarkers were analyzed. There was 
an average (mean ± standard error) 62.2% ± 5.1% reduction in serum ALT activity (2,603 ± 
500 versus 6,583 ± 719), whereas relative miR-122 abundance exhibited an average 96.9% ± 
0.8% reduction (56.8 ± 16.6 versus 5,734 ± 3,115) (figure 3.7A). Furthermore, 3 APAP ALI 
patients required orthotopic liver transplantation. Blood was taken on day 1 and after 
transplantation. Serum ALT activity had reduced by 88.3% ± 4%, on average, but still 
remained above baseline (546 ± 95.8 versus 7,256 ± 3,766), whereas miR-122 levels had 
reduced by 99.1% ± 0.65%, on average, and returned to baseline (ΔCt 27.9 ± 15.2 versus 
19,301 ± 16,989) (figure 3.7B). 
 
3.3.5 Circulating day one miR-218 levels are significantly higher in patients who 
develop grade 4 encephalopathy patients compared to grade 0 patients.  
The APAP-ALI cohort was stratified into groups based on the patient’s encephalopathy 
grade, either at admission or the maximal grade that was reached during the study. We 
focused on grade 4 patients versus grade 0 patients to determine whether day one circulating 
miR-122 (figure 3.8A) or miR-218 (figure 3.8B) levels could distinguish patients based on 
their maximum encephalopathy grade at presentation to hospital (figure 3.8 left panels) or at 
a later time during the study (figure 3.8 right panels). Only day one miR-218 levels could 
statistically distinguish patients who developed a maximum grade 4 encephalopathy during 
the study (P=0.02) (figure 3.8B). 
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Figure 3.8: Day One miR-218 levels are significantly higher in patients who exhibited a 
maximum grade 4 encephalopathy during the study compared to grade 0 patients. 
Panels show individual day one serum miR-122 levels (A) and miR-218 levels (B) from 
APAP ALI patients categorized into either Grade 0 or Grade 4 encephalopathy. Analyses are 
based on encephalopathy grade on admission (Admission Grade, left) or the maximum 
encephalopathy grade reached during the study (MAX HE Grade, right). Each open spot 
represents an individual relative miRNA level. The bars represent the interquartile range 
(25
th
, 75
th
 percentiles) from the median (horizontal line). Median (25
th
, 75
th
 percentiles) 
miRNA ∆∆Ct values [grade 4 vs grade 0] in admission HE grade categories are 1201 (229, 
2700) vs 1453 (554, 4829) and 0.271 (0.093, 0.4040) vs 0.158 (0.052, 0.516) for miR-122 
and miR-218 respectively. In maximum HE grade patients, ∆Ct values are 1868 (523, 4141) 
vs 1201 (387, 4796) and 0.284 (0.139, 0.620) vs 0.089 (0.039, 0.263) for miR-122 and miR-
218 respectively. Day One miR-218 levels in the grade 4 MAX HE group are statistically 
different to grade 0 patients (P = 0.02, Mann-Whitney U test). No other comparisons are 
statistically significant. 
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 3.3.6 Biological and bio-analytical variability and reproducibility 
To assess the biological variation for miR-122 and the reference species, U6 snRNA, raw Ct 
values obtained from healthy volunteers and APAP ALI patients were grouped and 
compared (figure 3.9A; table 3.5). To assess bioanalytical variability, four control and four 
APAP ALI serum samples were selected at random. Small RNA was extracted and purified 
from each sample three times before miR-122 was reverse transcribed and measured via 
qPCR separately. Mean Ct values (± standard deviation) are shown in table 3.6 and figure 
3.9B. miR-122 levels are reproduced within 2.86 Ct values, with the greatest %CV = 4.9%. 
 
 Healthy (Ct Range [%CV]) ALI (Ct Range [%CV]) 
U6 snRNA 29.1-33.1 (3.5%) 29.6 -36.3 (4.9%) 
miR-122 26.8 -28.2 (1.4%) 17.6-27.4 (12.2%) 
Table 3.5: Ct value range for U6 snRNA and miR-122 in healthy controls and ALI cohorts 
 Mean miR-122 Ct (± SD) 
Control 1 29.7 ± 0.53 
Control 2 30.3 ± 0.24 
Control 3 31.1 ± 1.54 
Control 4 31.5 ± 0.47 
APAP ALI 1 22.6 ± 0.60 
APAP ALI 2 21.8 ± 0.33 
APAP ALI 3 19.5 ± 0.36 
APAP ALI 3 21.7 ± 0.43 
Table 3.6: miR-122 Ct values in selected control and APAP ALI patients 
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Figure 3.9: Assay variability and reproducibility. The variation in Ct values of U6 
snRNA (left) and miR-122 (right) are shown in the control and APAP ALI cohort (A). The 
bars represent the standard deviation from the mean (horizontal line). The range of U6 
snRNA Ct Values (%CV) are 29.1-33.1 (3.5%) and 29.6 -36.3 (4.9%) for controls and 
APAP ALI patients respectively. The range of miR-122 Ct Values (%CV) are 26.8 -28.2 
(1.4%) and 17.6-27.4 (12.2%) for controls and APAP ALI patients respectively. In a 
separate experiment (B), we selected four healthy control samples at random (left) and four 
APAP ALI patients with high relative miR-122 levels (right, ∆∆Ct 19016-53231) and 
extracted miRNA (as described) three times to test the reproducibility of miR-122 analysis 
in our assay. An open circle represents a single miR-122 replicate Ct value around the mean 
(horizontal line). miR-122 levels are reproduced within 2.86 Ct values, with the greatest 
%CV = 4.9%.*** P < 0.001 (Student t-test). 
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3.3.7 Endogenous and exogenous normaliser performance 
The performance of the reference species, U6 snRNA, was tested by comparing raw Ct 
values in grouped controls (n=25) and APAP ALI patients (n=53) (figure 3.9A). A modest 
but statistically significant difference was observed in U6 snRNA Ct values between 
controls and APAP ALI patients (P < 0.001). After correspondence with Qi et al, two 
alternative reference species were identified (let-7d and miR-374a) (Qi et al, 2012). To test 
the performance of alternative endogenous circulating reference species, hsa-let-7d-5p and 
hsa-miR-374a-3p, was measured alongside U6 snRNA in further analysis. Fifteen healthy 
control serum samples and fifteen ALI serum samples were selected at random. Small RNA 
was extracted again from these samples as described. An exogenous reference species, 
Caenorhabditis elegans-specific lin-4 was added to compare endogenous versus exogenous 
normalisation strategies (figure 3.10) A statistically significant difference was observed 
between groups (healthy controls vs ALI patients) for both hsa-let-7d (figure 3.10A, 
P<0.001) and U6 snRNA (figure 3.10C, table 3.7, P<0.001). Although, no statistical 
difference was observed between groups for miR-374a-3p (figure 3.10B), the %CV was 
high (7.21%), had low mean abundance (Ct=40.1) and was undetected in 6 samples. The 
exogenous normaliser provided low variation in both groups (CV < 2%) and did not provide 
a statistical difference between groups. 
 Healthy Ct value range (%CV) ALI Ct value range (%CV) 
hsa-let-7d-5p 31.2 - 33.3 (1.74%) 32.5 - 36.7 (2.99%) 
has-miR-374a-3p 36.4 - 46.2 (7.58%) 37.6 - undetected (7.21%) 
U6 snRNA 31.0 - 35.2 (3.55%) 34.9 - 40.9 (4.69%) 
cel-lin-4-5p 34.7 - 36.4 (1.51%) 34.1 - 36.6 (1.88%) 
Table 3.7: Ct values and coefficients of variation (%CV) of different normalisers in healthy 
and ALI cohorts. 
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To further test the impact of applying different normalisers to the miRNA data set, the 
original miR-122 Ct values were normalised using four different reference species measured 
in the same samples; let-7d (figure 3.11A), miR-374a-3p (figure 3.11B),  U6 snRNA (figure 
3.11C) and cel-lin-4 (figure 3.11D). The data is shown in table 3.8. 
 
 
 
 
 
Figure 3.10: Profiling endogenous miRNA normalizers in healthy and ALI patient sera. 
Individual serum miRNAs were assayed from 15 randomly selected healthy controls and 
ALI patients from our study using TaqMan human microRNA assays (Applied Biosystems, 
Foster City, CA). To serve as an exogenous control species, 5 lL of a 10 fM solution of cel-
lin-4-5p was added to each denatured serum sample during RNA extraction. The Ct values 
of hsa-let-7d-5p (A), hsa-miR-374a-3p (B), U6 snRNA (C), and cel-lin-4-5p (D) are shown 
in panels in grouped healthy controls and ALI patients. Each open spot represents an 
individual Ct value.  
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Figure  3.11 Circulating liver-enriched miR-122 is significantly higher in ALI patients 
regardless of the normalization strategy applied. Panels show the relative dynamic range 
of circulating miR-122 in grouped controls (n = 15) and ALI patients (n = 15) when 
normalized with hsa-let-7d-5p (E), hsa-miR-374a-3p (F), U6 snRNA (G), and cel-lin-4-5p 
(H). The expression of serum miR-122 was significantly higher in ALI patients compared to 
healthy controls irrespective of the normalization strategy applied. ***P < 0.001, **P < 0.01 
(Mann-Whitney U test). 
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Figure  3.12 miR-122 levels are significantly different between healthy controls and 
ALI patients when normalisation is removed. Nonnormalized serum miR-122 Ct values 
show a highly significant difference between healthy controls and ALI patients. The 
variation in Ct values of serum miR-122 in healthy controls and ALI patients are shown in 
groups. The median (25th, 75th percentile) miR-122 Ct values are 27.3 (27.1, 27.5) and 23.8 
(21.1, 24.6) for controls and ALI patients, respectively. The range of miR-122 Ct values 
(%CV) are 26.8-28.2 (1.4%) and 17.6-30.4 (12.4%) for controls and ALI patients, 
respectively. ***P < 0.001 (Mann-Whitney U test). 
 
 
A statistical significant difference between healthy and ALI was observed between groups 
regardless of the normaliser used. Similar fold-increases, variations and levels of 
significance were observed between groups when let-7d, U6 snRNA or lin-4 was used to 
normalise the data. 
Normaliser Healthy (miR-122 ΔCt ± IQR) ALI (miR-122 ΔCt ± IQR) 
hsa-let-7d-5p 22.3 (19.0, 38.9) 1764 (907, 6724) 
hsa-miR-374a-3p 2906 (1184, 25268) 199358 (89889, 4155000) 
U6 snRNA 11.2 (6.89, 33.1) 923 (343, 4211) 
cel-lin-4-5p 294 (178, 420) 4689 (2410, 15662) 
Table 3.8: Relative miR-122 data (ΔCt) in healthy and ALI cohorts when applied with 
different normalisers 
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When the normalisation strategy is removed (Ct values alone), miR-122 levels in ALI 
patients are statistically significant (P < 0.001, figure 3.12). The median (25th, 75th 
percentile) miR-122 Ct values are 27.3 (27.1, 27.5) and 23.8 (21.1, 24.6) for controls and 
ALI patients, respectively. The ranges of miR-122 Ct values (%CV) were 26.8-28.2 (1.4%) 
and 17.6-30.4 (12.4%) for controls and ALI patients, respectively. 
3.4 DISCUSSION 
miR-122 is an abundant, liver-enriched miRNA species. It has been shown recently that 
circulating levels of miR-122 are significantly increased after ethanol and D-galactosamine 
treatment in rodents and in patients with viral hepatitis infection (Zhang et al, 2010) 
suggesting that miR-122 release into the circulation is a hallmark of liver injury developing 
from multiple aetiologies. Wang and colleagues showed recently that elevations in serum 
miR-122 and miR-192, another abundant liver miRNA, preceded significant rises in serum 
ALT activity, with respect to time and dose after APAP treatment in mice (Wang et al, 
2009). These findings suggest that circulating miR-122 and miR-192 can be detected before 
marked cell death occurs in the liver and hold potential to be used as predictive markers of 
injury. Here, these candidate biomarkers were tested in healthy controls and a cohort of 
patients who have taken an overdose of APAP and developed injury. These markers were 
also measured in a control group of patients who had an APAP overdose with no detectable 
liver injury (prevented through NAC treatment) and a group of patients who had ALI 
independent of APAP ingestion (see table 3.2). Because of the importance of the specificity 
of potential biomarkers, the panel of miRNAs was in a cohort of CKD patients to test the 
performance of liver-specific miRNAs in patients who had an underlying pathological 
condition in another organ. Kidney injury frequently occurs in parallel with liver injury and 
has been reported to occur in isolation during APAP poisoning. In testing the reproducibility 
of the assay, very similar levels of miR-122 and U6 snRNA were observed across three 
separate extractions from different control and patient samples (figure 3.9B). With regard to 
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the normalization protocol, it is considered important to include an endogenous internal 
standard in miRNA measurement of patient samples to control for variations in sample 
handling and different extraction efficiencies. It was observed that U6 snRNA levels were, 
on average, slightly lower in APAP ALI patients (figure 3.9A), but this did not result in a 
significant distortion to all miRNA levels, as shown by consistent levels of miR-1 across all 
cohorts (figure 3.3A). The highly significant increase in miR-122 levels in APAP ALI 
patients was evident with normalisation (figure 3.2A) or when normalization was removed 
(figure 3.12). The choice of particular normalization control for miRNA assays currently 
varies between laboratories. Adding exogenous nonmammalian miRNAs (e.g., 
Caenorhabditis elegans–specific miR-39 or lin-4) into the extraction procedure is an 
approach used to correct for technical variation (Mitchell et al, 2008, Mahn et al, 2011, 
Arroyo et al, 2011). However, an endogenous species may be required to correct for 
biological variation, especially where samples are isolated from patients. Due to 
practicalities, biological sampling in the clinic may be subject to greater variation through 
inconsistent sampling methods, variable sample handling and storage, and necessary 
transport of samples from care units to laboratories. Using endogenous normalisers can 
compensate for this variation in a sample by providing a reference reading of an invariable 
small RNA species. Several different small RNA species have been utilized previously, 
including U6 snRNA (as in this study), RNU48, and miR-16, (Zhang et al, 2010, Wang et 
al, 2011, Wang et al, 2010) although one group has recently reported miR-122 analysis in 
human patients without normalization (Bihrer et al, 2011). More recently, Qi et al 
discovered a panel of invariable circulating miRNA species (hsa-miR-374a, hsa- miR374b 
and hsa-let-7d) with potentially superior stability and reduced variability between various 
clinical groups, compared to U6 snRNA (including young and aging healthy volunteers, 
patients with autoimmune disease and patients with malignant melanoma) (Qi et al, 2011). 
The performance of these novel normalisers was tested in a random selection of 15 healthy 
controls against 15 ALI serum samples. It was observed that at let-7d has low variation 
within healthy controls (CV 1.7%) and ALI patients (CV 3.0%) (figure  3.10A). However, in 
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common with U6 snRNA (figure 3.10C), we observed a modest but statistically significant 
difference in let-7d levels between healthy controls and ALI patients which supports our 
notion that many reference molecules may be perturbed in these very sick, acutely injured 
patients. The serum profile of miR-374a-3p was less promising, with high variation in 
controls (CV 7.58%) and ALI patients (CV 7.21%) and low mean abundance (Ct = 40.1) 
(figure 3.10B). Furthermore, miR-374a-3p was not detected in 6 ALI patients. It would be 
interesting to profile the related miR-374a-5p in light of the findings by Qi and colleagues, 
however, these assays are currently unavailable on the Taqman platform. As expected, the 
exogenous species (cel-lin-4) provided the least variation in controls (CV 1.5%) and ALI 
patients (CV 1.9%) whilst exhibiting no difference between groups (figure 3.10D), however 
this serves to correct for technical variation and not biological variation. cel-lin-4 is a 
c.elegans-specific miRNA, that plays an important role during development by targeting lin-
41 mRNA during embryogenesis (Schulman et al, 2005). Although, lin-4 is described as c-
elegans-specific, a mammalian variant does exist, miR-125b, which shares function with lin-
4 (Schulman et al, 2005). However, the complementarily is not 100% (see figure 3.13), 
therefore the specificity of the taqman primers can distinguish mammalian and non-
mammalian isoforms allowing consistent quantification of lin-4 in clinical samples.   
 
Figure 3.13: Sequence complementarily between c.elegans lin-4 and mammalian miR-125b 
species. 
  
Nevertheless, regardless of the choice of normaliser applied, it is clear that miR-122 is raised 
in ALI patients compared to healthy controls (figures 3.11A-D). Moreover, a significant 
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difference was still observed when we remove normalization, a characteristic of miR-122 
that may greatly simplify a future ‘point of care’ clinical assay (figure 3.12). These data 
support the use of endogenous normalisers and suggest that let-7d-5p in particular may add 
value as a reference species alongside or instead of U6 snRNA, in certain circulating 
miRNA studies. This work will now allow the field to test reference molecules in 
prospective studies and may ultimately provide a more robust and accurate analysis strategy 
for circulatory miRNA studies.  
In the clinical study, the most abundant miRNA in every cohort analyzed was miR-122. This 
is not surprising, because miR-122 is highly abundant in the liver, comprising approximately 
70% of the entire miRNA hepatic complement (Lagos-Quintana et al, 2002). In the panel, 
the next most abundant circulating miRNA was miR-192 (figure 3.2B), which is also 
enriched in the liver, but is also expressed in the kidney and in the gastrointestinal tract 
(Liang et al, 2007). The levels of miR-1 (expressed in muscle and cardiac tissues) were, on 
average, the least abundant. Levels of miR-218, which is enriched in brain (Wang et al, 
2009) was more abundant than miR-1, but not as abundant as the liver enriched miRNAs in 
serum and plasma. Levels of miR-122 and miR-192 (liver-enriched miRNAs) were 
significantly higher in APAP-poisoned patients as were serum ALT activities (figures 3.2A-
B). However, heart enriched miR-1 levels were not different from healthy controls (figure 
3.3A). APAP ingestion alone is not sufficient to release high levels of hepatic miRNAs into 
the circulation, as shown in 6 patients who had taken an APAP overdose, but did not 
develop liver injury (figure 3.2A,B). MiR-122 was significantly higher in non-APAP ALI 
patients, compared to healthy controls. This confirms that the levels of miR-122, but not 
miR-192, are significantly higher in the circulation after multiple forms of liver injury, 
including hepatitis and malignancy (see table 3.2), suggesting that miR- 122 holds superior 
diagnostic potential over miR-192. Furthermore, miR-218, the brain-enriched miRNA, 
exhibited a small, but significant, elevation in the circulation of APAP ALI patients (figure 
3.2D). For comparison, miR-218 levels in non-APAP ALI patients did not differ from 
healthy controls. Liver-enriched miRNAs were slightly higher in CKD patients (figure 3.2), 
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compared to healthy controls, but ALT levels did not differ (figure 3.1). ALT tissue 
expression is mainly hepatic, but isoforms are present in other human tissues (e.g., muscle) 
(Glinghammar et al 2009, Lindblom et al 2007). Increased serum ALT activity has been 
noted in individuals after extreme-endurance exercise regimens highlighting potential 
contributing factors for false positives (Skenderi et al, 2006, Koutedakis et al, 1993). Zhang 
et al. have shown recently that serum ALTs are higher in patients with polymyositis and 
after exercise-induced muscle damage without a concomitant rise in miR-122, (Zhang et al, 
2010) further highlighting the possible additional benefit of miR-122 in diagnosing liver 
injury. Therefore, it will be necessary, in further work, to define changes in circulating 
miRNA levels that are of actual, rather than merely of statistical significance, analogous to 
the use of multiples of ULN in ALT measurements. 
Four subjects from the ALI cohort presented with miR-122 levels in the normal range 
(figure 3.2A) despite having ALI (ALT > 3 X ULN; table 3.4). The presentation clinical 
chemistry data for these patients indicated, unexpectedly, that these patients were extremely 
ill. All patients had coagulopathy (INR >1.3), all had raised serum creatinine levels, and 
three patients presented with a HE grade > 2 (fourth patient - data not available). These data, 
taken together, suggest that these patients presented to hospital very late after drug ingestion. 
In fact, one subject in this group died on day 2 of the study. It is possible that the miR-122 
signal has been missed in these patients due to the relatively short half-life of miR-122 in the 
blood. This may explain the unexpectedly low levels of miR-122 in this small group of 
extremely ill patients. This further highlights the urgent need to understand the kinetics of 
miR-122 in the blood of patients during both early and late phases of DILI. 
It is shown, for the first time, that miR-122 levels are significantly correlated with peak 
serum ALT activity in a heterogeneous cohort of APAP-poisoned patients (figure 3.4A), 
suggesting that miR-122 can inform on human liver injury. The dynamic range of relative 
miR-122 levels among all the samples analyzed was, in fact, higher than that of ALT (ΔCt 
0.154 53,231 versus 1.144-18,040 U/L). This could provide a key advantage, if it is possible 
to eliminate false positives and false negatives. Nevertheless, miR-122 did not correlate with 
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prothrombin time or total serum bilirubin levels, which are clinical markers of ALF (figure 
3.5A,B). These disparities may be explained by the circulatory kinetics of these biomarkers 
during the cascade of toxicity (i.e., it is possible that miR-122 release is an earlier event than 
the cessation of hepatic-clotting factor production or heme-metabolism pertubations during 
ALF). It is also important to consider the circulatory half-lives of these biomarkers during 
toxicity. ALT has been reported to have a half-life of 48 ± 17 hours in patients with 
hepatitis-associated liver injury (Saheki et al 1990). Indeed, prothrombin time correlates 
with ALT activity in these patients (data not shown). The relatively long circulatory half-life 
of ALT may provide more of a window for correlation with both early markers (e.g., miR-
122) and markers that present later (e.g., prothrombin time). To date, the circulatory half-life 
of miR-122 has not been ascertained in humans. Although the intracellular half-life of miR-
122 has been estimated to be >24 hours (Gatfield et al, 2009), the data suggests that the 
circulatory half life of miR-122 is considerably less than that of ALT as serum levels return 
to baseline sooner than ALT in APAP-poisoned patients (figure 3.7A). miR-122 did not 
correlate with serum creatinine levels, a marker of kidney function (figure 3.5C). This is not 
surprising, because miR-122 is not abundantly expressed in kidney tissues (Liang et al, 
2007). The muscle-enriched miRNA, miR-1, did not correlate with any of the markers in this 
study, suggesting that APAP toxicity did not cause a nonspecific elevation in circulating 
miRNA abundance (figure 3.4C). The brain-enriched miRNA, miR-218, correlated with 
serum ALT activity (figure 3.4D), although this was over a small dynamic range. This may 
be explained by the fact that APAP-induced ALF is associated with encephalopathy. We 
found that day 1 miR-218 levels were significantly higher in patients who reached a 
maximal encephalopathy grade 4 during the study, compared to grade 0 patients (Fig. 3.8B). 
It is also possible that miR-218 is present in the liver and other tissues at low levels, and that 
an increase in the circulation may be the result of APAP-induced damage in tissues, 
including the brain. 
Current biomarkers of liver injury are not predictive of outcome. Here, the predictive value 
of miR-122 was tested. Serum miRNA levels were measured in samples obtained from 
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patients on day 1 of their admittance into the study against outcome criteria after day 30: 
poor outcome (i.e., non-survival or required transplantation) versus recovery and whether 
patients met KCC for transplantation. Day 1 miR-122 levels were not predictive of any 
outcome in this small sample set. However, the trend suggested that miR-122 was more 
predictive than ALT (figure 3.6), and it would be valuable to test this possibility in further 
studies. In summary, we show, for the first time, that liver-enriched miR-122 levels are 
raised and correlate with an existing biomarker of DILI in a heterogeneous group of ALI 
patients. Also, it is shown that circulating miR-122 returns to baseline before serum ALT, 
indicating that miR-122 has a shorter circulatory half-life. This data suggests that circulating 
miRNAs can provide a novel addition to the existing catalogue of biomarkers to detect and 
diagnose human liver injury. Future challenges will be to define the mechanisms of release 
of cellular miRNAs, establish whether their release has a functional adaptive role in 
response to injury, and to determine whether miR-122 can provide clinical prognostic value 
over current biomarkers of DILI in future, prospective, clinical trials and real-life clinical 
situations with other etiologies of liver disease. 
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4.1  INTRODUCTION 
Overdose of APAP is a common reason to attend hospital. Statistical evidence collected for 
the financial year 2010-2011 found that there were approximately 38,000 emergency room 
visits in England (NHS Information Centre - Hospital Episode Statistics for England. Inpatient 
statistics). Similarly, in the United States, there are over 100,000 calls to poison control 
centres which are attributed to an overdose of APAP (Lee, 2004). Early identification of 
APAP overdose and extent of APAP exposure is critical in the early management of patients 
in the clinic. If the appropriate therapy is not administered at the appropriate time, patients risk 
developing hepatotoxicity which may lead to life-threatening acute liver failure. If the patient 
presents within 4 hours of APAP ingestion, then activated charcoal can be administered orally 
to sequester APAP and reduce systemic absorption. However, many patients present after this 
time, when much of the dose had already been absorbed. The current clinical triage strategy 
involves measuring plasma APAP levels and assessing risk through use of the Rumack-
Matthew nomogram which determines risk based on a circulating plasma half-life of 4 hours. 
However, an accurate time of ingestion is also required to determine risk which is often 
unreliable. If risk cannot be ruled out, then the patient will receive antidotal therapy through an 
intravenous NAC regimen. The full NAC regimen takes at least 20 hours to complete which 
not only causes patient discomfort but results in substantial hospital bed occupancy (47,000 
bed days per annum in England). Furthermore, NAC therapy itself is associated with several 
ADRs encompassing minor skin reactions to serious systemic anaphylactoid responses. In 
total, it is estimated that up to 45% of patients suffer an ADR who receive NAC therapy (Kerr 
et al, 2005). 
Clinical uncertainty exists in the utilisation of the Rumack-Matthew nomogram, which is 
prone to identifying false-positive and false-negative risk in APAP overdosed patients. A 
personalised biological approach is sought that identifies risk in patients and could supersede 
the current ‘one-size-fits-all’ strategy.  The current catalogue of clinical biomarkers that detect 
liver injury include the serum aminotransferase enzymes (ALT, AST), bilirubin and 
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parameters of liver function such as prothrombin time. However, these markers rise relatively 
late after APAP administration when hepatocellular damage has already occurred. Although 
serum ALT activity is the gold standard marker for the detection of liver injury, the enzyme 
typically rises between 12-36 hours after APAP ingestion. This latent period prevents the use 
of ALT being used as an early predictive marker of injury and therefore cannot be used to 
assess risk. 
Clearly, the identification and development of novel markers that rise at the earliest possible 
time after an APAP overdose is required in the clinic. Furthermore, novel markers are required 
that have enhanced liver specificity and reflect accurately the pathophysiological status of the 
liver. Such markers would provide the physician with a biological readout with which risk of 
hepatotoxicity could be assessed confidently soon after APAP ingestion. If high-risk patients 
could be identified in a personalised manner, this may allow safe discharge of low-risk 
patients without the need of administering time-consuming, unnecessary antidotal therapy. 
This type of approach would likely reduce both rate of NAC-related ADRs and reduce the 
clinical and financial burden of patient care. 
Recently, miR-122 has been found to be a sensitive blood-based biomarker of APAP-induced 
liver injury in a mouse model (Wang et al, 2009). In this study, it was found that rises in miR-
122 could be detected earlier than rises in ALT. Furthermore, miR-122 was raised at relatively 
low doses where ALT was not elevated suggesting that miR-122 provides substantial 
sensitivity for APAP-induced liver injury. Alongside these potential benefits, miR-122 also 
exhibits remarkable liver-enrichment in man (Liang et al, 2007). The clinical promise of this 
high-level enrichment was demonstrated by Zhang and colleagues who found that serum ALT 
activity provided false-positive readings for liver injury in patients with muscle-damage 
(Zhang et al, 2010). 
In this chapter, it is hypothesised that miR-122 can serve as an early informative marker of 
liver injury in a cohort of APAP-overdosed patients who have presented early after APAP 
ingestion. Due to enhanced liver specificity and potentially earlier time of release, circulating 
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miR-122 holds promise to identify patients with ALI at presentation to the hospital emergency 
department. 
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4.2  PATIENTS AND METHODS 
4.2.1 Patients 
Patients (total N=129) were recruited from the Royal Infirmary of Edinburgh, UK (N=107) 
and the Royal Victoria Infirmary, Newcastle-Upon-Tyne, UK (N=22). Full informed consent 
was obtained; the study was approved by the local research ethics committee. Inclusion 
criteria were: adult with a clear history of excess paracetamol ingestion and a timed blood 
paracetamol concentration that was judged by the treating physician to necessitate hospital 
admission for intravenous NAC therapy, as per UK guidelines at the time of study 
(www.toxbase.org).  Exclusion criteria were: patients detained under the Mental Health Act; 
patients with known permanent cognitive impairment; patients with a life-threatening illness; 
unreliable history of paracetamol overdose; patients who take anticoagulants therapeutically or 
have taken an overdose of anticoagulants; patients who, in the opinion of the responsible 
clinician/nurse, were unlikely to complete the full course of NAC. All patients completed the 
full course of NAC treatment. 97 patients were participants in the Scottish and Newcastle 
Antiemetic Pretreatment for Paracetamol Poisoning study (SNAP – EudraCT number 2009-
017800-10), a randomised clinical trial designed to assess if ondansetron is effective in 
reducing nausea and vomiting in patients poisoned with paracetamol treated with NAC. As a 
pre-defined part of the SNAP trial protocol, blood samples were collected for biomarker 
evaluation.  
 
4.2.2 Sample collection 
In all 129 study participants, blood samples were collected at the time of first presentation to 
hospital, before NAC (and for SNAP study participants, ondansetron or placebo) therapy had 
commenced. Plasma was separated and the samples were stored at -80
0
C until analysis. For all 
study participants, demographic data and blood results were recorded. ALI was defined as 
peak serum ALT activity greater than 3x the upper limit of the normal range (>150 IU/L), the 
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UK indication for continuing acetylcysteine therapy after completion of the initial regimen 
(www.toxbase.org) at the time of study.  
4.2.3  Clinical chemistry measurements 
Plasma or serum was obtained via pulse centrifugation from blood that had been allowed to 
clot overnight. Serum ALT levels, total bilirubin, serum creatinine, serum alkaline phophatase 
(ALP), serum gamma glutamyl-transpeptidase (GGT) and international normalised ratio (INR) 
determintion were all determined in the respective hospital laboratory after blood sampling, 
according to the standard hospital laboratory practice. 
 
4.2.4  miRNA extraction 
miRNA was extracted using an miRNeasy kit (Qiagen, Venlo, Netherlands), following the 
manufacturer’s instructions, with minor modifications. Briefly, 40 µL of biofluid was made up 
to 200 µL with nuclease-free water, then combined with 700 µL of QIAzol. The sample was 
mixed and left for 5 minutes before the addition of 140 µL of chloroform. Samples were then 
mixed vigorously for 15 seconds and centrifuged at 12,000 g for 15 minutes at 4 °C. Equal 
volumes (350 µL) of the upper aqueous phase and 70% ethanol were mixed in a fresh 
microtube before adding the total volume to an miRNeasy minispin column. The column was 
centrifuged at 8,000g for 15 seconds at room temperature. The flow-through, containing the 
small RNA fraction, including the miRNA complement, was mixed with 450 µL of 100% 
ethanol. The elute was then purified using a MinElute kit (Qiagen, Venlo, Netherlands). 
 
4.2.5  miRNA purification 
The small RNA elution mixture was applied to a MinElute column, 700 µL at a time. The 
immobilized RNA was then washed with various buffers before a final 80 % ethanol wash. 
The 
column was then dried by centrifugation. The small RNA fraction was eluted in 14 µL of 
nuclease-free water and stored at -80 °C. 
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4.2.6  Quantitative Polymerase Chain Reaction Analysis. 
miRNA levels were measured using Taqman-based quantitative polymerase chain reaction 
(qPCR). The small RNA elute was reverse transcribed using specific stem-loop reverse-
transcription RT primers (Applied Biosystems, Foster City, CA) for each miRNA species, 
following the manufacturer’s instructions. Next, 2 µL of RNA was used to produce the 
complementary DNA (cDNA) template in a total volume of 15 µL. Then, 1.33 µL of cDNA 
was used in the PCR mixture with specific stem-loop PCR primers (Applied Biosystems, 
Foster City, CA) in a total volume of 20 µL. Levels of miRNA were measured by the 
fluorescent signal produced from the Taqman probes on an ABI Prism 7000 (Applied 
Biosystems). miRNA levels were normalised to levels of hsa-let-7d, an invariable blood based 
miRNA species for biological standardisation, as described elsewhere (Qi et al, 2011). 
 
4.2.7  Plasma HMGB1 measurement 
NB: This analysis was performed by Dr Dan Antoine in collaborative work within the CDSS. 
Total HMGB1 was measured by ELISA according to the manufacturer’s instructions. A 
chicken anti-HMGB1 antibody was used as a catcher antibody (1 µg/well). Linear regression 
was used to determine the concentration of HMGB1 in each sample by comparison to known 
standards. A fluorescent signal was produced by 3,3’,5,5’-tetramethyl-benzidine turnover 
using a peroxidise linked anti-HMGB1 antibody. 
 
4.2.8  Plasma keratin 18 (K-18) measurement  
NB: This analysis was performed by Dr Dan Antoine in collaborative work within the CDSS. 
K18 (apoptosis) and K18 (necrosis) were determined using the M30 (apoptosis) and M65 
(total: apoptosis and necrosis) ELISAs respectively, according to the manufacturer’s 
guidelines (Peviva AB, Bromma, Sweden). Linear regression was used to determine the 
concentration of CK in both assays by comparison to known standards. A fluorescent signal 
was produced by 3,3’,5,5’-tetramethyl-benzidine turnover using a peroxidise linked anti-K-18 
antibody. The full-length K-18 (necrosis) data was obtained by subtracting the apoptosis K-18 
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assay data (M30 ELISA) from the total K-18 data (M65 ELISA) as performed previously 
(Antoine et al, 2012). 
 
 
 
4.2.9  Glutamate dehydrogenase (GLDH) measurement 
NB: This analysis was performed by Dan Antoine in collaborative work within the CDSS. 
GLDH levels were measured photo-optically using the DGKC kit as previously (Randox 
Laboratories, Kearneysville, WV, USA) (Harrill et al, 2012). A decrease in absorbance was 
measured in each sample caused by the oxidation of nicotinamide adenine dinucleotide at 340 
nm, as per the manufacturer’s protocol. 
 
4.2.  Statistical analysis 
Data are presented as median and range or inter-quartile range. Each data set was analysed for 
non-normality using a Shapiro-Wilk test. For two non-normal data sets, comparisons were 
made using the Mann-Whitney U test. The Kruskall-Wallis test was used to determine 
significance between more than two non-normal sample groups. All calculations were 
performed using StatsDirect statistical software. For correlative analysis, Pearson’s 
Correlation test, R
2
 and Receiver Operator Characteristic (ROC) curve analysis was carried 
out using the GraphPad PRISM software. Results were considered significant when p<0.05. 
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4.3  RESULTS 
4.3.1 Plasma miR-122  at hospital presentation correlated with subsequent liver injury 
In the cohort, there were 51 men (40 %) and 78 women (60 %) with a median age of 34 years 
(Table 1). Fifty four percent of this cohort had at least one risk factor for APAP-induced ALI. 
The median time (interquartile range, IQR) from APAP ingestion to first blood sample 
collection was 8.0 h (6.0-15.0 h). The median admittance blood paracetamol concentration 
was 120.0 mg/L (IQR, 63.0-179.0). From timed plasma paracetamol concentrations, the 
Rumack-Matthew nomogram indicated that all 129 patients required NAC therapy. The 
median (IQR) clinical chemistry values at first hospital presentation were: serum creatinine: 
67.0 µmol/L (60.0-81.5), bilirubin:  5.0µmol/L (7.0-11.0), serum ALT activity: 22.0IU/L 
(16.0-57.5), serum ALP activity: 75.0IU/L (60.5-94.5), serum GGT activity: 24.0IU/L (15.0-
46.0) and an INR of 1.0 (0.9-1.1). The number of patients presenting with a serum ALT 
activity less than 3xULN was 98 (75%) with 32 (25%) patients more than 3xULN. The 
number of patients presenting with an international normalised ratio < 1.5 was 107 (83%) with 
19 (17%) presenting with an INR > 1.5. No patients required liver transplantation or 
developed encephalopathy. 
Plasma miR-122 levels were measured in plasma obtained at the point of hospital admission, 
before NAC treatment had begun but when a time blood paracetamol concentration had 
indicated the requirement for NAC therapy. A Pearson correlation analysis was performed on 
values obtained from miR-122 against the peak serum ALT activity during patient 
hospitalisation. The presentation serum miR-122, significantly correlated with peak ALT 
activity values (P <0.0001, Fig 4.1A). The correlation coefficients (R
2
) was 0.14, and the 
Pearson R values (95% CI) was 0.37 (0.21-0.52). 
Then, a Pearson correlation analysis was performed from miR-122 values at first presentation 
against the peak INR value reached during patient hospitalization. The presentation values for 
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plasma miR-122 significantly correlated with peak INR values (P < 0.0001, figures 4.1B). The 
correlation coefficient (R
2
) was 0.24 and the Pearson R value (95% CI) was 0.49 (0.34-0.61). 
 
 
Table 4.1: Clinical parameters of the patient cohort. Various clinical parameters of the 
patient cohort who present early after APAP ingestion. Abbreviations: ALT, alanine 
aminotransferase; ALP, alkaline phosphatise; GGT, gamma glutamyl transpeptidase; INR, 
International Normalised Ratio; ULN, upper limit of normal.  
 
 
Number 129 
Sex (Male : Female) 51:78 
Age (Years) 34 (24.5 – 47.0) 
Risk Factors (% of cohort) 54 
Amount of APAP ingested (g) 18.0 (13.0 – 25.0) 
Time from ingestion to first blood sample (Hr) 8.0 (6.0 – 15.0) 
Admission paracetamol concentration (mg/L) 120.0 (63.0 – 179.0) 
Admission serum creatinine (µmol/L) 67.0 (60.0 – 81.5) 
Admission bilirubin (µmol/L) 5.0 (7.0 – 11.0) 
Admission ALT activity (IU/L) 22.0 (16.0 – 57.5) 
Admission ALP activity (IU/L) 75.0 (60.5 – 94.5) 
Admission GGT activity (IU/L) 24.0 (15.0 – 46.0) 
Admission INR 1.0 (0.9 – 1.1) 
Number with Admission ALT < ULN 94 
Number with peak ALT > 3x ULN 32 
Number with peak ALT > 1000 U/L 20 
Number with admission INR < 1.5 107 
Number with peak INR > 1.5 19 
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Figure 4.1 : Plasma miR-122 levels at hospital admission significantly correlate with 
peak serum ALT activity and peak INR values.  miR-122 levels were measured in patients 
who presented early (median time = 8 hours) after APAP overdose (n=129) and correlated 
against the peak ALT value (A) or peak INR value (B) from each respective patient during 
their hospital admission. Each closed circle represents values from individual patients. 
Presentation miR-122 levels significantly correlated with peak ALT (P<0.0001) and peak INR 
values (P<0.0001) (Pearson correlation test). The R
2
 values (Pearson R with 95% CI) were 
0.14 (0.37, from 0.21 to 0.52) and 0.24 (0.49, from 0.34 to 0.61). 
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4.3.2  In patients with a normal ALT activity on first hospital presentation, plasma 
miR-122, are higher in those who develop ALI 
From the cohort of 129 paracetamol overdose patients, the cohort was stratified to focus on the 
94 patients who presented with a normal serum ALT activity (<50U/L) to determine if miR-
122 is more sensitive than ALT at detecting ALI.  Of these patients, 11 (12%) developed ALI 
(> 3 x ULN serum ALT activity; median peak ALT (IQR) 403 (266, 1532) during their 
hospitalization whereas 83 (88%) patients did not develop ALI at any time during the study 
(serum ALT activity remained < 3xULN).  Plasma miR-122 levels were significantly higher at 
presentation in patients who developed ALI compared to those that did not (P<0.0001) (figure 
4.2A; table 4.2). In contrast, presentation ALT levels did not identify patients who developed 
ALI (P=0.27, figure 4.3B; table 4.2).  
 ALT < 3 x ULN ALT > 3 x ULN 
miR-122 (median ΔCt + IQR) 0.16 (0.05-0.43) 3.48 (0.81-15.56) 
ALT (median U/L + IQR) 19 (14, 25) 21 (12, 30) 
 
Table 4.2: Admission relative miR-122 levels (ΔCt) and serum ALT activity in patients who 
do not develop liver injury and patients who subsequently develop liver injury 
 
A ROC curve analysis was performed on these groups to provide a robust test of sensitivity 
and specificity for presentation plasma miR-122 (figure 4.2 C) and presentation serum ALT 
activity (figure 4.2 D). Plasma miR-122 performed with high AUC values (and sensitivity at 
90% specificity); 0.87 (0.72) suggesting that miR-122 could separate patients with and without 
ALI at a time when serum ALT activity was normal (P<0.0001). In accordance with the data, 
the AUC values (and sensitivity at 90% specificity) for serum ALT were lower; 0.6 (0.18) 
confirming that presentation serum ALT activity did not identify patients who develop injury 
(P=0.26). 
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Figure 4.2 : Plasma miR-122 levels at hospital admission are significantly higher in 
patients who develop ALI.  Presentation plasma miR-122 levels were measured in patients 
who presented with a normal ALT range (<50 U/L) (n=94). The patients were grouped into 
those who developed ALI (ALT > 3x ULN) during their hospitalisation (n=11) and those who 
did not develop ALI (ALT < 3x ULN) (n=83). The panels show the presentation plasma miR-
122 levels (A) and presentation serum ALT activity (B) in each group of patients. Each open 
circle represents the value measured from individual patients. The horizontal line represents 
the median between the whiskers (IQR). ROC curves were generated from the grouped data. 
Panels show plasma miR-122 (C) and serum ALT activity (D). The AUCs (and sensitivity at 
90% specificity) were 0.87 (0.72) and 0.6 (0.18) for plasma miR-122 and serum ALT 
respectively. 
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4.3.3 In patients with a normal ALT activity on first hospital presentation, plasma miR-
122 levels are higher in patients who develop APAP-induced coagulopathy (INR>1.3) 
From the cohort of 129 paracetamol overdose patients, the cohort was stratified to focus on the 
94 patients who presented with a normal serum ALT activity (<50U/L) to determine if miR-
122 is more sensitive than ALT.  Of these patients, 6 (6%) developed coagulopathy (INR > 
1.3) median peak INR (IQR) 1.5 (1.4, 2.0) during their hospitalization whereas 88 (94%) 
patients did not develop coagulopathy at any time during the study (serum ALT activity 
remained < 3xULN).  Plasma miR-122 levels were significantly higher in patients who 
developed coagulopathy compared to those that did not (P = 0.0038) (figure 4.3A; table 4.3). 
In contrast, presentation ALT levels did not identify patients who developed coagulopathy (P 
= 0.26, figure 4.3B, table 4.3). 
 INR ≤ 1.3 INR > 1.3 
miR-122 (median ΔCt + IQR) 0.17 (0.05, 0.53) 3.48 (0.62, 17.94) 
ALT (median U/L + IQR) 19 (14, 25) 21 (17.3, 40.8) 
 
Table 4.3: Admission relative miR-122 levels (ΔCt) and serum ALT activity in patients who 
do not develop coagulopathy and patients who subsequently develop coagulopathy 
 
A ROC curve analysis was performed on these groups to provide a robust test of sensitivity 
and specificity for presentation plasma miR-122 (figure 4.3 C) and presentation serum ALT 
activity (figure 4.3 D). Plasma miR-122 performed with high AUC values (and sensitivity at 
90% specificity); 0.89 (0.6) suggesting that miR-122 could identify patients who develop 
coagulopathy at a time when serum ALT activity was normal (P = 0.0038). In accordance with 
the data, the AUC values (and sensitivity at 90% specificity) for serum ALT were lower; 0.63 
(0.33) confirming that presentation serum ALT activity did not identify patients who develop 
injury (P=0.27). 
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Figure 4.3: Plasma miR-122 levels at hospital admission are significantly higher in 
patients who develop APAP-induced coagulopathy.  Presentation plasma miR-122 levels 
were measured in patients who presented with a normal ALT range (<50 U/L) (n=94). The 
patients were grouped into those who developed coagulaopathy (INR > 1.3) during their 
hospitalisation (n=6) and those who did not develop ALI (INR ≤ 1.3) (n=88). The panels show 
the presentation plasma miR-122 levels (A) and presentation serum ALT activity (B) in each 
group of patients. Each open circle represents the value measured from individual patients. 
The horizontal line represents the median between the whiskers (IQR). ROC curves were 
generated from the grouped data. Panels show plasma miR-122 (C) and serum ALT activity 
(D). The AUCs (and sensitivity at 90% specificity) were 0.87 (0.72) and 0.6 (0.18) for plasma 
miR-122 and serum ALT respectively. 
 
 
 
 
 
0.001 
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4.3.4 Circulating miR-122 is superior to serum ALT activity in identifying ALI in 
patients whose first blood sample was within 8 hours of overdose 
From the cohort of 129 paracetamol overdose patients, the group was stratified to focus on 63 
patients who presented within 8 hours of APAP ingestion to determine whether miR-122 could 
detect early ALI. Of these patients, 11 (17%) subsequently developed liver injury (> 3xULN 
serum ALT activity; median peak ALT (IQR) 487 U/L (266, 942 U/L) during their hospitalization 
whereas 52 (83%) patients did not develop liver injury at any time during the study (serum ALT 
activity remained < 3xULN). First presentation levels of miR-122 was significantly higher in 
patients who developed ALI compared to those that did not (P=0.0013) (figure 4.4B, table 4.4). 
In contrast, presentation ALT values were not different in patients who developed liver injury 
compared to those that did not (P=0.5) (figure 4.4A, table 4). We performed a ROC curve 
analysis (figures 4.4 C-D) which demonstrated the following AUC (and sensitivity at 90% 
specificity) values: 0.81 (0.45) for plasma miR-122 and 0.56 (0.09) for serum ALT.  
 8H NO ALI 8H ALI 
miR-122 (median ΔCt + IQR) 0.19 (0.07-0.73) 3.69 (0.43-96.0) 
ALT (median U/L + IQR) 20 (15 – 28) 21 (12-56) U/L 
Table 4.4: miR-122 levels (ΔCt) and serum ALT activity in patients who presented to hospital 
within 8 hours of APAP overdose who did or did not subsequently develop ALI. 
Furthermore, the median (IQR) plasma APAP concentration was not significant between 
patients that did and did not develop ALI; 177.0 (139.0-208.0) vs 165 (123.0-204.8) mg/l 
(P=0.68) (figure 4.5A). Also, back-extrapolation of the presentation paracetamol 
concentration to 4h was also not significant between patients that did and did not develop ALI; 
179.0 (165.0-354.0) vs 269.4 (179.7-351.0) mg/l (P=0.43) (figure 4.5B). Consistent with there 
being no statistical difference in plasma paracetamol concentration between groups, the ROC 
curve analysis for paracetamol concentration produced an AUC (and sensitivity at 90% 
specificity) value at presentation of 0.54 (0.18, P=0.68, figure 4.5C) and at 4h of 0.58 (0.18, 
P=0.43, figure 4.5D).
Chapter Four 
137 
 
 
Figure 4.4: miR-122 is superior over ALT in detecting ALI in APAP overdose patients 
who present within 8 hours. miR-122 levels were measured in all patients who presented 
within 8 hours (n=63). The patients were grouped into those who developed liver injury (ALT 
> 3x ULN) (n=11) and those who did not develop injury (n=52). The panels show the levels of 
serum ALT activity (A) or relative miR-122 levels (B) in both groups. Each open circle 
represents the value from individual patients. The median serum ALT activities (IQR) for 
patients who developed injury and for patients that did not develop ALI were 21 (12-56) U/L 
vs 20 (15 – 28) respectively. A ROC curve was produced for ALT (C) and miR-122 (D). The 
AUC values (sensitivity at 90% specificity) were 0.81 (0.45) for plasma miR-122 and 0.56 
(0.09) for serum ALT. 
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Figure 4.5: Presentation plasma APAP concentration or back-extrapolated 4-hour 
plasma APAP concentration does not identify patients who develop liver injury. Plasma 
APAP concentration was measured on plasma samples taken at admission. The patients who 
presented within 8 hours were grouped into those that developed liver injury (ALT > 3x ULN) 
and those that did not develop liver injury (ALT remained < 3x ULN). The absolute plasma 
APAP levels (A) and the plasma levels that were back-extrapolated to 4 hours (B) were plotted 
to determine if circulating APAP concentration could distinguish patients who develop liver 
injury. The median (IQR) plasma APAP values for patients who developed ALI and those that 
did not develop ALI were 177.0 (139.0-208.0) vs 165 (123.0-204.8) mg/l respectively. The 
median (IQR) back-extrapolated 4h plasma APAP values for patients who developed ALI and 
those that did not develop ALI were 179.0 (165.0-354.0) vs 269.4 (179.7-351.0) respectively. 
A ROC curve was produced for admission plasma APAP contration (C) and back-extrapolated 
4h plasma APAP concentration (D). The AUC values (sensitivity at 90% specificity) were 
0.54 (0.18) and 0.58 (0.18) for admission plasma APAP concentration and back-extrapolated 
plasma APAP concentration. 
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4.3.5  Circulating miR-122 strongly correlates with HMGB1 and necrosis keratin-18 
Plasma miR-122, HMGB1, necrosis keratin-18, apoptosis keratin-18 and GLDH levels were 
measured in plasma obtained at the point of hospital admission, before NAC treatment had 
begun but when a time blood paracetamol concentration had indicated the requirement for 
NAC therapy (n=129). A Pearson correlation test was performed with plasma miR-122 versus 
each of the novel mechanistic biomarkers of ALI (HMGB1, necrosis keratin-18, apoptosis 
keratin-18 and GLDH). The correlation coefficients (P values) were 0.21 (P < 0.0001) and 
0.19 (P < 0.0001), 0.06 (P = 0.005), 0.08 (P = 0.0012) between plasma miR-122 and HMGB1 
(figure 4.6A), necrosis keratin-18 (figure 4.4B), apoptosis keratin-18 (figure 4.5C) and GLDH 
(figure 4.6D) respectively. The Pearson R values (95% CI) were 0.46 (0.31 - 0.59), 0.43 (0.28 
- 0.57), 0.25 (0.08 to 0.41) and 0.29 (0.12 to 0.44) between miR-122 and HMGB1, necrosis 
keratin-18, apoptosis keratin-18 and GLDH respectively.  
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Figure 4.6 : Presentation plasma miR-122 correlates well with presentation HMGB1 and 
necrosis keratin-18. Plasma miR-122 levels. HMGB1, necrosis keratin-18 was measured on 
plasma samples taken at admission (n=129). The patients who presented within 8 hours were 
grouped into those that developed liver injury (ALT > 3x ULN) and those that did not develop 
liver injury (ALT remained < 3x ULN). The presentation plasma miR-122 levels are plotted 
against HMGB1 (A), necrosis keratin-18 (B), apoptosis keratin-18 (C) and GLDH (D). Each 
closed circle represents an individual patient values. The correlation coefficients (R
2
), 
statistical probabilities (P-values) and Pearson R values (95% CI) are tabularised in panel E. 
 
4.3.6  Longitudinal analysis of miR-122 and ALT in individual APAP-overdose patients  
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From the cohort of 129 APAP overdose patients, 10 patients were selected on an individual 
basis; 7 patients who developed ALI during their hospitalisation, median peak ALT (IQR) 
1122 (755, 1729), and 3 patients who did not develop ALI. All 10 patients had blood taken at 
admission to hospital where plasma APAP concentrations indicated that all 10 patients 
required NAC therapy. In total, three blood samples were taken from each patient; at 
presentation, 12 hours after the start of NAC therapy, and 20.25 hours after the start of NAC 
therapy. From these samples, plasma miR-122 and serum ALT activity was measured as 
described in order to measure each marker longitudinally. Patient characteristics, admission 
plasma APAP concentrations, serum ALT activities and plasma miR-122 values at admission, 
12 hours after the start of NAC therapy and 20.25 after the start of NAC therapy are tabulated 
in table 4.2. The data from individual patients is expressed graphically in figure 4.7 A-J. 
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Plasma APAP 
at admission 
(mg/L) 
Time post OD 
at admission 
(h) 
Blood 1 
(admission) 
Blood 2 
(admission + 12h) 
Blood 3 
(admission + 20.25h) 
ALT (U/L) miR-122/let7d 
(ΔCt) 
ALT (U/L) miR-122/let7d 
(ΔCt) 
ALT (U/L) miR-122/let7d 
(ΔCt) 
X21 46 F Y 
 
10 19 184  232.325 1032  3541.14 1122  1669.27 
X34 22 M 
Y 
17 20 
87  
18.189 
863  
105.786 
1504  
157.586 
11041 29 F 
Y 
177 8 61 217.519 306 27.002 531 16.111 
11067 17 M 
Y 
70 14 38 0.812 71 0.395 318 21.781 
12023 53 F 
Y 
46 16 80 56.689 360 1.061 480 57.68 
FV1 36 M 
Y 
386 4 12 0.111 755 471.136 662 20.393 
FV2 63 F 
Y 
120 10 30 3.47 53 10.966 319 57.083 
11006 31 F 
N 
148 8 18 0.73 17 0.76 20 0.35 
11008 43 M 
N 
254 8 12 0.648 16 0.125 15 0.087 
11009 42 M 
N 
37 11 26 0.022 28 0.455 29 0.485 
Table 4.2: Patient characteristics, admission plasma APAP levels and serial serum ALT activity and plasma miR-122 levels in 10 individual patients. 
Abbreviations: ALI, acute liver injury, APAP, paracetamol, ALT, alanine aminotransferase. 
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Figure 4.7: Longitudinal measurement of plasma miR-122 and serum ALT activity in 10 
individual APAP overdose patients. All 10 patients required NAC therapy based on plasma 
APAP concentration. All 10 patients had blood taken on admission, 12 hours after the start of 
NAC therapy and 20.25 hours after the start of NAC therapy. Each panel shows serum ALT values 
(closed circles) and plasma miR-122 values (open circles) from individual patients. Seven 
individual patients developed ALI (panels A-G) and three individual patients did not develop ALI 
(panels H-J). 
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4.4 Discussion 
 
There is an urgent requirement in the clinic to identify and develop novel biomarkers of ALI 
that show enhanced liver-specificity, and/or improved sensitivity over currently-used 
markers. The current validated method to assess liver integrity combines measurement of 
circulating aminotransferase activity with markers of liver function; either prothrombin time 
(PT), or PT normalised to the INR score. However, limitations with the currently-used 
clinical biomarkers of DILI are widely recognised, including lengthy time from drug 
exposure to detection, lack of tissue specificity and unacceptable rates of false 
positives/negatives. In a wider sense, there is also a need to develop novel markers for other 
forms of DILI, in particular that of idiosyncratic DILI which may be the result of chronic 
exposure to a drug. In this chapter, the work builds upon previous clinical investigations in 
chapter 3 by testing the earliness and sensitivity of miR-122 against the current gold 
standard marker of liver injury, ALT. 
 
Work by Wang and colleagues in a mouse model of APAP-induced ALI found that 
circulating levels of liver-enriched miRNAs were elevated earlier than serum ALT activity 
(Wang et al, 2009). Furthermore, this work also suggested that miR-122 was potentially 
more sensitive than ALT, as rises could be detected at lower toxic doses of APAP compared 
to serum ALT activity. However, whether this increased sensitivity is truly biological, or 
perhaps technical (i.e. improved bioanalytical sensitivity), has not been fully tested. In this 
chapter, plasma miR-122 and serum ALT were tested in a cohort of patients who presented 
early after APAP overdose (median presentation time after overdose = 8 hours). In these 
patients, miR-122 significantly correlates with both peak ALT levels and peak INR score 
(figures 4.1 A-B, P < 0.0001). This suggests that there is clinical promise in the early 
measurement of miR-122 to identify patients who are likely to develop liver injury, or 
coagulopathy (a functional marker of advanced liver injury). This finding supports data from 
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other APAP-overdose cohorts (see chapter 3) where day one miR-122 levels are 96% higher 
in patients who subsequently meet KCC for liver transplantation during their hospitalisation, 
although due to variation between groups this fell short of statistical significance (P=0.15). 
These data suggest that measurement of miR-122 holds clinical utility to predict liver injury 
at emergency room presentation. 
 
This data also shows that miR-122 is significantly raised (P<0.0001) in patients on 
admission to hospital who subsequently develop ALI (ALT > 3 x ULN) (figure 4.2A). In the 
same samples, the presentation serum ALT activity reading was in the normal range and did 
not identify which patients would develop ALI (P = 0.27, figure 4.2B). Importantly, 
presentation miR-122 provided superior separation between patients who develop ALI and 
those who do not (sensitivity at 90% specificity = 0.72), as shown in ROC curve analysis 
(figure 4.2C) over presentation serum ALT activity (sensitivity at 90% specificity = 0.18) 
(figure 4.2D). Similarly, miR-122 also identified patients who develop coagulopathy (an 
indicator of more severe poisoning) (figure 4.3A) whilst serum ALT activity could not 
(figure 4.3B). These data together suggest that, at presentation, a raised miR-122 reading 
may identify patients who not only develop ALI, but develop a decrease in liver function, 
which is associated with severe poisoning and poor outcome. If these findings can be 
validated and limits of normal ranges identified for miR-122 (analogous to 3 x ULN for 
ALT), then miR-122 holds promise as an early predictive marker for liver injury, and as a 
tool to highlight patients who may need more intensive therapy. Furthermore, chemical 
measurement of plasma APAP concentration within the first 8 hours of APAP overdose, 
either taken alone or back-extrapolated to 4 hours could not identify patients who develop 
liver injury (figure 4.5A-B). Plasma paracetamol concentration at admission is currently 
used to assess risk through the use of the Rumack-Matthew nomogram to highlight which 
patients are likely to require antidotal therapy, provided by NAC infusion. This finding 
supports the notion that a biological parameter would be better suited to identify risk in 
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patients on an individual basis, rather than using a fixed chemical threshold for all patients. 
Further development is necessary to validate these findings in multi-centre prospective 
clinical studies to test the predictivity of miR-122 during APAP-induced ALI. 
 
To specifically test the earliness of miR-122 and ALT, the cohort was stratified for those 
patients who presented within 8 hours (n=63). Within this time, all patients presented with a 
serum ALT activity below 3 x ULN; median ALT (IQR) 20 U/L (15, 31 U/L). Green and 
colleagues found that serum ALT activity does not rise in the first 12 hours after an acute 
APAP overdose in the majority of patients (Green et al, 2010). In this chapter, the data 
shows that in patients who present within 8 hours, the presentation serum ALT activity is 
below 3x ULN, even in patients who develop liver injury later (figure 4.4A).  In contrast to 
this, plasma miR-122 levels were already raised in patients who presented within 8 hours of 
APAP ingestion who develop liver injury (figure 4.4B). This finding builds upon previously 
published data in a mouse-model of APAP-induced ALI where miR-122 levels were raised 
at 1 hour after APAP exposure, before increases in serum ALT activity (Wang et al, 2009). 
Furthermore, data presented in chapter 2 also shows earlier increases of circulating miR-122 
compared to ALT in a different mouse model (CD-1) of APAP-induced ALI . These 
findings allow one to speculate on release mechanisms of biomarkers from injured or dying 
hepatocytes. The release mechanism of ALT has not been extensively studied; however, it is 
considered that ALT is passively leaked into the circulation once the hepatocyte loses 
membrane integrity (Rafter et al, 2012). It is likely that a population of hepatic miR-122 is 
also lost through the same passive mechanism, but this does not explain how miR-122 is 
detected before ALT in animal and human forms of APAP-induced ALI. Circulating 
miRNAs have been to found to exist either enveloped in exosomes and other small cell-
derived vesicular bodies, or in complexes with auxiliary proteins. This circulating cargo is 
thought to confer stability to circulating miRNAs which exhibit remarkable durability in 
serum/plasma; a matrix rich in RNase activity. Arroyo and colleagues found that circulating 
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miR-122 existed almost exclusively bound to argonaute 2 proteins in plasma and serum from 
healthy volunteers (Arroyo et al, 2011). However, in a mouse-model of APAP-induced ALI, 
time-dependant increases in miR-122 was observed in both exosome-rich and protein-rich 
serum fractions (Bala et al, 2012). This suggests that the nature of circulating miR-122 may 
indeed change during conditions of liver disease. Despite this, the exact nature of early 
release of miR-122 remains elusive. It is possible that miR-122 release may be bi-phasic 
with an early active release in response to stress, followed by massive late release during 
hepatocellular necrosis. However, this urgently requires experimental testing. 
In this cohort of patients, several novel mechanistic markers of liver injury were also 
measured, including HMGB1, full-length keratin-18 (necrosis K-18), caspase-cleaved 
keratin-18 (apoptosis K-18) and GLDH. HMGB1 is a nuclear protein that exhibits 
proinflammatory activity through the activation of toll-like receptors (TLRs) or receptor for 
advance glycation end-products (RAGE). Hyper-acetylated HMGB1 has been found to be 
released from activated monocytes and macrophages, while hypoacetylated HMGB1 is 
released from necrotic cells. HMGB1 is a known damage-associated molecular pattern 
(DAMP) molecule and has been shown to contribute to APAP-induced ALI through 
modulation of the immune response to inflammation (Scaffidi et al, 2002). Keratins are 
intermediate filament proteins found in a vast array of cell types. During apoptosis-mediated 
cell death, keratin-18 is cleaved in a precise manner. The caspase-cleaved fragment can be 
measured in the circulation as a surrogate marker of apoptotic cell death. The circulating 
full-length keratin-18 filament is associated with necrotic cell death. While both HMGB1 
and keratin-18 offer no liver-specificity, they can be used as robust mechanistic indicators of 
cell death when used in combination.  More recently, it has been shown that circulating 
forms of HMGB1 and keratin-18 can be used as mechanistic markers of APAP-induced ALI 
in pre-clinical models and in patients (Antoine et al, 2009, Antoine et al 2010, Craig et al, 
2011, Antoine et al 2012,). Furthermore, GLDH is an enzymatic marker of liver injury that 
has been suggested to be a more sensitive blood-based marker of APAP-induced ALI in rats 
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(O’Brien et al, 2002). GLDH can also provide mechanistic insight due to the large stores of 
GLDH within the mitochondria. Indeed, GLDH has recently been used specifically as a 
circulating marker of mitochondrial damage during APAP-induced ALI (McGill et al, 2012). 
Therefore, in a collaborative effort within the CDSS, these novel mechanistic markers were 
measured in the same samples from all patients within this study. Here, in this chapter, the 
data is focussed on the correlative analysis between miR-122 and the novel panel of 
mechanistic markers (HMGB1, necrosis K-18, apoptosis K-18 and GLDH) in an attempt to 
gain insight behind the mode of cell death associated with miR-122 release. The data shows 
that presentation plasma miR-122 correlates most strongly with HMGB1 and necrosis K-18 
(R
2
 = 0.21, P<0.0001 and R
2
 = 0.19, P<0.0001) respectively (figure 4.6 A-B). These markers 
are mechanistic indicators of necrotic cell death, which is recognised as the predominant 
form of cell death during APAP-induced ALI (Lawson et al, 1999; Gujral et al, 2002). 
Furthermore, in a cohort of hepatitis C infected patients, miR-122 is described as a marker of 
necroinflammation associating closely with ALT and histological activity index (HAI) score 
(Bihrer et al, 2011). These data suggest that the circulating miR-122 release is closely 
associated with necrotic cell death. Moreover, the data shows that miR-122 also correlates 
with apoptosis K-18, albeit with less strength and significance (R
2
 = 0.06, P = 0.005) than 
the necrotic markers (figure 4.6 C-D). The role of apoptosis in APAP-induced ALI is 
controversial. In animal models of APAP-induced ALI, apoptosis is considered to play a 
negligible role in hepatotoxicity. This is based on lack of caspase-activation, morphological 
findings and the fact that caspase-inhibitors do not protect against injury (Gujral et al, 2002; 
Jaeschke et al, 2006). However, it should be noted that animal models of APAP-induced 
ALI were fasted prior to APAP exposure. Nutritional status has a profound impact on 
hepatic ATP stores, and therefore, the ability of hepatocytes to fully commit to apoptosis. 
More recent evidence has found that apoptosis may play a modest role in APAP-induced 
liver injury under certain conditions (Antoine et al, 2010, Antoine et al, 2012). Nevertheless, 
in this study, circulating caspase-cleaved K-18 fragments are clearly raised in some patients 
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alongside miR-122 (figure 4.6C). Further studies are necessary to delineate the specific 
release mechanisms and kinetics of miR-122 and other liver-enriched miRNAs into the 
blood during specific conditions of apoptosis and necrosis.  
Here, the data also shows that miR-122 correlates with serum GLDH activity (figure 4.6D). 
The mitochondrion represents a key intracellular target for NAPQI, the toxic metabolite of 
APAP. It has been shown that inhibition of manganese superoxide dismutase (MnSOD, a 
critical mitochondrial defence enzyme) and subsequent mitochondrial stress, plays a key role 
in APAP-induced ALI (Agarwal et al, 2011, Ramachandran et al 2011). Here, GLDH (a 
mitochondrial-enriched enzyme) is used as a circulating marker of mitochondrial damage. 
Although the correlation between miR-122 and GLDH was significant (P = 0.012), the 
correlation was weaker than with the necrotic markers (R
2
 = 0.08). Circulating GLDH and 
ALT enzymes may share a similar release mechanism and/or exhibit similar times of release. 
Therefore, like ALT, GLDH may not be an early clinical marker of APAP-induced ALI. 
This represents a clear hypothesis to test in future work. 
It is also important to consider the kinetics of circulating markers during the evolution of 
hepatoxicity. In a separate cohort of APAP-induced ALI patients (see chapter 3), circulating 
miR-122 appears to return to baseline earlier than ALT, which has been estimated to have a 
circulatory half life of approximately 48 hours (Saheki et al, 1990). Here, we selected 10 
individuals from this cohort (n=129); 7 of whom developed ALI and 3 of whom did not 
develop ALI. All 10 patients had blood taken at admission (for patient characteristics see 
table 4.2) where plasma APAP concentrations had indicated the need for NAC therapy. 
Further blood samples were taken 12 hours and 20.25 after the start of NAC therapy in each 
individual. Circulating miR-122 and ALT activity was measured in plasma or serum. Firstly, 
in three patients who do not develop ALI, neither serum ALT nor plasma miR-122 is raised 
at any time (figure 4.7 H-J). This is important to show that both markers remained low and 
in accordance with each other, which may provide added confidence if used in parallel. 
Furthermore, in most patients who did develop ALI (patients X21, X34, 11067, FV1, FV2, 
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figure 4.7 A, B, D, F, G), plasma miR-122 tracks serum ALT activity closely. However, in 
two patients (patients 11041 and 12023, figure 4.7 C and E) plasma miR-122 and ALT were 
dissociated. In patient 11041, miR-122 levels were highest at presentation (ΔCt 217.6) 
before decreasing at 12 hours (ΔCt 27.0) and 20.25 hours (ΔCt 16.1) thereafter. However, 
serum ALT activity was lowest at presentation (61 U/L) before rising at 12 hours (306 U/L) 
and 20.25 hours (531 U/L) thereafter. A delayed presentation of ALT and longer circulatory 
half-life may account for delayed increase and opposite trend in this patient; it should be 
noted that miR-122 levels were relatively high at all three time-points. Without histological 
examination of a liver biopsy from these patients, it is impossible to state what the true 
degree of liver injury was at each time. However, this analysis shows that plasma miR-122 
levels and serum ALT activity may be different in certain conditions. 
In summary, the data obtained from this cohort supports previous pre-clinical data where 
histological changes can support circulatory biomarker data. Now, the challenge is to build 
upon these findings and further develop miR-122 as a clinical marker.  One important 
challenge will be to define normal miR-122 levels in a heterogenous group of patients so a 
threshold can be set, beyond which ALI can be diagnosed with confidence.  Another 
challenge is the need to develop and test a clinical assay that can be used between different 
clinical laboratories. Whilst qPCR offers good bioanalytical sensitivity, the entire assay can 
take up to 8 hours from patient sampling to result. There is a pressing need for a fast, robust, 
and sensitive clinical assay for the measurement of circulating miRNAs that can be used 
routinely at the bed-side, given that APAP-induced ALI can develop rapidly. In general, the 
findings presented here in this retrospective study are underpinned by the heterogeneity of 
the cohort, with respect to dose ingested and time to presentation. Therefore, these data 
should add to the body of evidence for the development of circulating miR-122 as a clinical 
biomarker of APAP-induced ALI. 
In conclusion, the data presented here suggest that miR-122 is an early marker of APAP-
induced ALI that can outperform existing markers of liver injury in patients at emergency 
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room presentation. Furthermore, miR-122 also holds promise in the ability to predict injury, 
including severe injury (coagulopathy) in APAP-induced ALI patients at presentation. 
However, none of the patients in this cohort required a liver transplant or died, so further 
testing is required to test miR-122 against patient outcome.  Circulating miR-122 has the 
potential to refine patient care in a number of ways. In prospective clinical trials, circulating 
miR-122 could be included in the patient inclusion criteria to test novel treatment strategies, 
i.e. in the identification of low and high-risk patient groups using a biological personalised 
strategy. The use of such an approach, if successful, may reduce unnecessary administration 
of protracted NAC therapy. Furthermore, miR-122 may allow earlier exclusion of injury in 
patients in APAP-induced ALI patients, rather than reliance on late markers of liver function 
which are used currently. If injury can be confidently excluded in well patients, this could 
significantly reduce bed occupancy and reduce the clinical burden of APAP-induced ALI. 
The key point is that this retrospective study and other studies (see chapter 3) provide the 
first justification of the use of miR-122 to be included in future clinical trials to test the 
ability of this marker to detect APAP-induced ALI early, and predict hard-clinical outcomes. 
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THE ROLE OF CIRCADIAN RHYTHMS IN DILI 
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5.1  Introduction 
Circadian (derived from latin, circa diem) rhythms are defined at rhythms in biological or 
biochemical events that have a periodicity of approximately 24 hours. Circadian rhythms are 
distinct from other biological rhythms such as ultradian rhythms (biological rhythms with a 
periodicity less than 24 hours, e.g. 90 minute cycles of R.E.M. sleep) and infradian rhythms 
(biological rhythms with a periodicity longer than 24 hours, e.g. menstruation cycles). Many 
intrinsic physiological processes exhibit a daily cyclic pattern, e.g. heart rate, blood pressure, 
body temperature and metabolism all show time-of-day differences in their level or activity. 
This is considered to confer an advantage to organisms to allow anticipatory rather than 
reactionary behaviour to stimuli such as food availability (Gehring & Rosbash, 2003). 
Circadian rhythms are observed throughout nature; plants, animals and bacteria show 24-
hour rhythms in their biology. Furthermore, in man, it is accepted that the wellbeing of 
individuals is dependent on functioning and unperturbed circadian biology. For example, 
studies have shown that rotating shift workers are at more risk of developing cancer and 
cardiovascular disease due to a constantly disrupted circadian system (Schernhammer et al, 
2001, Boggild & Knutsson, 1999). Furthermore, there is a strong link between sleep 
disorders and other morbidities such as metabolic syndrome and depression (Ford & 
Kamerow, 1989, Punjabi & Polotsky, 2005). This growing body of evidence suggests that 
the effects of circadian regulation are extensive on core physiology. 
The evidence governing the complex coordination of circadian physiology is still evolving. 
A major breakthrough occurred in early 1990’s upon the discovery of the first clock gene in 
mice (Vitaterna et al, 1994). This provided a genetic basis (rather than simply being a 
behavioural phenomenon) behind circadian regulation. Since then, many clock genes and 
their variants have been found in species as diverse as bacteria and humans. A master clock 
exists in the suprachiasmatic nuclei (SCN) region of the brain, which has been found to 
orchestrate the dynamics of peripheral clocks in numerous cell types, including hepatocytes 
(Schibler & Sassone-Corsi, 2002). Light information is sensed by photoreceptive regions of 
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the retina and relayed to the SCN via the retinohypothalmic tract (Berson et al, 2002). The 
rhythmicity of light availability entrains the master clock exquisitely to a twenty four hour 
period. Peripheral clock synchronisation is achieved by direct neuronal signalling and from 
cyclic release of melatonin from the pineal gland with other glucocorticoids also being 
implicated (Arnedt & Skene, 2005). This, essentially, provides peripheral organs with a 
timing cue (zeitgeber) in relation to the environment and geophysical time. The clock 
machinery is consistent between central and peripheral clocks, with Bmal1 and Clock 
proteins forming an active heterodimer to upregulate the expression of Cryptochrome 
(CRY1-2) and Period (PER1-3) genes and a catalogue of other genes containing E-Box 
motifs. When the concentrations of CRY and PER genes reach a threshold in the cytoplasm, 
they dimerise, move to the nucleus and attenuate the effects of Bmal1-Clock, completing the 
negative feedback circuit (Reppert & Weaver, 2002). When one considers that the period of 
this intrinsic oscillation is twenty-four hours, the basis of the biologic clock can be 
envisaged. 
 
Recently, other zeitgebers have been implicated in entrainment of peripheral organs, 
especially in the liver where food availability acts as the dominant timing cue (Suter & 
Schibler, 2009). Food intake, which ultimately determines the energy status of the cell, can 
affect the stability of core clock gene products and alter the dynamics of the clock directly. 
The AMP:ATP ratio in the hepatocyte, essentially the cellular energy status, can be sensed 
by liver kinases including LKB (Lamia et al, 2009). Such kinases phosphorylate AMPK 
which targets CRY1, a key transcription factor in the core clock machinery, for proteasomal 
degradation. Not only can food availability affect clock gene dynamics but it can actively 
change hepatic rhythmic gene expression (Vollmers et al, 2009). It is likely that other 
regulatory mechanisms will also emerge as additional sensory pathways that confirms 
nutrient intake as the dominant zeitgeber in the liver.  
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Circadian regulation influences many aspects of molecular physiology including metabolism 
and cell cycle control (Rutter et al, 2002, Matsuo et al, 2003). The detoxification systems of 
the liver and kidney are regulated through central and peripheral circadian coordination. It 
becomes evident that the disposition of some drugs may not remain constant over the course 
of the day. Almost every aspect of drug disposition, from absorption to excretion has the 
potential to change over a daily cycle (Bruguerolle, 1998). This may explain how the 
presentation of some adverse drug reactions in patients appears to be dependent on the time 
of day at which the drug was administered. This has been reported with indomethacin, 5-
fluorouracil and a number of angiotensin-converting-enzyme (ACE) inhibitors (Levi et al, 
1985, Levi et al, 1995, Ohmori & Fujimura, 2005)  suggesting that this effect is independent 
of chemical structure or drug class. Other compounds have exhibited diurnal rhythmicity in 
tolerance when tested in laboratory rodent models including cyclosporine and loratidine 
(Magnus et al, 1985, Dridi et al, 2005). The term ‘chronopharmacology’ is now used to 
describe how drug response can change over the circadian phase. 
APAP is a widely studied analgesic and antipyretic drug that is very well tolerated at sub-
toxic doses. APAP, however, is considered a model hepatotoxicant in overdose and 
mechanisms of toxicity have been well characterised. Overdoses of APAP overwhelm the 
intrinsic clearance pathways of glucuronidation and sulfation in the hepatocyte, allowing 
APAP to be bioactivated through several cytochrome P450s (CYPs) to form n-acetyl-p-
benzoquinoneimine (NAPQI), a reactive metabolite (Nelson, 1995, Dahlin et al, 1984). This 
reactive metabolite is sequestered by hepatic stores of glutathione (GSH), a sulfhydryl-
containing antioxidant, and then excreted as a nontoxic mercapturate (Yuan & Kaplowitz, 
2009). Intracellular stores of GSH are rapidly depleted after a toxic insult which allows 
NAPQI to bind to macromolecules in the cell and initiate a cascade of hepatotoxicity 
(Jaeschke & Bajt, 2006; Jaeschke et al, 2006; Park et al, 2005). It has been shown 
previously that the hepatotoxicity of paracetamol follows a circadian rhythm (Matsunaga et 
al, 2004). Key biological determinants of APAP-mediated hepatotoxicity, such as hepatic 
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glutathione (GSH) content, have been reported to oscillate over a twenty-four hour period 
which may explain the temporal difference in toxicity (Jaeschke & Wendel, 1985).  
In the present work, hepatotoxicity was investigated following morning and evening 
administration of a single dose of either APAP (350 mg/kg, i.p.) or furosemide (FS) (400 
mg/kg, i.p.) to the young CD-1 mouse. These model hepatotoxins were selected based on 
their mechanism of injury; APAP depleted GSH which is an obligatory event in the 
manifestation of hepatotoxicity whereas FS causes injury independent of GSH depletion. 
DILI was assessed through a series of conventional and emerging biomarkers of 
hepatotoxicity, including serum ALT activity and circulating miRNAs. After characterising 
archetypal clock gene expression in our rodent model over time, hepatic GSH dynamics and 
temporal Cyp2e1 levels were measured across the light-phase. Separately, the safety of a 
common vehicle, polyethylene glycol-400 (PEG-400) was assessed for its safety in DILI 
studies. 
 
The overall goal of this part of the thesis is to improve our understanding of the area of 
chronotoxicology.  A firm understanding of the key determinants of drug disposition could 
potentially improve the therapeutic index of many drugs and reduce ADRs in patients.  
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5.2  Materials & Methods 
 
5.2.1 Animal Experiments.  
The protocols described were performed according to the regulations defined in the project 
licence granted under the Animals (Scientific Procedures) Act 1986 and approved by the 
University of Liverpool Animal ethics committee. All animals were purchased from Charles 
River (Manston, UK) and housed at constant temperature and humidity with free access to 
food and water. All animals were allowed to acclimatise to a 12-hour light-dark cycle (lights 
on: 08:00 (ZT00)/lights off: 20:00 (ZT12)) for at least 14 days prior to experimentation. 
Mice were humanely culled via rising concentration of CO
2
 before exsanguinations 
according to the Humane Killing of Animals Under Schedule 1 to the Animals (Scientific 
Procedures) 1 Act 1986. 
 
5.2.2 Dosing regimen.  
For normal circadian analysis, male CD-1 mice (5-7 weeks old, n=5/6 per group, 30-40g, fed 
ad libitum) were culled via schedule 1 as described at 09:00 (ZT01), 13:00 (ZT05), 17:00 
(ZT09) and 21:00 (ZT13). Blood was obtained via cardiac puncture. Tissues were harvested 
and snap frozen on liquid nitrogen for storage at -80°C until use. For toxicity experiments, 
male CD-1 mice (5-7 weeks old, n=6, 30-40g, fed ad libitum) were administered a single i.p. 
dose of APAP (350 mg/kg, in warmed saline) or FS (400 mg/kg, in warmed PBS, pH 8.0) or 
vehicle alone using a 25-gauge needle at either 09:00 (ZT01) or 21:00 (ZT13). In some 
experiments, PEG-400 was used as a vehicle for FS administration. All mice were culled 8 
hours after dosing via a rising CO2 concentration. Blood was extracted immediately via 
cardiac puncture. Livers were removed, rinsed in phosphate-buffered saline (PBS), and one 
large lobe was semi-homogenised before being snap frozen in liquid nitrogen. Tissues were 
stored at -80°C until use. 
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5.2.3  Serum ALT Activity Determination 
Blood was collected in microtubes and allowed to clot overnight at 4 °C. The blood clot was 
initially separated and serum removed by centrifugation (1500g, 5 mins, 4 °C). Residual red 
blood cells were pelleted by centrifugation (10,000g, 5 mins, 4 °C) to yield cell-free 
supernatant. Serum ALT levels were determined immediately (to prevent freeze-thawing 
effects) using a Thermo Infinity ALT Liquid stable reagent-based (Thermo, Waltham, MA) 
kinetic assay, at 37°C, according to the manufacturer’s instructions. 
 
5.2.4 Determination of temporal hepatic GSH abundance.  
The kinetic 5,5’dithiobis(2-nitrobenzoic acid)-GSH disulfide recycling assay was used to 
determine hepatic GSH abundance from normal mouse livers excised at 09:00 (ZT01), 13:00 
(ZT05), 17:00 (ZT09) and 21:00 (ZT13). The method used is described by Vandeputte et al, 
1994. 
 
5.2.5 Determination of total protein concentration.  
Total protein concentration was determined using the method described by Lowry et al 
(1951). 
 
5.2.6 Immunoblotting 
Immunoblotting was performed against Cyp2e1. Briefly snap-frozen livers were 
homogenised in PBS. After total protein concentration was determined, pools were 
generated for each time point (ZT01, ZT05, ZT09, ZT13) from six individual liver 
homogenates. From pooled homogenates, 10 µg of protein was added to a 10 % homemade 
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acrylamide gel and run (1.5 h, 125 V) before being transferred to a nitrocellulose film (1 h, 
100V). Films were blocked with 10 % (w/v) non-fat milk overnight before ponceau red 
staining to ensure sufficient protein transfer. Membranes were then cut at the appropriate 
molecular weight to separate β-actin (loading control) from Cyp2e1. Each film was treated 
with primary antibody overnight (anti-Cyp2e1, raised in mouse, BD Gentest, San Jose, CA). 
Films were washed (0.1 % TWEEN/1% TBS buffer) before secondary antibody treatment (1 
hour). Films were washed again and treated with Lumiglo chemiluminescent reagent (New 
England Biolabs, Ipswich, MA) for 5 min, before exposure to ECL Hyperfilm (Amersham, 
Chalfont St. Giles, UK).  
 
5.2.6 Total RNA extraction.  
Total RNA was obtained using a phase-extraction method as described by Chomczynski & 
Sacchi 1987. Briefly, liver tissue (50 mg) excised from mice at 09:00 (ZT01), 13:00 (ZT05), 
17:00 (ZT09) and 21:00 (ZT13) was lysed in Trizol reagent (Invitrogen, Carlsbad, CA) as 
per the manufacturer’s instructions. RNA was DNase treated using the DNA-free kit 
(Ambion, Carlsbad, CA) before spectrophotometric quantification via Nanodrop (Nanodrop 
technologies, Wilmington, DE), cDNA was generated using the imPromptII reverse 
transcription system (Promega, Fitchburg, WI) by using 2 µg of RNA as per the 
manufacturer’s instructions. 
 
5.2.7 Temporal clock gene expression analysis.  
Expression of seven clock genes was analysed. Briefly, clock genes were co-amplified 
sequentially by quantitative polymerase chain reaction (qPCR) with a reference 
housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as described by 
Kitteringham et al, 2000. The selected clock genes and their respective primer pairs are 
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summarised in table 1. Primers were bought from Eurofins MWG Operon (Ebersberg, 
Germany). qPCR was performed using the SYBR ® Green I JumpStart Taq polymerase kit 
(Sigma Aldrich, Poole, UK) on an AbiPrism7000 (Applied Biosystems, Carlsbad, CA). 
 
5.2.8  miRNA extraction 
miRNA was extracted using an miRNeasy kit (Qiagen, Venlo, Netherlands), following the 
manufacturer’s instructions, with minor modifications. Briefly, 40 µL of biofluid was made 
up to 200 µL with nuclease-free water, then combined with 700 µL of QIAzol. The sample 
was mixed and left for 5 minutes before the addition of 140 µL of chloroform. In some 
experiments, 10µL of cel-lin-4 (5fM) was added to denatured serum before the addition of 
chloroform (to serve as exogenous control). Samples were then mixed vigorously for 15 
seconds and centrifuged at 12,000 g for 15 minutes at 4 °C. Equal volumes (350 µL) of the 
upper aqueous phase and 70% ethanol were mixed in a fresh microtube before adding the 
total volume to an miRNeasy minispin column. The column was centrifuged at 8,000g for 
15 seconds at room temperature. The flow-through, containing the small RNA fraction, 
including the miRNA complement, was mixed with 450 µL of 100% ethanol. The elute was 
then purified using a MinElute kit (Qiagen, Venlo, Netherlands). 
 
5.2.9  miRNA purification 
The small RNA elution mixture was applied to a MinElute column, 700 µL at a time. The 
immobilized RNA was then washed with various buffers before a final 80 % ethanol wash. 
The 
column was then dried by centrifugation. The small RNA fraction was eluted in 14 µL of 
nuclease-free water and stored at -80 °C. 
 
5.2.10 Quantitative Polymerase Chain Reaction Analysis (miRNA). 
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miRNA levels were measured using Taqman-based quantitative polymerase chain reaction 
(qPCR). The small RNA elute was reverse transcribed using specific stem-loop reverse-
transcription RT primers (Applied Biosystems, Foster City, CA) for each target miRNA 
species, following the manufacturer’s instructions. Next, 2 µL of RNA was used to produce 
the complementary DNA (cDNA) template in a total volume of 15 µL. Then, 1.33 µL of 
cDNA was used in the PCR mixture with specific stem-loop PCR primers (Applied 
Biosystems, Foster City, CA) in a total volume of 20 µL. Levels of miRNA were measured 
by the fluorescent signal produced from the Taqman probes on an ABI Prism 7000 (Applied 
Biosystems). All samples were assayed in duplicate. miRNA levels were normalized to 
levels of U6 snRNA, a ubiquitous small nuclear RNA (snRNA) species used as an 
endogenous control, as described elsewhere (Zhang et al, 2010). 
 
Gene Primer Nucleotide sequence 
Bmal1 F TCATTGATGCCAAGACTGGA 
 R ACTGAAGGCCTGTTGCACTT 
CRY F CGGACAGCCACCTCTAACAT 
 R GACAGAGGGGTCATGCACTT 
DBP F ACCGTGGAGGTGCTAATGAC 
 R TGGTTGAGGCTTCAGTTCCT 
Per2 F CAGGCTGAGTTCCCTAGTCG 
 R ACTGCCTCTGGACTGGAAGA 
Rev-erb-a F AGCCGCACAACCTACAGTCT 
 R CAGCTCCTCCTCGGTAAGTG 
ROR-gamma F GAAGGCAAATACGGTGGTGT 
 R GGGCAATCTCATCCTCAGAA 
Sirt1 F GATACCTTGGAGCAGGTTGC 
 R CTCCACGAACAGCTTCACAA 
GAPDH F CAAGGTCATCCATGACAACTTTG 
 R GGGCCDTCCACAGTCTTCTG 
 
Table 5.1: Primer sequences used for qPCR analysis of clock gene expression. 
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5.3 Results 
 
5.3.1 Large changes in hepatic clock gene expression occurs over the light-phase of 
the day 
Total RNA was extracted from livers (n=6) which were harvested at ZT01, ZT05, ZT09 and 
ZT13. From this, expression of six clock genes (BMAL1, REV-ERBα, PER2, CRY1, 
RORɣ, SIRT1) and one circadian gene (DBP) was measured. For normalisation, GAPDH 
provided a consistent baseline across all time points. All data was compared to the ZT01 
timepoint; fold-changes and P-values for each gene in shown in below (table 5.2). Large 
differences in expression was observed for DBP (45-fold change, at ZT09), REV-ERBα (16-
fold change, at ZT05) and BMAL1 (41-fold change, at ZT09) (figure 5.1). BMAL1 and its 
inhibitor REV-ERBα showed an anti-phase relationship. Furthermore, CRY1 (-2.4 fold 
change) and PER2 (5.4 fold change) showed more modest yet significant maximal changes 
in expression at ZT05 and ZT13 respectively. RORɣ and SIRT1 did not show any significant 
difference in expression during the light-phase. 
Clock 
Gene 
ZT01 vs ZT05 ZT01 vs ZT09 ZT01 vs ZT13 
 
Mean 
Fold 
Change 
P-value Mean 
Fold 
Change 
P-value Mean 
Fold 
Change 
P-value 
BMAL1 -3.6 P = 0.0002 -40.5 P < 0.0001 -3.9 P < 0.0001 
Cry1 -2.4 P < 0.0001 -2.1 P = 0.0004 1.2 P = 0.3131 
DBP 31.8 P < 0.0001 44.6 P < 0.0001 7.0 P = 0.0078 
PER2 2.0 P = 0.2001 3.6 P = 0.0012 5.4 P < 0.0001 
REV-ERB 15.7 P < 0.0001 1.3 P = 0.5897 -3.8 P = 0.001 
RORɣ 1.5 P = 0.5616 1.2 P = 0.7709 2.0 P = 0.1556 
SIRT1 1.1 P = 0.8181 -1.0 P = 0.3843 -1.3 P = 0.1017 
 
Table 5.2: Average fold changes and P-values of hepatic clock gene expression 
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Figure 5.1: Clock gene expression in liver tissue harvested throughout the light-phase. Total RNA was extracted from livers harvested at ZT01, 
ZT05, ZT09 and ZT13 (n=6). Each gene was measured by qPCR on SYBR Green I platform using primer sequences in Table 5.1. The panel shows 
the relative levels of expression (ΔCt) normalised to GAPDH). The average ΔCt and S.E.M. is plotted for each group. Coloured lines connect the 
mean ΔCt between groups for each gene where DBP (green line), BMAL1 (pink line), CRY1 (purple line), RORɣ (grey line), SIRT1 (black line), 
REV-ERBα (blue line) and PER2 (red line). The shaded area indicates when lights were switched off (from ZT12). Fold-changes and P-values are 
shown in table 5.2. Kruskall-Wallis test.
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5.3.2 Extent of APAP and FS-induced liver injury is dependent on the time of day of 
administration 
To investigate the effect of time-of-day of administration on the extent of liver injury caused 
by two model hepatotoxins, mice (n=6) were administered a single dose of either APAP 
(350 mg/kg, i.p., in warm saline) or FS (400 mg/kg, i.p., in warm PBS, pH 8.0) for 8 hours. 
Serum was extracted (as described). Serum ALT activity analysis was performed 
immediately to prevent unnecessary freeze-thawing of the samples. For miR-122 analysis, 
U6 snRNA (for APAP) and lin-4 (for FS) provided standardisation. 
For APAP, two mice died unexpectedly from toxicity after evening treatment with APAP 
providing n=4 for this group. All other mice survived providing n=6 in other groups. 
Biomarker analysis showed that mice are more sensitive to APAP after evening 
administration. (figure 5.2A; table 5.3). Average serum ALTs were 26-fold higher after 
evening APAP administration compared to morning, although due to variation provided by 
one animal that did not develop severe hepatotoxicity in the evening group (ALT=151), this 
fell short of statistical significance (P=0.11). Likewise, average serum miR-122 values were 
18.3-fold higher after evening administration compared to morning administration, with 
variation between animals accounting for the lack of statistical significance (P=0.08). 
Together, with the increased mortality rate observed in mice (33% vs 0% for evening and 
morning administration of APAP respectively), it is concluded that mice were more sensitive 
to APAP after evening (ZT13) administration compared to morning administration (ZT01). 
For FS, all mice survived providing n=6 in all treatment groups. FS generally produced a 
milder injury after 8 hours compared to APAP (average APAP ALT = 4357, average FS 
ALT = 352). Biomarker analysis showed that mice were more sensitive to FS after morning 
exposure. Average serum ALTs were 4.4-fold higher after morning administration 
(P=0.022) (figure 5.2D; table 5.4). Likewise, serum miR-122 levels were 2.6-fold higher 
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after morning administration, although this did not reach statistical significance (P=0.08) 
(figure 5.2E; table 5.4). 
 ZT01 ZT13 
 Control APAP Control APAP 
ALT (Median U/L ± IQR) 18.5 (11.1, 26.1) 380 (59.6, 662) 29.6 (17.4, 
45.7) 
12785 (2846, 
15281) 
miR-122 (Median ΔCt ± IQR) 2.95 (1.87, 9.50) 88.8 (18.3, 159) 9.3 (6.4, 20.4) 1779 (256.7, 
3147) 
 
Table 5.3: Serum miR-122 levels and serum ALT activity in control and APAP treated mice 
when administered in the morning (ZT01) or in the evening (ZT13) 
 
 ZT01 ZT13 
 Control FS Control FS 
ALT (Median U/L ± IQR) 12.8 (8.3, 37.4) 562  (149, 924) 17.9 (11.7, 
32.9) 
69.2 (36.4, 
226) 
miR-122 (Median ΔCt ± IQR) 683 (372, 9240) 40471 (10320, 
64111) 
1830 (291, 
4379) 
8864 (1614, 
26995) 
 
Table 5.4: Serum miR-122 levels and serum ALT activity in control and FS treated mice 
when administered in the morning (ZT01) or in the evening (ZT13) 
 
Serum ALTs and Serum miR-122 levels correlated significantly for APAP-induced ALI 
(P<0.0001, R
2
=0.76, figure 5.2C) and FS-induced ALI (P<0.0001, R
2
=0.78, figure 5.2F). 
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Figure 5.2: APAP and FS-induced liver injury is dependent on the time of day of 
administration. Serum ALT activity and serum miR-122 levels were measured from mice 
treated with either APAP (350 mg/kg, i.p.) or FS (400 mg/kg, i.p.). Each open circle 
represents an individual biomarker value. Statistical P-values are shown in the panels. Panels 
show grouped controls (saline-treated) vs drug-treated at ZT01 (white background) or ZT13 
(shaded background). Serum ALTs are shown in panels A (APAP) and D (FS). Serum miR-
122 levels are shown in panels B (APAP) and E (FS). Biomarker correlations are shown in 
panels C (APAP) and F (FS). 
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Figure 5.3: Hepatic GSH levels follow a circadian rhythm. Hepatic GSH levels were 
measured in individual mice culled at ZT01, ZT05, ZT09 and ZT13 (n=5). The panel shows 
grouped data where each open circle represents an individual GSH value obtained for each 
mouse. The shaded area indicates the dark-phase (starting at ZT12). Statistical significance 
is assigned in the panel (Kruskall-Wallis test). 
 
5.3.3 Hepatic GSH levels are higher in the morning than in the evening. 
Livers were harvested from normal untreated mice at ZT01, ZT05, ZT09 and ZT13 (n=5) 
before being snap-frozen on nitrogen and stored at -80°C until use. Hepatic GSH was 
measured from 50 mg tissue as described. Hepatic GSH levels were standardised to protein 
levels using the Lowry method. Levels were highest at ZT1 and declined at ZT05 exhibiting 
a 20% drop (figure 5.3; table 5.5). Hepatic GSH levels reached a nadir at ZT09 with a 38% 
drop (compared to ZT01) and levels remained 36% lower at ZT13. Statistical significance 
was observed between ZT01 vs ZT09 (P = 0.002) and ZT13 (P = 0.003). 
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 ZT01 ZT05 ZT09 ZT13 
GSH µmol/g 
protein (+SD) 
46.6 (12.3) 37.4 (8.1) 28.9 (3.2) 29.7 (3.2) 
 
Table 5.5: GSH levels over the circadian phase 
 
 
 
Figure 5.4: Hepatic CYP2E1 levels follow a circadian rhythm. Cyp2e1 levels were 
probed in pooled liver homogenates using a specific Cyp2e1 antibody. Each sample was run 
in triplicate on the same gel. β-actin levels ensured equal loading. A typical blot showing 
Cyp2e1 and β-actin are represented in panel A. Densitometric analysis of this blot is shown 
in panel B. Gray bars represent the mean ratio between Cyp2e1 and β-actin, and the bars 
represent the SD. The shaded area indicates the dark-phase. Statistical significance is 
assigned in the panel (Two-way ANOVA). Average (SD) densitometry ratios were 1.17 
(0.07), 1.00 (0.14). 0.93 (0.11) and 1.43 (0.11) for ZT01, ZT05, ZT09 and ZT13 
respectively. 
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5.3.4 Hepatic Cyp2e1 levels are higher at ZT13 compared to ZT01 
To investigate the circadian variation in hepatic Cyp2e1 levels, livers were extracted at 
ZT01, ZT05, ZT09 and ZT13 (n=6). Liver homogenates were generated from individual 
mice, in PBS. Pools were generated for each group based on extraction time, with an equal 
amount of protein from individual samples contributing to the pool. Hepatic Cyp2e1 was 
measured via immunoblotting as described. Protein levels were visualised on 
autoradiography film (figure 5.4A) and then semi-quantified by densitometry (5.4B). To 
ensure equal protein loading, β-actin was also measured. Densitometric analysis of Cyp2e1 
was standardised against β-actin. The immunoblot was repeated 3 times to ensure 
reproducibility. This data shows that hepatic Cyp2e1 levels were 22% higher in mice at 
ZT13 compared to ZT01 (P=0.024). 
 
5.3.5 PEG-400 is an unsuitable vehicle for DILI studies 
PEG-400 was investigated for hepatotoxicity after unexpected rises in serum ALT activity 
were observed during DILI studies. PEG-400 was used as the vehicle of choice due to 
apparent superior safety over DMSO and the poor solubility of FS in corn oil and aqueous 
preparations. FS chronotoxicity studies, we observed rises (> 50 U/L) in serum ALT activity 
(figure 5.5A) after morning (mean ALT = 80.8) and evening dosing (mean ALT = 319.8). In 
one mouse, a serum ALT activity of 968 was recorded, suggesting substantial liver injury 
had occurred. Serum miR-122 levels were also measured to rule out non-specific ALT rises. 
In the same animals, mean miR-122 levels after morning and evening dosing were ΔCt 0.06 
and 15.51 respectively (figure 5.5B). The animal with high ALT exhibited a serum miR-122 
ΔCt of 89.3. 
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To rule out batch-specific effects (with respect to mouse batch and chemical batch), new 
batches of PEG were tested from two suppliers (Sigma-Aldrich and Fisher Scientific) in a 
separate mouse experiment. Furthermore, in one group, PEG was diluted 2:1 with saline 
(this concentration dissolves FS) to test if hepatotoxicity could be abolished with a more 
physiological vehicle. The data shows that serum ALTs were raised in all mice (n=4) treated 
with PEG from either suppler (Aldrich - mean ALT = 421 U/L; Fisher - mean ALT = 362 
U/L) (figure 5.5C). Serum ALTs were also raised in all mice administered with the 66% 
PEG (v/v) (mean ALT = 162), although this was significantly lower than the 100% (Sigma) 
group P = 0.02. 
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Figure 5.5: PEG-400 causes serum ALT rises independent of time of day or batch. In 
chronotoxicity studies using FS, PEG was administered to mice as vehicle controls. Serum 
ALTs are raised in mice who received PEG only. Panels show serum ALT activity (A) and 
serum miR-122 levels (B) in groups receiving PEG and PEG/FS at morning or evening. The 
dashed line in panels A and C indicates the ULN for ALT activity in mice. Panel C shows 
serum ALT activities in a separate batch of mice administered 66% or 100% (v/v) from 
different suppliers. Statistical significance is displayed in the panel (Kruskall-Wallis test).
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Figure 5.6: PEG-400 causes one- to two-cell deep subcapsular hepatic necrosis in mice. 
Formalin-fixed liver sections of the right lobe were stained with H&E. The image shows the 
edge of a liver section, including the liver capsule. One- to two-cell deep subcapsular 
necrosis is visible (black arrows). Magnification = 4x. 
 
PEG-induced hepatotoxicity was confirmed by histology in FFPE preparations derived from 
formalin-fixed livers. Histology revealed one- to two-cell deep subcapsular necrosis in all 
control animals administered PEG-400 (figure 5.6) which account for the rises in circulating 
ALT and miR-122 levels. 
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5.4  Discussion 
Circadian rhythms regulate many physiological processes and metabolic systems including 
those implicated in drug disposition. Many drugs are known to exert differences in efficacy 
and/or toxicity depending on the time-of-day they are administered, which can be attributed 
to circadian fluctuations in a drug’s pharmacokinetics or pharmacodynamics. Circadian 
rhythms are regulated at the molecular level by clock genes which exhibit substantial 
temporal changes in expression over the circadian phase. In this chapter, we confirm that in 
untreated young mice, robust, high-amplitude oscillations were observed in the expression of 
clock genes and genes known to be regulated directly by the clock (figure 5.1). The genes 
which expressed the largest change in expression in the time-frame analysed were DBP, 
BMAL1 and REV-ERBα, three genes which are known to exhibit large circadian variations 
in expression. This suggests that the effects of the biological clock on key transcription 
factors can be substantial. DBP, and other related PAR-domain basic leucine zipper (PAR 
bZip) transcription factors have been implicated in regulating the transcription of many 
genes including those directly involved in drug disposition (Gachon et al, 2006). The 
expression of PER2 and CRY1 showed milder variations over this time-frame whilst SIRT1 
and RORɣ remained consistent over all times analysed. The phases and amplitudes of the 
clock gene expression in our model were in accordance with other published mouse models 
(Zhang et al, 2009). This data confirms that the young CD-1 male mouse model is an 
applicable model for us to study the role of circadian rhythms in DILI. 
 
Chronotoxicity of two model hepatotoxins was then assessed by morning and evening 
administration of fixed toxic doses of either APAP (350 mg/kg) or FS (400 mg/kg) in the 
young mouse model (figure 5.2). APAP is an analgesic compound known to cause 
centrilobular necrosus in man and rodent models. FS is a potent loop diuretic which causes 
centrilobular necrosis in mice, but not in man. In contrast to APAP, FS does not cause GSH 
Chapter Five 
174 
 
during the evolution of hepatotoxicity. These hepatotoxins were used as chemical tools to 
study the role of circadian rhythms on DILI and selected based on their disparate toxic 
mechanisms. The data shows that there is a clear difference in murine sensitivity to APAP 
between morning and evening administration. Evening administration (ZT13) of APAP 
caused more severe liver injury than morning administration, as determined by two 
circulating biomarkers of hepatotoxicity: serum ALT activity and serum miR-122 levels. 
This time-of-day dependent toxic response in mice has been reported by other groups who 
also show increased sensitivity in the early dark-phase (Matsunaga et al, 2004, Kim & Lee et 
al, 1998). The differences in chronotoxicity were previously attributed to rhythmic levels of 
Cyp2e1 and hepatic GSH. In this chapter, further experiments set out to confirm whether 
these changes are applicable in our model. 
 
In contrast, the chronotoxicity exhibited by FS was different to APAP. FS produced a more 
mild toxicity after 8 hours and this was slightly more pronounced after morning 
administration. The metabolism of FS has yet to be fully elucidated in mice. However, it is 
known that FS does not deplete GSH and a pan-CYP inhibitor protects against 
hepatotoxicity (Williams et al, 2007). This suggests that toxicity is mediated by a 
chemically-reactive metabolite, possibly an epoxide or dialdehyde derivative of FS. Clearly, 
an understanding of the enzymology of FS metabolism is required to further investigate the 
basis for the chronotoxicity observed with FS. However, this time-of-day dependence on 
toxicity is much more modest in comparison to APAP. APAP chronotoxicity can be 
attributed largely to the circadian rhythm of hepatic GSH levels which is a key determinant 
of APAP-induced hepatotoxicity. However, this does not seem important in FS-induced 
hepatotoxicity. 
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To explore the molecular basis of these observations, the levels of Cyp2e1 were measured in 
pooled liver homogenates generated from six mice per time-point over the light-phase 
(ZT01-ZT13). We observed that hepatic Cyp2e1 levels were constant over the early light 
phase but increased approximately 20% during the early dark phase (figure 5.4). These data 
suggest that the metabolism of APAP may not remain consistent over the day. Higher levels 
of Cyp2e1 during the early dark phase suggests that there is a greater propensity for APAP 
to undergo bioactivation and form the toxic metabolite. Previously published data shows that 
Cyp2e1 levels follow a circadian rhythm in mouse liver (Matsunaga et al, 2008). The same 
report shows that HNF1α, a circadian nuclear transcription factor, is implicated in the 
periodical transcription of Cyp2e1 as mRNA and protein levels increase steadily in the early 
dark phase in accordance with the data shown here. Furthermore, an alternative theory 
suggests that a shift from carbohydrate metabolism to a more lipolytic energy source may 
account for increased Cyp2e1 production (Bruckner et al, 2002). Mice are nocturnal animals 
and rest during the day, therefore they do not feed and switch energy sources to maintain 
glucose homeostasis. A by-product of lipid metabolism is ketone formation (including 
acetone) which has been detected in mouse serum at an early evening time-point (Bruckner 
et al, 2002). Acetone and other ketones are known to induce Cyp2e1 expression (Forkert et 
al, 1994). The circadian nature of Cyp2e1 levels may lie at a crossroads between clock-
mediated transcriptional regulation via HNF1α and daily exposure to inducers of Cyp2e1 
due to feeding rhythms. To further explore the molecular basis governing the circadian 
rhythm behind APAP-induced ALI, a global proteomic analysis is warranted to identify 
other candidate determinants that may contribute to the chronotoxicity of APAP and other 
drugs. However, a transgenic model may be needed to fully elucidate the role of the hepatic 
clock during DILI, due to cross-talk between feeding rhythms and entrainment of the hepatic 
clock. 
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Hepatic GSH levels were measured in mice with access to food and water ad libitum at time 
points from early light-phase to early dark-phase. GSH is one of the most important 
antioxidants as it sequesters many electrophilic species including NAPQI, the reactive 
metabolite of APAP. It is found abundantly in the liver where it acts as a multifunctional 
peptide, maintaining thiol status, providing antioxidant defence and detoxifying toxic 
species. GSH status in the hepatocyte is therefore considered a function of the detoxification 
potential of the liver. We observed that GSH abundance in the hepatocyte was highest in 
early morning and decreased steadily until ZT9 where it remained low through to ZT13 
(figure 5.3). To understand why GSH levels were not constant we considered that the 
synthesis of GSH may not be static over a daily cycle. Two important factors which 
determine the rate GSH synthesis are constituent amino acid availability and GSH-
generating enzyme activities (Lu, 2009). Methionine, an essential sulphur-containing amino 
acid derived from the diet, is implicated in the formation of cysteine, one of the constituent 
amino acids that comprise GSH. Cycles of methionine availability (feeding patterns) may 
contribute to the oscillatory nature of hepatic GSH levels throughout the day. Studies have 
shown that GSH can be depleted by either starvation or feeding on a protein-free diet 
(Jaeschke & Wendel, 1985), suggesting that methionine availability is a key determinant of 
hepatic GSH levels. Clearly, the circadian rhythm in hepatic GSH levels is an important 
feature that may influence the chronotoxicity of many hepatotoxins. Further work is required 
to measure Cyp2e1 activity over the circadian phase to test if changes in the levels of 
Cyp2e1 correlate with changes in Cyp2e1 activity. 
 
The solubility of FS is extremely poor in aqueous vehicles (< 1 mg/mL). Previous studies 
using FS have used a variety of organic or oil-based solvents, including 10% DMSO and 
corn oil (Francois et al, 2007, Randle et al, 2007). However, DMSO is an inappropriate 
vehicle to study FS-induced liver injury due to DMSO-mediated white cell infiltration in the 
liver (Masson et al, 2008). Furthermore, corn oil is also unsuitable as large volumes would 
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be required to be dosed i.p. to deliver the appropriate amount of FS needed to evoke toxicity. 
Therefore, PEG-400 was used as a vehicle to administer FS, as used previously (Williams et 
al, 2007). However, an unexpected increase in serum ALT activity and elevated serum 
miRNA levels were observed in mice treated with PEG-400 alone, indicative of liver injury 
(figure 5.5). Subsequent studies using different batches of PEG confirmed these findings and 
apparent hepatotoxicity followed a dose-response trend. Finally, PEG-induced 
hepatotoxicity was confirmed via histopathology (figure 5.6). PEG-400 causes subcapsular 
necrosis in mice and therefore should not be considered as an appropriate vehicle for use in 
pre-clinical DILI studies. A non-toxic vehicle was identified in alkaline PBS (pH 8.0), which 
did not cause necrosis in any mice, as used by McGill et al, 2012. This safer vehicle was 
used in subsequent chronotoxicity studies shown in figure 5.2. Mechanistic studies using FS 
can now be performed in mouse models within the CDSS through use of a non-toxic vehicle. 
In summary, a mouse model which is routinely used within the CDSS has an active liver-
clock and exhibits high-amplitude circadian variations in clock genes and clock-controlled 
genes (i.e. DBP). This provides an appropriate model in which to study the time-of-day 
dependence on drug response. Using two model hepatotoxins, the data shows that mice are 
profoundly more sensitive to APAP when administered in the early dark-phase. In contrast, 
FS shows a milder injury with pronounced toxicity occurring after morning dosing. We have 
confirmed that GSH levels are highest in the early light-phase and reach a nadir at late light 
phase and early dark phase. Furthermore, Cyp2e1, the oxidative enzyme which yields the 
chemically reactive metabolite, has a higher abundance at early dark-phase which may 
promote the transformation of APAP to NAPQI and contribute to dark-phase hepatotoxicity. 
In this chapter, a safer vehicle was also identified for FS administration. A previously-used 
vehicle, PEG-400, is hepatotoxic and should not be considered appropriate for DILI studies 
in mice. These data together increase the understanding of the toxicity profile of two model 
hepatotoxins which should result in improvements in the design of toxicity experiments. 
This work provides a platform to further explore the mechanistic basis of chronotoxicity in 
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model hepatotoxins that may be applicable to other drugs associated with hepatotoxicity. 
Identifying the most appropriate time of day to administer drugs could provide enhanced 
efficacy or reduced risk in patients. Major advances have already been achieved in the 
cancer field with safer chemotherapy regimens based on refined rhythmic circadian 
administration optimised to improve drug tolerance in patients (Levi et al, 1997, Mormont & 
Levi, 2003). It remains to be seen if the same strategy can be applied to other drugs 
associated with risks of hepatotoxicity and other ADRs. 
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6.1  Introduction 
As discussed earlier, ADRs have a significant impact on patient health, healthcare systems 
and represent a major impediment in the generation of new medicines, being a main cause of 
drug attrition in pre-clinical settings (Kola & Landis, 2004; Lazarou et al, 1998; 
Pirmohamed et al, 2004). Despite a worldwide effort to investigate the reasons that underpin 
the formation of DILI, the casual mechanisms remain controversial and poorly defined. 
Clearly, better tools and more appropriate models are required to drive translational research 
in pre-clinical and clinical settings, in order to bridge DILI between molecule (i.e. defining 
chemical liabilities in NCEs), mouse (i.e. more appropriate models of DILI) and man (i.e. a 
better understanding of the relationship between drugs and patient populations). One of the 
most important tools needed to help advance research in the field of DILI is identification 
and development of novel biomarkers of liver injury. Identification of sensitive and specific 
markers of DILI is required in vitro, in vivo and in the clinic, so that they can complement or 
supersede the existing catalogue of biomarkers. 
The existing set of validated DILI biomarkers in the clinic (and in the laboratory), are 
limited to the circulating aminotransferases (AST/ALT), and markers of functional 
impairment such as prothrombin time/INR or serum bilirubin. Whilst these markers have 
been validated for use in the clinic, limitations are recognised with these markers which 
impede research in drug development and similarly cause uncertainty in patient management 
in the clinic. The “gold-standard” marker of DILI is serum ALT activity. This enzyme is a 
good sensitive marker of DILI; however it lacks true liver-specificity as isoforms are 
expressed at moderate levels in the muscle tissue leading to the risk of false positives. 
Furthermore, in the clinic, whilst serum ALT activity is increased before markers of liver 
function impairment like prothrombin time, there is a distinct latent period in the first 12-18 
hours that occurs with toxic doses of APAP, a model hepatotoxin that causes rapid 
centrilobular necrosis and potentially fatal ALF. Blood sampling within this latent time 
frame does not indicate any liver injury, even in patients who later develop substantial 
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hepatotoxicity. Biomarkers that rise at the earliest possible time would benefit the physician 
in identifying or ruling out injury in patients early. Furthermore, in the laboratory, despite a 
larger set of markers that are utilised to detect liver injury, none have superseded ALT. 
Clearly, novel markers have the potential to improve on these limitations that exist presently 
with the current set of markers. Whilst identifying and developing new DILI markers will be 
challenging, the advantages of doing so will benefit patients, clinicians and the 
pharmaceutical industry. 
 
6.2 Circulating miR-122 as a novel marker of DILI 
MiRNAs are small (approx 22 nucleotides in length) non-coding RNA species that have an 
important regulatory role in cells. MiRNAs have recently emerged as a promising class of 
biomarkers for a range of pathologies due to high abundances in cells, remarkable tissue 
enrichment and extracellular stability. To date, the potential of circulating miRNAs have 
been assessed in many disease settings such as cancer (Mitchell et al, 2008), Myocardial 
infarction (D’Alessandra et al, 2010), stroke (Gan et al, 2012), nephrotoxicity (Lorenzen et 
al, 2011) and hepatitis (Zhang et al, 2010). With respect to DILI, it was shown in a recent 
publication that circulating levels of liver-specific miRNAs (most notably miR-122 and 
miR-192) are substantially raised after toxic APAP exposure in mice (Wang et al, 2009). 
The aim of this thesis was to further investigate the role of circulating miRNAs as potential 
markers of DILI. Using a similar approach to Wang and colleagues, the sensitivity of 
circulating miRNAs was tested in parallel to ALT, albeit in a younger CD-1 strain with ad 
libitum access to food. Despite the low-powered study, it was clear that rises in circulating 
miRNAs occurred early after APAP administration resulting in a statistically significant rise 
at 2 hours when ALT had not yet risen (see chapter 2). This finding confirms the earlier 
detection of miR-122 using in vivo models. However, using the same model, a sensitivity 
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study did not show miR-122 performed better than ALT, although this may be attributed to 
the exposure time used in the original study, where time may have been a factor. 
Also in chapter 2, in situ hybridisation studies were performed in healthy liver and liver 
exposed to toxic doses of APAP which revealed that miR-122 is lost early from liver tissue, 
which coincides with early detection in blood. This data also shows that loss of miR-122 is 
associated with cells that are not yet necrotic. This finding raises the suggestion that early 
release of miR-122 is mediated through an active mechanism, although it is likely that miR-
122 is also lost passively via necrosis when more severe hepatotoxicity develops later. It is 
possible that hepatocytes are triggered into preferential loss of miR-122 as a means to drive 
proliferation and regenerate injured cells, due to the regulation of miR-122 on proliferation 
pathways. Furthermore, it has recently been shown that the form of circulating miR-122 is 
dependent on the mechanism of injury (Bala et al, 2012). Further studies are warranted to 
test the relationship between circulating forms of miR-122 and how they change over time 
as hepatotoxicity evolves. 
In this thesis, the potential of circulating liver-enriched miRNAs to serve as informative 
clinical markers of liver injury was assessed retrospectively in two independent cohorts of 
APAP-overdose patients. The first cohort included a very heterogeneous group of 53 
patients who presented at different times with various exposures of APAP. Some of these 
patients developed fatal liver failure, whilst others spontaneously recovered after transient 
rises in ALT. As discussed in chapter 3, the major conclusions from this study were: i) liver 
specific miRNAs (miR-122 and miR-192) are raised in two ALI cohorts, ii) miR-122 levels 
did not correlate with functional markers of liver impairment in the same samples, and iii) 
miR-122 levels returned to baseline sooner than serum ALT activity in follow-up analysis. 
These data provide the first evidence in man that liver-enriched miRNAs hold potential as 
biomarkers of DILI. However, because it is clear from this study that miR-122 did not 
correlate with markers of liver function, the dynamics/kinetics of circulating miR-122 during 
ALI deserve further investigation. 
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In order to further investigate miR-122 as a clinical marker of DILI, a separate patient cohort 
was characterised (see chapter 4). This cohort was distinct from the previous patient cohort 
in that the majority of these patients presented early after APAP overdose when serum ALT 
was in the normal range. None of these patients required liver transplantation, or died from 
severe toxicity. However, all patients required NAC therapy as indicated by presentation 
plasma APAP concentration. This study showed that miR-122 was raised earlier than ALT 
in a subgroup of patients who subsequently developed liver injury. Also, when miR-122 or 
ALT was not raised in patients, they did not develop injury at any time due to therapeutic 
intervention with NAC. These findings suggest that further development of miR-122 as a 
novel clinical marker of APAP-induced ALI is warranted, as this biomarker has the potential 
to provide the physician with an early indication of risk of a patient developing serious 
hepatotoxicity. A high miR-122 reading on admission, even if serum ALT activity is within 
the normal range might indicate that the patient is likely to develop liver injury at a later 
time and should be treated accordingly.  Vice versa, if the presentation miR-122 is low in 
parallel with ALT, then the patient might be at lower risk of developing liver injury, and 
may even require less rigorous antidotal therapy, which could reduce costs and the 
likelihood of developing ADRs associated with antidotal therapy. Clearly, these are 
hypotheses which can be tested in prospective clinical studies. 
 
6.3 miRNAs - bioanaltyical perspectives 
Here, we took advantage of a taqman-based qPCR method that shows great analytical 
sensitivity (miRNA amplification) with the specificity of stem-loop primers that can 
discriminate between one nucleotide in the amplicon. Even so, questions remain about the 
most efficient strategy to quantify miRNAs: One consideration must be the starting 
biological matrix which is assayed; two major options being serum or plasma. Serum is the 
cell-free supernatant that is obtained after blood has clotted and the clot has been removed 
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via centrifugation. Plasma is the cell-free supernatant of blood that has not clotted due to the 
presence of an anticoagulant, and cells are removed via centrifugation. The purity of the 
resulting supernatant is an important factor to consider. Specific miRNAs are enriched in 
blood cells, therefore a thorough and consistent protocol is required with meticulous sample 
preparation. Substantial haemolysis due to red blood cell carry over or inappropriate sample 
handling/storage can lead to increases in baseline plasma miRNA levels. This can be a 
confounding factor: for example miR-16 is a popular choice of endogenous normaliser and 
also found at appreciable levels in red blood cells (Kirschner et al, 2011). Clearly, 
haemolysis could impinge on the utility of this miRNA to serve as a reference species. 
Serum is the most common blood-based fraction which is obtained from pre-clinical animals 
in the laboratory, and frequently in the clinic for serum ALT analysis. Importantly, it has 
been shown that miR-122 levels specifically do not differ considerably between serum and 
plasma in humans (Arroyo et al, 2011), but this has only been ascertained in healthy 
individuals and not in cases of liver injury where the circulating forms of miRNAs may be 
biologically different (Bala et al, 2012). Clearly, this represents a hypothesis that can be 
tested for in future work.  
Plasma is sometimes used clinically to measure certain analytes such as glucose. For plasma, 
the main issue that needs to be considered is the choice of anticoagulant used. The major 
concern with plasma is the use of the popular anticoagulant heparin, which is a potent PCR 
inhibitor (Kroh et al, 2010). All heparinised plasma samples are incompatible with qPCR 
analysis and cannot be used for miRNA measurement, heparinase treatment of plasma can 
reduce the impact but other anticoagulants should be sought in the first instance (Kim et al, 
2012). A side-by-side analysis of serum and plasma using various anticoagulants found that 
sodium fluoride/potassium oxalate (NaF/KOx) (commonly used for glucose analysis) 
provided the sensitivity for miR-16 and miR-223. Levels of these endogenous miRNAs were 
higher in NaF/KOx plasma tubes compared to EDTA plasma, sodium citrate plasma, serum 
and heparinised plasma. Intriguingly, the use of NaF/KOx tubes also improved the 
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sensitivity of exogenous ‘spiked-in’ miRNA species. This was not attributed to 
anticoagulant effects on PCR efficiency or RNA stability. Therefore, it is possible that 
NaF/KOx may improve the efficiency of the reverse transcription. 
Another consideration is selection of starting volume of serum/plasma. Due to the 
abundance of miRNAs in serum and plasma coupled with the amplification technology of 
qPCR, miRNAs can be detected easily from very small volumes, as low as 10 µL (Kim et al, 
2012).  The same article found that increasing the starting volume from 50 µL to 200 µL did 
not increase the sensitivity of detection. In fact, paradoxically, miR-16 levels were lower 
when RNA was extracted using 200 µL of serum or plasma compared to 50 µL. This 
counterintuitive finding suggests that molecules that interfere with the qPCR assay are 
inherent in blood, and by reducing the starting volume, these molecules get diluted below a 
threshold that reduces this interference. 
Thirdly, consideration should be given to the method of quantification. A standard curve is 
sometimes used against test samples to determine absolute copy number of target miRNAs. 
The risk of contamination is a factor when the same miRNA is used for the standard curve 
and samples, especially considering the relative copy numbers typically used for standard 
curve dilutions. A less risky approach is to create a standard curve using a non-biological 
(synthetic) miRNA to use as a surrogate for the miRNA of interest (analagous to the use of a 
serum albumin standard curve in protein determination assays). However, RNA extraction 
and reverse transcription may not be 100% efficient and the copy number generated by using 
absolute quantification is not likely to be relevant to the actual biological level. Another 
approach is to use a reference species to standardise to, and use relative quantification via 
the 2^-(ΔΔCt) method, similar to the use of GADPH or actin for mRNA measurement. The 
advantage of this approach is the ability to utilise endogenous normalisers as a reference to 
control for biological and technical variation in serum/plasma simultaenously. To date, no 
universal normaliser exists and many reference species have been used in this rapidly 
evolving field including U6 snRNA (Zhang et al, 2010), let-7d (Qi et al), miR-16 (Wang et 
Chapter Six 
186 
 
al, 2010) and miR-24 (Baraniskin et al, 2011) among others. From correspondence between 
our group and Qi and colleagues (Qi et al, 2012), let-7d was highlighted as a potentially 
superior normaliser over U6 snRNA with less variation between patient groups. Qi et al 
found that U6 snRNA levels were significantly different among young and aged subjects, 
however, no relationship existed between U6 snRNA and age in the APAP-induced ALI 
cohort (n=53; data not shown). An alternative quantification approach for circulating 
miRNA studies is through use of the addition of ‘spiked-in’ exogenous normalisers. Usually, 
this method involves the addition of a synthetic or non-mammalian miRNA species that is 
added to denatured serum/plasma samples. Care should be given as exogenous ‘naked’ 
miRNA exhibits altered biological stability, and must only be added when the biofluid is 
fully denatured (ectopic miRNAs degrades immediately when introduced to non-dentaured 
serum, Mitchell et al, 2008). Using exogenous miRNAs as a reference is an increasingly 
popular approach as it offers extremely low variation between samples. However, whilst this 
is an excellent approach to control for technical variation, it does not control for biological 
variation. In the clinical samples here studied, it was important to use an endogenous 
normalisation approach to control for biological variation through use of U6 snRNA and 
later let-7d. Since the samples were generated in the clinic, this provides greater risk of inter-
sample variation through inconsistent sampling technique, processing, storage and shipment 
of samples between laboratories. Typically, 5% of clinical samples that were assayed in the 
studies contained within this thesis had degraded miRNA and were not used for further 
analysis. 
Other biological/bioanalytical variables that should be investigated in future work include 
the effects of circadian rhythm on circulating miRNA levels, fed versus fasted subjects 
(particularly with respect to lipid content in the blood after fatty meals), white blood cell 
count effects (i.e. in HIV patients) and sampling method (optimisation of needle gauge used 
in phlebotomy/site of blood draw). 
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6.4 Establishment of miR-122 as a clinical biomarker of DILI 
One of the short-term challenges to further develop miR-122 as a clinical marker will be to 
identify baselines and limits of normal for miR-122 in healthy volunteers so that “a rise” can 
be set against a clear reference, analogous to 50 U/L which is used for serum ALT activity in 
the clinic. This can only be done in prospective studies with clear sampling protocols in 
place before a large n-number of patients can be profiled. Before then, a consistent 
bioanalytical method needs to be approved and universally accepted in the field. Currently, 
by far the most popular method for miRNA quantification is based around end-point or 
qPCR. Whilst this technique offers high-sensitivity and high-specificity, a typical assay 
takes at least 6 hours to complete, from sample RNA extraction to amplification, 
quantification and analysis. This time frame is incongruous to the needs of the clinic. As 
described, APAP-induced ALI is a very rapid illness that can lead to potentially fatal ALF if 
the correct clinical decision is not made in a timely fashion. In particular for APAP-induced 
ALI, the correct decision must be made quickly in the early-phase post APAP-ingestion, as 
soon as possible after emergency room presentation. Therefore, a robust, cost-effective and 
rapid bioanalytical method is needed for miRNA quantification in the clinic. From a 
bioanalytical perspective, time-consuming amplification-based technology is unsuitable. 
Therefore, a method to detect miRNAs directly in the femtomolar range is required. Despite 
this huge challenge, several novel methods of direct, fast miRNA quantification have been 
described with high potential for use in clinical scenarios (reviewed in de Plannell-Sageur & 
Rodicio, 2011). Promising methods for direct miRNA quantification include solution-phase 
bioluminescene (Renilla luciferase-quantum dot and DNA hybridisation; Cissell et al, 
2008a), fluorescence correlation spectrometry (DNA-based probe with fluorescence label; 
Neely et al, 2006), and bioluminescence miRNA detection (protein complementation and 
DNA hybridization; Cissell et al, 2008b). Clearly, these methods need to be developed 
further and tested against existing techniques of miRNA detection to ensure novel assays are 
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sensitive, specific and robust. Ultimately, any technique for miRNA detection/measurement 
in the clinic will require full validation by regulatory bodies. 
The data contained herein suggests that circulating miR-122 are at least as informative as 
ALT in both pre-clinical models and clinical settings of APAP-induced ALI. Coupled with 
superior liver-enrichment, high bioanalytical sensitivity, non-invasive sampling source, 
relatively inexpensive assay costs and low sampling volume, high mammalian conservation, 
miR-122 holds real potential to be a powerful translational biomarker of DILI. Clearly, 
further development of this biomarker is warranted. So far, this biomarker has been assessed 
in settings of acute liver injury. It remains to be seen if miR-122 can be as informative in 
chronic disease states or in idiosyncratic cases of DILI. This represents a clear hypothesis 
that can be tested in future work. At the moment, there is lack of knowledge on baselines 
and dynamic ranges of circulating levels of miRNAs in patients and in pre-clinical species. 
Currently, an international consortium (Safer and Faster Evidence-Based Translation, SAFE-
T) developed by the Innovative Medicines Initiative (IMI) is facilitating research into a 
panel of exploratory biomarkers including miR-122. This should augment the development 
and provide a platform for the clinical validation of miR-122 as a biomarker of DILI. 
6.5 The role of circadian rhythms in drug safety 
 Circadian rhythms have been found to regulate core biology in mammalian species (as well 
as in plants and bacteria) in a profound way. The extent of circadian regulation at the 
molecular level is extensive with 2-10% of the transcriptome exhibiting circadian variation 
(Kornmann et al, 2001; Panda et al, 2002). A number of publications have highlighted that 
genes implicated in drug disposition (including drug metabolism) exhibit circadian variation 
at the mRNA or protein level. For example, in mice devoid of three clock-controlled PAR 
bZIP transcription factors (DBP, TEF HELF), many genes involved in xenobiotic 
metabolism were found to be significantly underexpressed including members of the 
CYP450 superfamily (Cyp2a4/5, Cyp2b9, Cyp2b10, Cyp2c37, Cyp2c50), carboxylesterases 
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(Ces1, Ces3), UGTs (UGT2b37) GSTs (Gstα3, Gstθ1), aldehyde dehydrogenases (Aldh1a1, 
Aldh1a7) and drug transporters (MRP4, BCRP1) (Gachon et al, 2006). This work suggests 
that a catalogue of genes involved in xenobiotic detoxification is regulated directly by the 
hepatic molecular clock. Clearly, this is likely to have implications on the time-of-day 
variation in drug response. 
A number of drugs have shown to exhibit circadian variation in safety and efficacy in the 
clinic. A pharmacokinetic study of a sustained-release theophylline preparation found that it 
exhibited marked pharmacokinetic circadian variation in asthmatic children; levels were 
substantially lower when administered in the morning compared to evening dosing 
(Smolensky et al, 1987). Moreover, in cancer patients, a pronounced circadian rhythm in 
plasma 5-fluorouracil (5-FU) concentration exists despite constant rate intravenous infusion 
(Petit et al, 1988; Metzger et al, 1994). Circadian variation in drug response also occurs in 
pre-clinical animals. This is exemplified by the diurnal variation observed in halothane-
induced sleeping time which is doubled during the light phase compared to the dark phase 
(Turnbull & Watkins, 1976). Furthermore, the toxicity of archetypal hepatotoxins APAP and 
carbon tetrachloride also show significant circadian variation (Matsunaga et al 2004; 
Bruckner et al, 2002).  
Here, the potential chronotoxicity of two model hepatotoxins were assessed in a young CD-1 
mouse model. In this model, four out of six core clock genes showed high-amplitude (up to 
40-fold changes) time-of-day variation in expression. Furthermore, a direct clock-controlled 
PAR bZIP transcription factor known to be drive the expression of drug-processing genes, 
DBP, also showed marked circadian variation (up to 45-fold change in expression). The 
toxicity of both APAP and FS showed time-of-day dependence on toxicity. A moderately 
toxic dose of APAP (350 mg/kg) produced 26-fold higher levels of serum ALT activity after 
evening administration compared to morning administration. Serum miR-122 levels 
correlated with serum ALTs and also were 18-fold higher after evening administration 
compared to morning administration. These findings coupled with the increased lethality of 
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this ‘moderate’ dose of APAP (33% evening vs 0% morning) shows that APAP-induced 
ALT also shows circadian toxicity in the young CD-1 male mouse. This finding corroborates 
other mouse studies where toxic doses of APAP produced more severe injury after evening 
administration (Matsunaga et al, 2004). In comparison, the toxicity evoked by FS showed a 
reverse pattern in chronotoxicity, serum ALT and miR-122 levels were 4.4-fold and 2.8-fold 
higher after morning administration compared to evening administration. The observation 
that FS was not more toxic in the evening fits with the hypothesis that GSH does not deplete 
hepatic GSH. Interestingly, FS also shows circadian rhythm in its pharmacology in the rat 
(Stoynev et al, 1986) but it is not known if this is associated with the circadian rhythm in 
hepatotoxicity. Currently, there is a lack of knowledge with respect to the metabolism of FS 
in rodents. A pan-CYP inhibitor protects against FS-induced ALI in rodents which suggests 
toxicity is manifested through production of a CRM. Future work is required to characterise 
the metabolism of FS in the mouse in order to explore the mechanisms behind FS 
chronotoxicity. Furthermore, it is likely that the model is under severe pharmacological 
stress (400 mg/kg is 100-fold higher dose than pharmacological levels) in the kidney. It is 
currently unknown if this is a function of hepatotoxicity. 
To explain these observations, we confirmed that a circadian rhythm exists in hepatic GSH 
levels in our model which reflects previously published work (Jaeshke & Wendel, 1985; 
Matsunaga et al, 2004). The circadian variation in GSH levels is likely to reflect the 
circadian rhythm in feeding as it has been shown that switching the natural feeding time to 
day-time feeding (during the rest phase of the mouse) reverses the periodicity of the GSH 
cycle (Matsunaga et al, 2004). It is difficult to study the role of the hepatic clock in isolation 
due to the myriad of networks which govern circadian regulation such as rhythms in 
behaviour and temperature. For example, feeding rhythms have been shown to act as a 
zeitgeber on the molecular oscillator in hepatocytes. Periodical feeding rhythms cause 
rhythms in the energy levels in hepatocytes (AMP:ATP). This can be sensed by liver kinases 
including LKB (Lamia et al, 2009). Such kinases phosphorylate AMPK which target bona 
Chapter Six 
191 
 
fide clock genes such as CRY1 for proteasomal degradation. Not only can food availability 
affect clock gene dynamics but it can actively change hepatic rhythmic gene expression 
(Vollmers et al, 2009). To study the role of the molecular clock in isolation, a liver-specific 
conditional transgenic is currently being assessed within the CDSS. Using such an approach, 
the molecular clocks should be abrogated in a liver-specific fashion due to the engineering 
of the model (based on Kornmann et al, 2009). This will allow us to test the system using 
model hepatotoxins with and without a functioning hepatic clock. 
Also, in normal CD-1 mice, hepatic Cyp2e1 levels were 20% higher in the evening 
compared to morning levels. This is likely to play a role in the toxicity of APAP, as this 
CYP isozyme plays a major role in the conversion of APAP to the toxic metabolite, NAPQI. 
Further work will be to ascertain if these changes at the protein level correlate with Cyp2e1 
activity. Previously, it has been shown that Cyp2e1 levels at the mRNA and protein are 
higher during the early dark phase in rodents (Matsunaga et al, 2008; Bruckner et al 2002). 
This has been attributed to rhythmic levels of HNF1α, a circadian nuclear transcription 
factor known to regulate Cyp2e1 expression (Matsunaga et al, 2008). Furthermore, serum 
acetone levels follow a circadian rhythm which peak in the early dark phase. Acetone may 
play a role in Cyp2e1 circadian rhythm due to its ability to induce Cyp2e1 (Forkert et al, 
1994). It will be worthwhile in future work to characterise the circadian profile of other 
Cyp450s at the mRNA, protein and activity level in rodent models, notably Cyp3a and 
Cyp1a isoforms which may play a role in APAP-induced ALI. A detailed knowledge of the 
circadian profile of a catalogue of genes implicated in drug disposition (particularly genes 
involved in phase I, phase II and phase III drug metabolism) will help predict chronotoxicity 
in vivo models. To this end, a global proteomic analysis of liver tissue harvested over the 
circadian phase may help explore the molecular mechanisms governing the chronotoxicity 
with APAP, FS and other drugs. 
These studies show that knowledge of the circadian profile at the molecular levels of key 
determinants that ultimately effect drug response can explain the time-of-day variation 
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observed with drugs.  Identifying the most appropriate time of day to administer drugs could 
provide enhanced efficacy or reduced risk in patients. Major advances have already been 
achieved in the cancer field with safer chemotherapy regimens based on refined rhythmic 
circadian administration optimised to improve drug tolerance in patients (Levi et al, 1997; 
Mormont & Levi, 2003). Similar methodologies could be applied to other drugs currently 
used in the clinic that are associated with poor efficacy or limited by safety issues. 
Chronopharmacology studies may also become standard practice in the development of 
NCEs to identify the optimal time for drug administration in order to maximise efficacy and 
minimise toxicity. Essentially, a better understanding in the dynamics of the molecular clock 
and how it affects drug response may improve the risk:benefit ratio of drugs in clinical and 
pre-clinical settings. 
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6.5 Final comments 
The hypotheses that were addressed in this thesis were: 
 Circulating liver-enriched miRNAs can be used as biomarkers of liver injury in an 
APAP model of DILI and a FS model of DILI. 
Comment: Circulating miR-122 was able to inform on both APAP-induced ALI and FS-
induced ALI  in a young CD-1 mouse model. Circulating miR-122 correlated with the gold-
standard marker of ALT, providing sensitive and specific detection of liver injury. 
 Circulating liver-enriched miRNAs can be used as sensitive, non-invasive 
biomarkers to detect DILI in a heterogeneous cohort of APAP-overdose patients. 
Comment: For the first time, it is shown that serum levels of liver-enriched miRNAs (miR-
122 and miR-192) are raised in a cohort of patients with varying degrees of APAP-induced 
ALI. Most promising was serum miR-122 levels which correlated with serum ALT and 
exhibited reduced circulatory half-life. 
 
 Circulating liver-enriched miRNAs can detect APAP-induced ALI before ALT and 
can predict patients who will develop acute liver failure. 
Comment: In a separate cohort of specific patients who presented early after APAP 
overdose, miR-122 was raised before serum ALT. Most strikingly, miR-122 was raised in 
the patients who later developed liver injury (as determined by peak serum ALT activity) 
and developed coagulopathy (as determined by peak INR). If it can be shown in prospective 
clinical studies that miR-122 can predict peak INR (a marker of ALF), then analysis of miR-
122 has potential to be routinely used in the clinic and help drive clinical decision making. 
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 APAP and FS murine models of DILI show distinct time-of-day dependence on 
severity of toxicity. 
Comment: In a routinely-used murine model of DILI, both APAP and FS show time-of-day 
dependence on severity of hepatotoxicity. Strikingly, APAP exhibits severe lethal toxicity 
when a moderate dose is administered during the evening. In contrast, FS, which confers 
toxicity through a different mechanism, shows a reversed circadian rhythm in hepatotoxicity. 
For APAP, chronotoxicity can be associated with diurnal rhythms in hepatic GSH levels and 
Cyp2e1 content.  
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